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Abstract 
Endothelial cells maintain vascular integrity by regulating a number of physiological and 
pathophysiological processes, including haemostasis, thrombosis and inflammation. A 
pivotal contribution to these processes is the exocytosis of cargo from specialized endothelial 
storage organelles, namely Weibel-Palade bodies (WPBs). WPBs provide an intracellular 
storage pool of pro-thrombotic and pro-inflammatory mediators which can be differentially 
released in response to different stimuli. Ca2+ raising agonists such as thrombin and 
histamine, respectively released following vascular injury or an immunogenic insult, evoke 
WPB exocytosis. However, inappropriate and untimely exocytosis of WPBs can promote the 
pro-thrombotic and pro-inflammatory environment evident in cardiovascular diseases. The 
mechanisms underlying differential cargo release in order to produce physiologically distinct 
responses are poorly understood. Some Rab GTPase family members, have been reported 
to be implicated in regulating the exocytosis of WPBs. 
Here, we describe a novel Rab GTPase (Rab46) in endothelial cells that is located on WPBs. 
Super-resolution microscopy confirmed that Rab46 is juxtaposed to von Willebrand Factor 
(vWF), on the cytosolic side of individual WPBs, whilst quantitative imaging analysis 
suggested that Rab46 may regulate a subpopulation of WPBs. Interestingly, Rab46 was 
necessary for acute histamine, but not thrombin, WPB trafficking towards the perinuclear 
area identified as the Microtubule Organizing Centre (MTOC). Biochemical analysis and 
mass spectrometry was used to investigate the molecular mechanisms underlying Rab46-
dependent retrograde trafficking and the dynein heavy chain was identified as a candidate 
effector protein. Further biochemical experiments suggested a direct interaction between 
endogenous Rab46 and the dynein motor complex. Taken together, these results suggest that 
after acute histamine stimulation, dynein-bound Rab46 mediates retrograde transport of a 
subset of WPBs along microtubules to the MTOC.  
These observations indicate Rab46 as a key regulator of differential WPB cargo secretion, 
allowing an appropriate acute pro-inflammatory response whilst avoiding release of excessive 
pro-thrombotic mediators. Characterization of in vivo model of Rab46 represents the 
beginning of understanding the physiological contribution of Rab46 as well as its response 
to pathological conditions.  Understanding the Rab46/WPB signalling axis, both in vitro and 
in vivo, could be important for achieving better appreciation of how the endothelial cell fine-
tunes it’s secretory response and thereby providing novel therapeutic targets for the 
prevention of endothelial dysfunction, which is often the trigger for cardiovascular diseases. 
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Chapter 1 Introduction 
The luminal surface of the entire vasculature is delimited by a continuous monolayer of 
endothelial cells. The endothelial layer provides a strategic structural barrier between blood 
and the surrounding tissue. In addition to serving as a physical semipermeable barrier, 
endothelial cells also control many important functions in vascular homeostasis depending 
on their location. This phenotypic heterogeneity is due to exposure to different 
environmental as well as genetic factors. Endothelial cells have both metabolic and synthetic 
functions that influence vascular haemodynamics in the physiological and pathological state. 
Adaptation to physiological and pathological cues is essential to maintain vascular integrity. 
The endothelium is indeed, equipped to rapidly respond to local changes caused by trauma 
or inflammation. Specialized storage organelles, namely Weibel-Palade bodies (WPBs), are 
the main emergency machinery, which enable the endothelium to actively maintain a dynamic 
equilibrium between an antithrombotic physiological and a prothrombotic or 
proinflammatory state. WPBs are unique secretory organelles equipped with a 
multifunctional pack of haemostatic, inflammatory and angiogenic mediators that can be 
released upon demand. Regulated exocytosis of WPBs is a pivotal mechanism via which 
endothelial cells ensure differential release of bioactive molecules under different 
physiological conditions. Due to the complexity of WPB biogenesis and exocytosis, many 
aspects underlying these processes are still poorly understood.  Several GTPases of the Rab 
family of small GTPases have recently been identified as regulators of WPB exocytosis and 
biogenesis.  Rab GTPases are master regulators of cellular membrane trafficking, acting from 
organelle biogenesis to vesicle trafficking and exocytosis. Thus, the identity and function of 
Rabs associated with WPBs has been a particularly active area of WPB research in the last 
few years. 
This chapter will offer a short background on the physiological role of endothelial cells and 
the consequences of endothelium dysfunction. Attention is then turned to the role of WPBs 
and the machinery that drives exocytosis of WPB contents from endothelial cells, focusing 
on the role of Rab GTPases and their effectors in intracellular trafficking.  
Understanding how endothelial cells finely tune their secretory response in order to achieve 
context-dependent release of bioactive molecules from WPBs will potentially expose novel 
therapeutic targets for the treatment of haematological and cardiovascular dysfunction. 
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1.1 Vascular endothelium 
The vascular endothelium constitutes approximately 1% of body mass (1 kg) with about ten 
trillion (1013) cells covering an area between 1-7 (x 103) m2 1. Endothelial cells are strategically 
positioned within the vessel wall, located between blood flowing through the vessel, and the 
surrounding tissues such as the vascular smooth muscle cells (VSMC) forming the tunica 
media of arteries and veins (Figure 1.1). Endothelial cell structure and functional integrity are 
important in the maintenance of the vessel wall and circulatory function, but the endothelium 
is much more than an inert semipermeable barrier that determines the exchange of 
substances between blood vessels and tissue spaces. The endothelium is a specialised organ 
that plays different roles in different locales of the vascular tree and in different organs; 
manifesting distinctive responses to injury according to its structure and location2. The 
endothelial layer as a dynamic and active tissue has vital metabolic and synthetic functions in 
addition to the secretory function that controls vascular homeostasis3. The endothelium 
senses and assesses the haemodynamic, humoral, and inflammatory signals to which it is 
constantly exposed and responds by secreting factors that affect vessel tone and structure. 
Endothelial cells contribute to the regulation of blood pressure and blood flow by releasing 
vasodilators such as nitric oxide (NO) and prostacyclin, as well as vasoconstrictors, including 
endothelin-1 (ET-1) and platelet-activating factor4. Normally the endothelium balances the 
equilibrium between vasorelaxation and vasoconstriction on the side of promoting 
vasodilatation and inhibiting cellular proliferation5. To this end, for instance, the release of 
NO has several beneficial effects on the cardiovascular system including inhibition of platelet 
aggregation and smooth muscle cell proliferation, culminating in an anti-atherosclerotic 
environment. 
In addition to haemodynamic function, endothelial cells also regulate haemostasis and 
thrombosis. Haemostasis is mediated by a balance of procoagulant and anticoagulant 
factors4. Under normal conditions, the endothelium facilitates blood flow, maintaining its 
fluid state, by providing an antithrombotic surface that inhibits platelet adhesion and blood 
clotting. For example, thrombomodulin, which is present on endothelial surfaces, binds to 
thrombin and prevents platelet activation and fibrin production6. However, when the 
endothelium is perturbed by physical forces or by specific mediators, the cells rapidly 
undergo strategic biochemical changes that culminate in their transformation to a 
prothrombotic surface. The pivotal step in transforming the endothelial cell membrane from 
an anticoagulant to a procoagulant surface is the induction of tissue factor (TF). Tissue factor 
expression leads to the activation of factor X, which then combines with factor Va to convert 
prothrombin to thrombin7. Thrombin is a multifunctional protein with various pro-
coagulant effects. For example, thrombin evokes von Willebrand factor (vWF) expression 
on the surface of endothelial cells which then interacts with the platelet glycoprotein receptor 
complex, initiating platelet adhesion and aggregation3. A dynamic equilibrium exists between 
a pro-thrombotic and anti-thrombotic state, which modulates all the physiological processes 
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to prevent excessive bleeding at the site of injury as well as maintaining normal blood flow 
in an unperturbed blood vessel, providing proper haemostatic balance.  
In addition to the contribution of the endothelium in regulating blood coagulation, 
endothelial cells also express cell surface molecules that orchestrate the trafficking of 
circulating white blood cells as part of the immune response. The cell adhesion molecules 
expressed on the  endothelial cell surface, such as integrins and selectins, help direct the 
migration of leukocytes into specific tissues under physiologic conditions and accelerate 
migration towards sites of inflammation4,8. Movement of leukocytes between tightly adjacent 
endothelial cells into the tissue towards the site of infection or injury occurs via a complex 
and highly regulated multistep cascade, maintaining the integrity of the endothelium whilst 
at the same time allowing the migration of activated inflammatory cells out of the circulation1. 
An early “rolling” adhesion of leukocytes occurs within the first 1–2 h of an assault followed 
by leukocyte activation as a result of upregulation of cell surface selectins. The interaction 
between chemokine receptors on leukocytes and proteoglycans on endothelial cells mediate 
firm adhesion of leukocytes prior to transendothelial migration. Lastly, transendothelial 
migration (diapedesis) involves integrins, ICAM-1 and VCAM-1, and changes in vascular 
permeability to recruit leukocytes to the site of inflammation9. Each of these sequential steps 
ensures that the appropriate leukocytes accumulate for a restricted period in response to a 
specific challenge. 
It is evident how the endothelium, first described in 1980 as a simple cellophane wrapper, is 
now considered a large complex endocrine organ with a prominent role in vessel remodelling, 
vasomotion, vascular structure, secretion and mediation of interaction between circulating 
blood and the vessel wall. All these functions, summarised in Figure 1.2, are paramount to 
maintain the homeostasis of the entire vascular tree in the physiological state.  
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Figure 1.1 Schematic of an artery.  The vascular endothelium consists of a monolayer of 
endothelial cells that line the blood vessel. They are strategically located next to vascular 
smooth muscle cells and the flowing blood. The endothelium supported by the sub-
endothelium form a thin layer called tunica intima. The smooth muscle cells with elastin 
fibres compose the tunica media. The thick outside layer, called tunica externa is composed 
by an external elastic membrane and connective tissue.  
 
 
Figure 1.2 Schematic representation of the main endothelial cell functions. 
Endothelial cells maintain vascular homeostasis by maintain a fine equilibrium between the 
functions summarized in the above diagram.  
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1.1.1 Endothelial dysfunction 
Given the number and range of processes in which the endothelium participates, endothelial 
dysfunction can be expected to have major pathological implications. It has been increasingly 
recognized that disruptions in normal endothelial function play a part in the progression of 
several diseases; for example, the development and progression of atherosclerosis, 
hypertension, diabetes, hypercholesterolaemia, and coronary artery disease5. 
Dysfunction of the endothelium can be defined as an imbalance between relaxing and 
contracting factors, between anti- and pro-coagulant mediators or growth-inhibiting and 
growth-stimulating factors. This imbalance can develop by impaired synthesis and release of 
protective factors or increased synthesis and release of pro-coagulant/growth promoting 
factors10. Phenotypic and functional alterations of endothelial cells lead to compensatory 
responses which alter the normal vascular homeostasis. Most forms of cardiovascular 
diseases are caused by functional and structural changes in the blood-vessel wall. 
Endothelial dysfunction in atherosclerosis is demonstrated by impaired endothelium-
dependent relaxation. Decreased production or activity of NO, manifested as impaired 
vasodilation, causes phenotypic changes to pro-thrombotic and pro-inflammatory state 
which may be one of the earliest signs of atherosclerosis. Several studies have reported an 
increased plasma vWF levels as a consequence of impaired endothelial NO production11, 
suggesting the possibility that NO inhibits vWF endothelial secretion12 (implying that 
impaired NO production increases vWF secretion). While elevated vWF levels may 
contribute to the pro-thrombotic state, the pro-inflammatory condition associated with 
atherosclerosis is mainly supported by increased expression of P-selectin on the cell surface, 
mediating leukocyte adhesion. It has been suggested that P-selectin may be involved in 
atherosclerosis because P-selectin deficiency also delays and reduces atherosclerotic lesion 
formation13,14. These changes increase monocytes adhesion and penetration through the 
vascular wall. Atherosclerosis is, indeed, a systemic disease triggered by chronic inflammatory 
processes. It is characterised by the thickening of the intimal and medial layers of the arteries 
due to the deposition of atheromatous plaques along the vessel together with loss of 
elasticity15. Low-density lipoproteins (LDL), monocytes and macrophages are able to 
accumulate in the vessel due to an increase in vessel permeability, another key characteristic 
of endothelial dysfunction. The monocytes in the intima differentiate into macrophages and 
engulf modified lipoproteins to become foam cells (the hallmark of early fatty streak lesions).  
Atherosclerotic lesion progression leads to the switch of medial smooth muscle cells to their 
migratory and proliferative phenotype and an increase synthesis of extracellular matrix 
molecules generating a fibromuscular plaque. Macrophages and smooth muscle cells that 
have accumulated in the intimal layer of the vessel begin to die and their lipid contents can 
accumulate in the central region of the plaque (the necrotic core) resulting in the formation 
of a fibrous cap16. Plaque development compromises the artery lumen leading to disturbed 
blood flow provoking tissue ischaemia. Rupture of the plaque exposes pro-coagulant material 
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and triggers thrombus formation which results in blockage of the vessel lumen causing 
clinical events such as myocardial infarction or stroke16. 
Accelerated atherosclerosis, associated with increased oxidative stress, is also a prominent 
characteristic of diabetic cardiovascular complications. Diabetes mellitus is a chronic 
condition that occurs when the body cannot produce enough or effectively use of insulin. 
Type 2 diabetes is characterized by a two-to fourfold increased risk of cardiovascular disease. 
In patients with diabetes, endothelial dysfunction appears to be a consistent finding, generally 
attributed to the adverse effects of hyperglycaemia and oxidative stress on vascular biology17. 
In healthy vessels, as already mentioned, the endothelium maintains a balance between 
opposite vasoactive factors to maintain vascular tone. An imbalance in this homeostasis with 
a predominance of vasoconstrictive elements, like ET-1, and vascular wall thickening leads 
to hypertension, a major risk factor for coronary events. Endothelial cell damage occurs in 
many vascular beds during hypertension. However, it is not clear whether hypertension is 
the cause or the result of this damage18. 
It is evident that endothelial cells are multifunctional cells, involved in the regulation not only 
of haemostasis but also of vascular tone, leukocyte adhesion and fibrinolysis among other 
functions which if impaired contribute to the onset and progression of different diseases.  
Most of the molecules (like vWF, P-selectin, angiopoietin-2 and ET-1) that contribute to 
these processes are co-stored in endothelial specific secretory granules called Weibel-Palade 
Bodies (WPBs). How do endothelial cells control the release of granule content to allow 
differentiated responses? Understanding the mechanisms behind these responses will allow 
a better characterisation of the events causing the endothelial dysfunction which is often 
associated with cardiovascular diseases.  
Therefore, the endothelium can act as a measure of cardiovascular health and investigation 
into targeting endothelial dysfunction and treatment of early endothelial dysfunction is 
paramount for future therapeutic strategies. 
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1.2 Weibel-Palade Bodies 
Weibel-Palade bodies (WPBs) were first described in 1964 by Ewald Weibel and George 
Palade as “New cytoplasmic components of arterial endothelia”19. Using electron microscopy 
(EM), they observed rod‐shaped constituents of the endothelial cytoplasm of 0.1 x 2-3 μm 
in size which consist of a bundle of fine tubules aligned parallel to the longitudinal axis, 
enveloped by a tightly fitted membrane (Figure 1.3). Although they suggested a connection 
between these bodies and vascular or blood physiology, the nature and significance of these 
cytoplasmic components remained unknown for the next twenty years.  
In October 1982, evidence for the function of WPBs emerged from the Wagner lab. Using 
light and electron microscopy, Denisa Wagner and co‐workers functionally rediscovered 
these organelles showing that the haemostatic protein vWF was stored in WPBs ‘so as to 
allow rapid release of this protein upon appropriate stimulus or physiologic demand’20. The 
Wagner group went on to demonstrate that WPBs also stored other pre-made cargo, such as 
P-selectin with the potential to profoundly affect vascular function when released from cells.  
Endothelial cells heterogeneity between different vascular beds21 may explain the 
heterogeneous distribution of WPBs along the vascular tree22. The amount of WPBs in 
individual cells can vary between endothelial cells and differential distribution of vWF in the 
vascular endothelium has been shown23. vWF is not uniformly expressed on cells from all 
type of vessels as veins exhibit higher vWF content than arteries. However, WPBs can still 
be detected in ECs of all small arteries, the pulmonary arteries and arterioles, whereas these 
storage organelles are absent from pulmonary capillaries24. Therefore analysing spatial and 
temporal expression of vWF and others WPB components along the vasculature axis could 
give insight into their physiological role in anatomically restricted segments. 
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Figure 1.3 First micrograph of rod-shaped organelles in 1962. Endothelium of a small 
pulmonary artery of a rat, showing the cluster of rod‐shaped particles, depicting the tubular 
structure of their content (arrows) in cross‐section and in oblique sections. Higher‐power 
micrograph of the same specimen (bottom panels), showing parallel arrangement of internal 
tubules (H) and arrow pairs on the right panel point to clearly visible outlines of internal 
tubules (T) in transverse or longitudinal sections. From Weibel ER, Palade GE, JCB (1964)19 
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1.2.1 Biogenesis of WPBs 
vWF is the main cargo of WPBs and is a prerequisite for the existence of WPBs.  It is 
synthesized only by endothelial cells25 and megakaryocytes and is crucial for platelet adhesion 
at the site of vascular injury to form the first haemostatic plug20.  Endothelial cells of vWF-
deficient animals do not contain WPBs26,27. The expression of recombinant vWF in other cell 
types is enough to induce formation of  cigar-shaped WPB-like granules28, indicating that 
vWF has the intriguing property of inducing the elongated organelle in which it is stored. 
Therefore, the first step of WPB formation is vWF synthesis. Figure 1.4 summarises the 
main steps of WPB biogenesis and vWF processing. The vWF precursor is composed of a 
signal peptide followed by conserved structural domains (pre-pro-vWF). The signal peptide 
is responsible for ensuring the nascent polypeptide chain enters the endoplasmic reticulum 
(ER) where it is then cleaved and lost. Mature vWF is highly glycosylated and this process 
starts in the ER, where the pro-vWF also assembles into dimers in a “tail-to-tail” fashion by 
forming interchain disulphide bonds29. Both the N-linked glycosylation and C-terminal 
dimerization steps are required for vWF dimers to pass into the Golgi apparatus30. Within 
the trans-Golgi network (TGN), dimers of pro-vWF assemble into multimers by forming 
“head-to-head” interchain disulphide bonds and subsequently the pro-peptide is cleaved. 
Multimerization depends on the decrease in pH between the ER (pH 7.2) and TGN (pH 
6.2)30. The vWF multimers and pro-peptide condense into tubules and become incorporated 
into nascent vesicles with clathrin/AP-1 coats that protrude from the TGN29. vWF pro-
peptide is required for both multimerization of vWF and its storage into WPBs31.  There also 
exists a relationship between the multimeric state of vWF and its’ sorting to WPBs, i.e. less 
highly oligomerised vWF leaves the TGN and is constitutively secreted whilst high molecular 
weight vWF is sorted into WPBs, forming a pool of vesicles whose secretion is highly 
regulated32. Once a nascent WPB granule has left the TGN, there are still other steps through 
which it must pass before achieving maturation. One marker of maturation is acquiring the 
small GTPase Rab27a33. Rab27a is recruited after leaving the Golgi and forms part of a 
complex which anchors the WPBs to actin at the cell periphery. Moreover, with maturation, 
vWF tubules also become closer to each other and granule width decreases becoming more 
electron dense34.  
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Figure 1.4 Biogenesis of WPBs and processing of vWF.  Locations of vWF processing 
are indicated on the right and the nature of the main vWF modifications are on the left. Pre‐
pro‐vWF is synthesized at the endoplasmic reticulum (ER) where the signal peptide (green) 
is cleaved to give a precursor, pro‐vWF which is transported to the Golgi apparatus. At this 
time pro‐vWF starts to multimerize through the formation of N‐terminal disulphide bonds. 
The remodelling of the multimerizing protein into a protein tubule commences at the TGN 
where earliest-forming vWF tubules are incorporated into an immature carrier. The 
immature WPB then carries the vWF towards the cell periphery, and, during its subsequent 
maturation, the vWF continues multimerizing and forming high molecular weight multimers. 
At exocytosis, very high molecular weight vWF is released as long platelet-catching strings 
that are particularly effective in primary haemostasis. 
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1.2.2 Weibel-Palade Body cargo 
Although vWF is the primary component of the WPBs, an increasing number of additional 
proteins (Table 1.1 and Table 1.2) are known to be recruited to these organelles35, in line with 
the wide range of processes that involve WPB release such as inflammation, haemostasis, 
regulation of vascular tone and angiogenesis. 
 
Table 1.1. List of known WPB components, role and recruitment point 
WPB cargo Role Recruitment 
vWF Haemostasis TGN 
P-selectin Inflammation TGN 
Osteoprotegerin Vascular homeostasis TGN 
Angiopoietin-2 Angiogenesis TGN 
Endothelin-1 Vasoconstriction TGN 
Interleukin-8 Inflammation TGN 
Eotaxin-3 Inflammation TGN 
CD63 Membrane organisation Post-Golgi 
α 1,3-fucosyltransferase VI Inflammation TGN 
Calcitonin gene-related peptide Vasodilation TGN 
Insulin-like growth factor-
binding protein 7 
Angiogenesis To be determined 
 
Table 1.2 List of potentially novel components of WPBs36 
Accession  Description 
P11021 78 kDa glucose-regulated protein 
P02765 Alpha-2-HS-glycoprotein 
P21810 Biglycan 
P27797 Calreticulin 
P43121 MUC18 
P10909 Clusterin 
P02452 Collagen alpha-1(I) chain 
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P02461 Collagen alpha-1(III) chain 
Q12805 FIBL-3 
P14625 Endoplasmin 
Q9UNN8 Endothelial protein C receptor 
Q9Y2E5 MAN2B2 
P02751 Fibronectin 
P14616 Insulin receptor-related protein 
P08648 Integrin alpha-5 
Q86SG7 Lysozyme g-like protein 2 
P08493 Matrix Gla protein 
Q13201 Multimerin-1 
Q02818 Nucleobindin-1 
P26022 PTX3 
Q9BTY2 Alpha-L-fucosidase 
Q9Y646 Plasma glutamate carboxypeptidase 
P05121 PAI-1 
P16284 PECAM-1 
Q9Y4D7 Plexin-D1 
P30101 Protein disulphide-isomerase A3 
P13667 Protein disulphide-isomerase A4 
P07237 Protein disulphide-isomerase  
A6NEC2 Puromycin-sensitive aminopeptidase-like protein 
P50454 Serpin H1 
P09486 SPARC 
P07996 Thrombospondin-1 
Q5TIE3 Von Willebrand factor A domain-containing protein 
5B1 
Q5VU13 V-set and immunoglobulin domain-containing 
protein 8 
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Some additional components of WPBs are recruited at the TGN whereas several others are 
delivered to mature WPBs. The secretory proteins angiopoietin-2, osteoprotegerin, and the 
leukocyte adhesion receptor P-selectin, are recruited during initial organelle formation at the 
TGN.   
P-selectin is a transmembrane protein that is expressed on the endothelial cell surface upon 
activation and plays an essential role in leukocyte adhesion to the endothelium37. P-selectin 
promotes interaction of leukocytes with the endothelium and mediates the rolling of 
leukocytes over the endothelial surface leading to firm adhesion and transmigration to the 
site of inflammation. P-selectin incorporation into WPBs is directed by targeting motifs 
within the cytoplasmic tail as well as by its luminal domain which is recruited to nascent 
WPBs as it passes through the TGN and is able to interact with specific domains of vWF38. 
Deficiency of vWF disrupts the targeting of P-selectin to endothelial WPBs. Conversely, 
deficiency of P-selectin has no effect on the targeting of vWF26. Following its exposure at 
the cell surface, in response to appropriate stimulation, P-selectin is rapidly internalized and 
transported to the early and late endosomes, from where P-selectin can be recycled to the 
TGN and can be incorporated in newly forming WPBs by direct interaction with vWF32. 
Like P-selectin, osteoprotegerin appears to be incorporated into WPBs through direct 
interaction with vWF39. Thus, both P-selectin and osteoprotegerin are actively sorted into 
WPBs by virtue of their ability to interact with vWF.  
Angiopoietin-2 is an autocrine regulator of Tie-2 signalling that is markedly induced in 
endothelial cells by vascular endothelial growth factor or hypoxia40. The Ang–Tie system 
functions as a key regulator of vascular quiescence. Angiopoietin-2 is the dynamic player of 
the system and its functions are context-dependent41. Therefore, further studies will be 
needed to unravel the molecular mechanisms by which angiopoietin-2 modulates rapid 
vascular homeostatic functions and responsiveness towards different cytokines and to 
elucidate the effects of angiopoietin-2 on chronic vascular disease, most notably, 
atherosclerosis, arthritis and tumour growth. Considering that many proangiogenic factors 
have been proposed to play a role in the setting of inflammatory angiogenesis, angiopoietins 
can be considered as proinflammatory mediators contributing to initial steps of pathologic 
angiogenesis42.  Angiopoietin-2 incorporation into WPBs, probably occurring at the TGN, 
requires vWF and release of angiopoietin-2 from endothelial cells is increased in vWF-
deficient cells. It has also been suggested a direct interaction between Angiopoietin-2 and 
vWF within the Golgi body where angiopoietin-2  bound predominantly to the vWF A1 
domain43. However storage of angiopoietin-2 into WPBs occurs only into WPBs that lack 
P-selectin;  thus the storage of angiopoietin-2 and P-selectin appears to be mutually 
exclusive44. Such findings suggest a further level of complexity in the control of WPB 
biogenesis; to generate subpopulations within a cell might require sequential formation of 
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the varied organelles through control of transcription of the non-vWF cargo or by 
differential recruitment. 
Interestingly, another WPB cargo, is the potent vasoconstrictor endothelin-1 (ET-1)45. ET-1 
is generated by processing of its precursor, big ET-1, by endothelin-converting enzymes. As 
endothelin-converting enzyme 1 is also localised to the WPBs, conversion of big ET-1 into 
vasoactive ET-1 most likely occurs in WPBs. This provides a mechanism for the rapid release 
of large amounts of the vasoconstrictive ET-1 in response to vascular injury46. 
Some WPB components are recruited post-Golgi in a time or maturity-dependent manner. 
A well-established membrane protein of mature WPBs is the tetraspanin CD6347. CD63 is 
delivered to maturing WPBs in an AP-3-dependent manner via late 
endosomes/multivesicular bodies. Sorting of endosomal proteins to post–Golgi secretory 
granules is a characteristic route of lysosome-related organelles suggesting that WPBs share 
some properties with lysosome-related organelles38. The function of CD63 is unclear, but it 
is a member of the tetraspanin family. These proteins have been shown to associate with 
integrins, which play important role in leukocyte recruitment. Moreover, it has been 
demonstrated that upon activation of endothelial cells and subsequent WPB exocytosis, 
CD63 is transported to the cellular surface where it forms co-clusters with P-selectin, 
suggesting that it may play a role in early stages of the endothelial inflammatory response48. 
Several additional components are only stored in the WPBs after prolonged activation of the 
cells with inflammatory mediators. This phenomenon has been observed for the cytokines 
interleukin-8 (IL-8) and interleukin-6 (IL-6) which are only expressed in the WPBs following 
their upregulation by interleukin-1β (IL-1β)49,50. Similarly, it was observed that eotaxin-3 was 
present in the WPBs after prolonged stimulation with interleukin-451. Storage of pro-
inflammatory mediators in WPBs following upregulation of their synthesis temporarily 
provide endothelial cells with a rapidly available source of inflammatory mediators. 
Thus, endothelial cells appear to tailor WPB cargo in response to various stimuli; certain 
cargo are constitutively carried in WPBs whereas other constituents are only recruited to 
WPBs following an inflammatory stimulus. However, this is not sufficient to explain the 
coexistence of proinflammatory and prothrombotic proteins whose release could be evoked 
by functionally distinct stimuli. Interestingly, it has been suggested that subsets of granules 
can be subject to differential exocytosis and/or trafficking to tailor its response to the 
prevailing vascular condition, although the mechanism behind this differential release 
remains elusive. It is evident however that these cargos are powerful proteins that play a 
major role in vascular function. 
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1.2.3 WPB function 
The extensive list of the different biologically active compounds contained into these 
distinctively cigar-shaped granules, reflect their role in the local and systemic regulation of 
processes as diverse as haemostasis, vasomotion, inflammation and fibrinolysis, as well as 
modulating vascular permeability and angiogenic sprouting. A myriad of stimulatory 
mediators that result from injury or inflammation, such as thrombin and histamine, cause 
WPB secretion, leading to surface expression of vWF and P-selectin (Figure 1.5). Thus, the 
Weibel-Palade body is a prominent link between inflammation and thrombosis52.  
 
 
Figure 1.5 Schematic representation of WPB interplay in thrombosis and 
inflammation. On endothelial activation through vascular injury or inflammation, WPBs 
release their contents, leading to vWF and P-selectin expression. These adhesion molecules 
mediate platelets and leukocyte rolling on the vessel wall. The rolling step, mediated by P-
selectin exposure on the cell surface, is crucial for leukocyte extravasation to the site of 
inflammation and it likely helps in the formation of the platelet plug. Vascular injury 
immediately induces vWF unfurling and formation of long haemostatic strings which play a 
crucial role in the adhesion of platelets to the damaged site. The platelet plug is stabilised by 
strands of fibrin. 
 
1.2.3.1 vWF function 
vWF is an adhesive plasma glycoprotein which performs its haemostatic functions through 
binding to FVIII, to platelets surface glycoproteins, and to constituents of connective tissue. 
vWF acts as a stabilizer of FVIII in the circulation. Formation of a non-covalently bound 
vWF-FVIII complex protects FVIII from degradation by activated protein C and localises 
FVIII to sites of platelet plug and subsequent clot formation53. When FVIII is activated 
during blood coagulation, thrombin destroys the vWF binding site and releases FVIIIa. 
Following a vascular injury, vWF binds specifically to fibrillar collagen type I and III. Once 
vWF is immobilised in subendothelial connective tissue, its main function is to mediate 
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adhesive interactions of platelets exposed to rapid blood flow. Hence, highly pro-thrombotic 
ultra-large vWF released from WPBs is able to form long strings under blood flow which 
spontaneously bind the GPIb–IX–V complex on platelets, resulting in spontaneous platelet 
aggregation to the damaged site. These platelet-binding strings are likely to play a significant 
role in forming a haemostatic plug. Platelet‐bearing strings are prothrombotic, and can be 
cleaved into smaller, less prothrombotic vWF multimers by the metalloprotease ADAMTS‐
13. Haemostasis depends on the balanced participation of vWF multimers and their 
degradation by the ADAMTS-13 metalloprotease.  
The clinical significance of vWF is also discussed in the section 1.2.5 
1.2.3.2 P-selectin function 
Alongside vWF, a considerable number of inflammatory and angiogenic mediators are co-
packaged into WPBs. Their simultaneous release from this vascular emergency package will 
also direct leukocytes to sites of inflammation and promote vessel repair. The secretion of 
P-selectin from WPBs initiates the multistep process of leukocyte recruitment54. In the 
systemic microvasculature, P-selectin and E-selectin mediate the initial leukocyte capture and 
rolling along the wall of postcapillary and collecting venules. Circulating leukocytes may bind 
to the selectins expressed by activated endothelium, making the leukocyte quickly decelerate 
by rolling on endothelial cells. Leukocytes roll on stimulated endothelium and become 
activated before migrating to sites of inflammation or vascular injury. After activation, 
leukocytes firmly adhere to endothelial cells as a result of the interaction between their β2 
integrins and members of the immunoglobulin superfamily on the endothelium. The same 
types of receptors also mediate the extravasation of leukocytes. A chemotactic signal present 
outside the venule induces leukocytes to squeeze between endothelial cells of the venule and 
migrate into the inflammatory centre55.  
P-selectin expression is crucial for leukocyte extravasation, but it also supports platelets 
rolling, helping the formation of the haemostatic plug. P-selectin can signal into leukocytes 
producing procoagulant microparticles containing TF that are recruited into the growing 
thrombus, where they facilitate generation of thrombin and fibrin52.  
The physiological processes of thrombosis and inflammation greatly influence each other. 
Therefore, it is not surprising that some of the first response mechanisms, such as secretion 
of WPBs, are shared in thrombosis and inflammation. 
1.2.3.3 Additional WPB functions  
WPBs are very versatile and provide the endothelium with a first emergency kit in order to 
rapidly respond to changes in its microenvironment. For instance, in case of vascular injury 
in addition to vWF and P-selectin, WPBs also release ET-1 which induces vasoconstriction 
to prevent unnecessary loss of blood components56. Angiopoietin-2 which is upregulated 
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following angiogenic activation is also readily released from WPBs destabilising endothelial 
cells by acting as a functional antagonist of Ang-1/Tie-2 system41. Following inflammation, 
some chemokine like IL-8 or eotaxin-3 can be also released from WPBs to support 
recruitment and migration of leukocytes.  
Given WPB role in thrombosis and inflammation to maintain vascular haemostasis, learning 
how to control WPB trafficking and release will, inevitably, have important consequences 
for therapeutic interventions.  
 
1.2.4 Mechanisms of WPB exocytosis 
vWF is a large multifunctional glycoprotein, synthesised and secreted by endothelial cells, 
that is central to haemostasis, thrombosis and vascular inflammation. vWF provides a sticky 
platform that captures all the important components which contribute to these vascular 
processes. Following its journey through the biosynthesis and maturation process, vWF finds 
a critical crossroad at the trans-Golgi network: here, vWF is either packaged into nascent 
WPBs, distinctive regulated secretory organelles, or is secreted directly through the 
“constitutive” secretory pathway. WPBs store vWF for “regulated” secretion upon 
endothelial activation, but they can also fuse and release vWF in the absence of activation, a 
process termed “basal” secretion to distinguish it from “constitutive” secretion57. Therefore, 
vWF secretion from endothelial cells occurs via three main routes: constitutive secretion and 
basal secretion, both of which occur in the absence of stimulation, and regulated secretion 
of WPBs in response to stimuli (Figure 1.6). The degree of vWF multimerization is the first 
well recognised difference between the constitutive and basal/stimulated secretion pathways. 
While constitutively secreted vWF is composed of mainly low-molecular weight (LMW)-
vWF multimers, basally secreted vWF, originating from WPB in the absence of stimuli, is 
composed of mostly ultra large (UL)-vWF multimers together with a prominent dimer band; 
and regulated vWF release is exclusively composed of UL-vWF multimers58. The multimeric 
form of secreted vWF largely dictates its haemostatic efficacy, as UL-vWF multimers have a 
much higher binding affinity for platelets. The secretion of such functionally distinct pools 
of vWF also differ in polarity of release58. Release from the constitutive pathway, is mainly 
directed to the basolateral side of endothelial cells and is mostly composed of LMW-vWF 
multimers. Basal vWF release from WPBs, occurs mostly toward the apical side of 
endothelial cells, with a small amount secreted basolaterally, and is composed of UL-vWF 
multimers which mediates platelet adhesion when the matrix is exposed following damage 
to the vessel wall. Regulated release, originating from WPBs after a secretagogue stimulant, 
occurs predominantly to the apical side of endothelial cells, with some release to the 
basolateral side, and is exclusively composed of UL-vWF multimers. Highly multimerized 
vWF, released into the vascular lumen, unfurl and assemble into large strings providing a 
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spiderweb-like network that function as adhesive platform for circulating platelets initiating 
a haemostatic event59. 
 
 
Figure 1.6 Various pathways of vWF secretion from endothelial cells. vWF secretion 
occurs via three pathways: (i) constitutive secretion of low molecular weight vWF, which is 
primarily released at the basolateral side of the endothelium; and (ii) basal and (iii) regulated 
secretion of high molecular weight vWF from WPBs, which is primarily directed towards the 
apical surface. From the large number of WPBs that undergo exocytosis upon stimulated 
release, UL-vWF multimers are released and assemble into vWF strings on the apical side of 
the endothelium. 
 
1.2.4.1 Stimuli and signalling  
The endothelium receives multiple stimuli: from surrounding cell types; from molecules and 
cells in the blood stream60; and from shear force61. Such signals may be pro-inflammatory, 
pro-angiogenic, pro-thrombotic and fibrinolytic. After maturation WPBs become responsive 
to a large number of these signals, termed secretagogues (Table 1.3). These agonists which 
trigger WPB secretion can be divided into two distinct groups, those that act by elevating 
intracellular Ca2+ levels and those that act by raising cAMP levels in the cell56.  
 
Table 1.3. Agonists of regulated WPB exocytosis 
Secretagogue Mediator 
Thrombin Ca2+ 
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Histamine Ca2+ 
VEGF Ca2+ 
Complement Ca2+ 
Sphingosine-1 phosphate Ca2+ 
Superoxide anion Ca2+ 
Ceramide Ca2+ 
Purine nucleotides Ca2+ / cAMP 
Epinephrine cAMP 
Vasopressin cAMP 
Serotonin cAMP 
 
Distinct sets of stimuli exist that induce WPB release through different pathways. As part of 
an integrated response to vascular injury, Ca2+-mediated secretagogues such as histamine and 
thrombin locally promote a proinflammatory or prothrombotic state (respectively) by 
immediately causing release of vWF and other WPB constituents (P-selectin, etc.), while 
simultaneously increasing endothelial permeability and vascular tone. In contrast, cAMP-
mediated stimuli such as epinephrine and vasopressin act systemically, increasing endothelial 
barrier function and inducing a slow but sustained release of WPBs56.  
The acute release of intracellularly stored factors in WPBs, achieved by secretagogues such 
as histamine and thrombin through intracellular Ca2+ release, is one of the main mechanisms 
controlling homeostasis in the vascular system. Histamine and thrombin use both distinct 
and common signalling circuits to converge at the same effector pathways which control 
differential WPB release in line with the appropriate physiological need. In case of vascular 
damage, thrombin binds a G-protein coupled protease-activated receptor (PAR1) and 
induces activation of phosphatidylinositol pathway, resulting in a rise of cytoplasmic Ca2+. 
Ca2+ in complex with calmodulin62 binds the small GTP-binding protein Ral which induces 
cytoskeleton rearrangements that precede the rapid and local exocytosis of most of the WPBs 
present in the cell63. 
Acute inflammatory processes can also challenge endothelial cells triggering rapid WPB 
exocytosis via activation of specific signalling pathways. Histamine is a potent pro-
inflammatory mediators which induces WPB release that operates to elevate intracellular free 
calcium ion concentration ([Ca2+]i) through a G-protein–phospholipase C coupled H1 
receptor and production of the second messenger inositol trisphosphate (IP3)64,65. 
Combination of transient increase of Ca2+ (with formation of Ca2+-calmodulin complex) and 
activation of RHO pathway leads to increase myosin light chain (MLC) phosphorylation. 
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Phosphorylated MLC initiates contraction of actin filaments opening small gaps between 
adjacent endothelial cells to recruit plasma proteins. The activation of MLC in endothelial 
cells, in addition to causing plasma protein leakage, initiates the exocytosis of WPBs, bringing 
P‑selectin to the luminal cell surface66. Interestingly, exocytosis of vWF induced by histamine 
is also dependent on nicotinic acid adenine dinucleotide phosphate (NAADP) signalling 
which evokes Ca2+ release from both acidic organelles and ER67. Therefore, the rise in 
intracellular Ca2+ in endothelial cells has a major role in leukocyte recruitment by the display 
of P-selectin on the endothelial luminal plasma membrane however this must be temporally 
and spatially controlled in order to achieve stimuli-specific responses.  
The contents of WPBs are released into the circulation (e.g. angiopoietin-2) or exposed at 
the plasma membrane (e.g. P-selectin) in response to distinct physiological conditions. 
Different modes of exocytosis may enable the release of subsets of molecules from WPBs 
in response to diverse stimuli29. For example, WPBs can undergo transient fusion with the 
plasma membrane forming a small pore which acts as a molecular filter. During this 
“lingering kiss” small pro-inflammatory cargos such as IL-8 and eotaxin-3 are released 
whereas vWF is retained. In contrast, multigranular exocytosis has been proposed to be a 
significant mode of exocytosis in which WPBs coalesce into a “secretory pod” before fusing 
with the plasma membrane via a large pore. The formation of secretory pods may facilitate 
vWF string formation by accumulating the content of multiple WPBs before release of vWF 
long strings responsible for platelet recruitment.  However, exocytosis of single WPBs may 
prevail when the release of other WPB constituents is required, such as the exposure of P-
selectin to initiate leukocyte binding. Thus, different modes of regulating WPB secretion at 
the plasma membrane may provide a mechanism for selective release of WPB components 
in a stimulus-dependent manner (Figure 1.7).  
The data suggests that release of cargo from WPBs is tightly controlled by either integration 
of distinct signalling pathways activated by different WPB-agonists or by the endothelial cells 
exocytotic machinery. To date, there has been no evidence of differential trafficking of 
subpopulations of WPBs, which could tailor the response in time and space. 
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Figure 1.7 Schematic representation of different regulated WPB exocytosis. Lingering-
kiss exocytosis is shown, where single WPBs fuse with the plasma membrane via a small 
fusion pore. Because of the small size of the fusion pore, larger cargo proteins such as P-
selectin and vWF are retained, whereas the smaller cargo are released. “Conventional” full-
fusion exocytosis in which single WPBs fuse with the plasma membrane, thereby releasing 
their cargo. The actin ring boost the release of vWF. Multigranular exocytosis where WPBs 
coalesce into large intracellular membrane vesicles, termed secretory pods, prior to 
exocytosis. The secretory pods then fuse with the plasma membrane and release vWF strings 
via a large pore. 
 
 
1.2.4.2 Exocytotic machinery 
Exocytosis of WPBs involves a series of discrete stages: loading of cargo into the nascent 
granule, granule budding, targeting of the granule to the endothelial membrane, priming of 
the granule, fusion of the granule and plasma membranes, and, finally, granule recycling.  
Several super families of proteins control these stages: N-ethylmaleimide-sensitive factor 
(NSF), soluble NSF receptor (SNARE) proteins, Sec1/Munc18 proteins, and Rab proteins68. 
After emerging from the TGN, in a maturation-dependent manner, WPBs recruit several 
GTPases of the Rab family (discussed later), including Rab27a, several Rab3 isoforms and 
Rab15. These Rabs are responsible for the subsequent recruitment of effector proteins to 
WPBs that correlate with the acquisition of secretion competence and enable redistribution 
of WPBs population to the cell periphery via interaction with the cytoskeleton and/or plasma 
membrane. 
Rab27a was the first WPB-associated Rab identified in endothelial cells. Rab27a is recruited 
to WPBs in a content-driven, maturation-dependent mechanism33. Acquisition of Rab27a 
allows mature WPBs to interact with MyRIP (Rab27a specific effector) and myosin Va 
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(MyoVa);  together these proteins anchor WPBs to cortical actin at the cell periphery69,70. The 
actin cytoskeleton plays opposing roles in the release of WPBs. On the one hand, it is 
necessary for peripheral distribution of WPBs, which is important for a ready releasable pool 
and depends on myosin IIa. On the other hand, anchoring WPBs to cortical actin at the 
TGN inhibits release of immature WPBs, allowing full multimerization to be completed 
before vWF exocytosis. The role of this tripartite complex (Rab27a-MyoVa-MyRIP) in WPB 
anchoring to actin filaments has been investigated in several studies70,71; inhibition of any 
member of this complex results in increased vWF secretion and a redistribution of WPBs 
from a peripheral to a more perinuclear localization.  
It is noteworthy that Rab27a is involved in more than one stage of secretion, acting in 
different ways on each occasion. Munc13-4 and synaptotagmin-like protein 4-a (Slp4a) are 
other two important effectors of Rab27a which promote exocytosis by tethering and docking 
WPBs to release sites on the plasma membrane, which contain the annexin A2–S100A10 
complex72,73. The Rab27A–Slp4-a complex docks WPBs and also forms the link between the 
WPB and the SNARE complex by recruitment of syntaxin-binding protein 1 (STXBP1)74. 
Balance between the negative and positive effectors recruited by Rab27a and cooperation 
with other Rab proteins like Rab15 and Rab3d, will determine the probability of WPB release 
allowing endothelial cells to fine-tune its secretory response. 
It has also been suggested that Rab3d has a role in biogenesis of WPBs75. Overexpression of 
an active variant of Rab3d resulted in bigger and more spherical WPBs. However, 
overexpression of an inactive variant of Rab3d resulted in the absence of WPBs suggesting 
its role in biogenesis and regulation of granule size. 
In the final phase of exocytosis, the WPB fuses with the plasma membrane; this process is 
catalysed by a complex of SNARE proteins that are positioned on the two opposing 
membranes: the target membrane (plasma membrane) and the vesicle membrane (WPB)59. 
VAMP3 on WPBs has been shown to form a complex with the plasma membrane t-SNARE 
proteins syntaxin 4 and SNAP23 in endothelial cells which is responsible for membrane 
fusion during WPB exocytosis. Other regulatory molecules such as synaptotagmin isoforms, 
Sec/Munc proteins, or syntaxin‐binding proteins could interact with these SNARE 
members, further modulating exocytosis. Once the membrane has fused, there may be a 
further role for actin in expelling the vWF contents. An actomyosin ring has been proposed 
to form and localise to WPBs during exocytosis and help 'push' the vWF out into the 
extracellular environment76. 
A novel addition to the list of Rab proteins participating in the maturation and/or evoked 
exocytosis of WPBs is Rab3577. Rab35 activity is known in the endosomal system, however 
Bieseman et al., identified Rab35 and some potential downstream effectors as novel 
regulators of WPBs exocytosis and proposed a model where histamine-evoked WPB release 
is supported by Rab35 at the level of the plasma membrane. Rab35 depletion significantly 
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interfered with histamine evoked vWF secretion. Thus, Rab35 is another positive regulator 
of WPB exocytosis. Future experiments will be required to reveal whether Rab35 shares 
some effectors and cooperates with any of the other Rabs in the course of WPB exocytosis. 
Based on the Rab35 activity in the endosomal recycling system, it also remains possible that 
it acts indirectly by enhancing the recycling of components of the WPB fusion machinery 
(e.g. plasma membrane-resident SNAREs) back to the plasma membrane. Table 1.4 
summarises all the components participating to WPB exocytosis. 
Although many of these proteins operating on the fusion machinery represent the core of 
WPB exocytosis, these are only the skeleton of the complex process of regulated WPB 
secretion; how they interact with each other, what other components are involved and how 
they interact with the signalling pathways arising on endothelial activation are questions that 
are still to be addressed.  
 
Table 1.4. List of WPB exocytotic machinery 
WPB exocytotic machinery 
GTPases 
Rab27a 
Rab3b-d 
Rab15 
Rab35 
RalA 
Rap1 
RhoA 
Rac1 
GTPases-binding proteins 
MyRIP 
Slp4-a 
MyoVa 
RalGDS 
Epac 
P115RhoGEF 
SNAREs 
VAMP3 
VAMP8 
Syntaxin-4 
SNAP23 
SNAREs-interacting 
proteins 
Munc18-c 
Munc13-4 
Syntaxin-binding protein 1 
Syntaxin-binding protein 5 
Others 
Annexin A2 S100A10 
Phospholipase D 
Zyxin 
Alpha-actinin 
 
1.2.5 Clinical importance of vWF 
In 1926, Dr Erik von Willebrand, a Finnish physician, described an inherited bleeding 
disorder in the families in Aland Islands with features that suggested that this was distinct 
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from haemophilia. In contrast to haemophilia, both sexes were affected and a prolonged 
bleeding time with a normal platelet count was the most important abnormality78. It was not 
until 1971 that it was understood that the deficiency of a new factor, called von Willebrand 
factor (vWF) and different from FVIII, was actually responsible for the initially called 
“hereditary pseudo-haemophilia” disorder which was then renamed Von Willebrand’s 
disease (VWD)79.  
Von Willebrand’s disease is the most common inherited bleeding disorder and has an 
autosomal inheritance pattern80. The disease is characterized by defective platelet adhesion 
and aggregation with mainly mucosa-associated bleeding and bleeding after surgery and 
trauma. The diagnosis is based on a personal or family history of bleeding and laboratory 
evidence of abnormalities in vWF, factor VIII, or both. Affected patients have reduced levels 
of functional vWF, and various types of VWD can be distinguished on the basis of 
phenotypic characteristics. VWD is subdivided into types 1, 2, and 3.  
o Type 1, which accounts for 70 to 80% of cases, is characterised by a quantitative 
deficiency of vWF.  
o Type 2, accounting for approximately 20% of cases, is caused by dysfunctional vWF. 
This qualitative deficiency in vWF levels can be further subdivided into 4 sub-types:  
- Type 2A; decreased platelets adhesion due to selective absence of the largest, 
most biologically active multimers. 
- Type 2B; increased affinity for GpIbα leads to increased platelet binding and   
subsequent clearance of vWF. 
- Type 2M; decreased affinity for GpIbα leading to present but ineffective 
vWF. 
- Type 2N; decreased affinity for Factor VIII leading to present but ineffective 
vWF. 
o Type 3 is rare (accounting for <5% of cases), is the most severe form, and is caused 
by the total loss of circulating vWF. In 80% of the patients the genetic defects in the 
vWF gene are null alleles, explaining the complete absence of vWF. 
Even though many mutations causing type 1 VWD have been identified, no mutations are 
found in approximately 30% of patients. Genetic modifiers outside the vWF gene and 
physiological factors, such as age or pregnancy, probably play a role in reducing vWF levels. 
Genome wide association studies have identified several other genetic loci that are associated 
with vWF levels, including the ABO locus and loci involved in clearance or exocytosis of 
vWF (STX2 and STXBP5-components of the SNARE machinery)81. These newly recognised 
genetic loci may explain the variability in the VWD phenotypes. 
A complication in VWD patients (5-20%), which arise from perturbated WPB release is 
angiodysplasia that causes recurrent gastrointestinal bleeding through small vascular 
malformations in the gut. The absence of storage compartment, such as in type 3 VWD, 
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leads to a dysregulated release of a number of angiogenic mediators, such as angiopoietin-2. 
Absence of WPBs induces constitutively release of angiopoietin-2 promoting pathological 
angiogenesis82.  
An interesting finding in two recent studies is that the risks of cardiovascular disease and 
ischaemic stroke are reduced among patients with VWD83. vWF deficiency is associated with 
decreased prevalence of arterial thrombosis among VWD patients and may provide 
protection against cardiovascular events. 
In contrast, several studies have associated elevated levels of vWF with prevalence of 
cardiovascular disease (CVD), including coronary artery disease, myocardial infarction (MI), 
and ischemic stroke83. Almost all acute coronary syndromes result from thrombus formation 
in pre-existing atherosclerosis. As a result of plaque rupture and exposure of prothrombotic 
subendothelial matrix, local thrombus formation occurs, which subsequently leads to 
coronary artery occlusion and acute myocardial infarction (AMI). Several studies have shown 
the colocalisation of vWF with platelet thrombi, tissue factor, and platelets with fibrin in 
fresh coronary thrombi of patients with MI. Furthermore, the presence of vWF at sites of 
high shear, e.g, at the sites of lesions in the coronary arteries has been shown to play a pivotal 
role in enhanced platelet aggregation in patients with AMI compared with control plasma84. 
Interestingly, certain rare diseases, such as thrombotic–thrombocytopenic purpura (TTP), 
provide significant indirect evidence of a pathogenic role of vWF in AMI85. TTP is a rare 
disease caused by a decreased activity of metalloprotease ADAMTS13 and an accumulation 
of unusually large multimers of vWF. Pronounced rise in circulating UL-vWF which 
spontaneously binds to platelets to form large aggregates, is associated with tissue ischaemia 
and myocardial infarction. These various lines of evidence support the hypothesis that vWF 
is not merely a prognostic marker for presence of CVD and for outcome in AMI but rather 
directly involved pathogenically as a causative agent84. 
The relationship between altered biogenesis and secretion of WPBs and disease is quite direct 
in the case of VWD. However, changes in the quantity and quality of WPB exocytosis 
influence the plasma level of vWF and other prothrombotic and proinflammatory mediators, 
which in turn contribute to the pathophysiology of cardiovascular disorders. Therefore, 
advances in understanding the biogenesis and secretion of WPBs will help to identify 
additional targets for therapeutic intervention in a variety of haematologic and cardiovascular 
disorders. 
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1.3 Rab GTPases 
Rab proteins are small GTP-binding proteins that form the largest family within the Ras 
superfamily. Ras superfamily contains five major kinds of small GTPases including Ras, Rho, 
Ran, Rab and Arf86. The GTPase proteins of each subfamily have similar structures, 
sequences and functions. However, different family proteins play multiple and divergent 
roles. The Ras family members mainly regulate signalling transduction, gene expression, cell 
proliferation and differentiation. The Rho family members mainly regulate cytoskeletal 
organisation but also have an effect on gene expression. The Sar/Arf family control vesicle 
budding whereas the Ran family regulate nuclear transport as well as microtubule 
organisation during mitosis. The Rab (Ras-related in brain) GTPase family consist of 
essential regulators of vesicular trafficking. 
It has been 30 years since the yeast Ypt1 and Sec4 and the mammalian Rab GTPase were 
first identified as evolutionarily conserved, essential regulators of membrane trafficking87,88. 
Rab GTPase in mammalian cells were first identified by Touchot and colleagues in 198789. 
By screening a rat cDNA library, they identified four genes encoding proteins homologous 
to the yeast YPT proteins; these genes were named Rab (Ras-like GTPase from rat brain)-
1,-2,-3,-4. To date, more than 60 members of the Rab family have been identified in humans 
that are involved in regulating various stages of intracellular trafficking and exquisitely 
localised to specific intracellular membranes where they recruit a cohort of effectors to carry 
out their function90. 
 
1.3.1 Rab GTPase structure 
A common structural design and shared molecular mechanism distinguish proteins in the 
GTPase superfamily91. Each protein in the family is a precise molecular switch that can be 
turned ON by binding guanosine triphosphate (GTP) and back OFF by hydrolysing GTP to 
guanosine diphosphate (GDP). This versatile switch enables the transduction of different 
signals. All Ras GTPases have a GTPase domain consisting of 5 regions (G1‐G5) critical in 
GDP/GTP exchange, conserved throughout all GTP‐binding proteins and comprised of 6 
β‐sheet strands flanked by five α‐helices. The C-terminal of the GTPase fold consist of the 
hypervariable region (35-40 amino acids) followed by the prenylation motif that normally 
contains two cysteine residues available for geranylgeranylation; a crucial lipid modification 
that allows membrane association of Rab GTPases. Additionally, Pereira-Leal and Seabra 
performed bioinformatic analysis and identified additional features that distinguishes Rabs 
from other members of the Ras superfamily92. They identified five conserved motifs, the Rab 
Family (RabF) motifs 1‐5. RabF1 is in the Switch I domain and RabF2, RabF3, RabF4 and 
RabF5 motifs are in the Switch II domain. The analysis also led to the identification of Rab 
subfamily-conserved sequences, named SF1– 4, that allowed for grouping of Rabs into 
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various subfamilies and were predicted to define the sites of interactions with their respective 
effectors (Figure 1.8). 
Because of the overall structural conservation, the differences between the active and inactive 
states must define the regions that determine the specific functions of each Rab. The switch 
I and II regions of Rabs are the primary determinants of nucleotide-dependent Rab function 
as both switch regions interact with the γ phosphate of GTP. When GDP-bound, the switch 
regions tend to be disordered and undergo major changes to adopt a structurally well-ordered 
conformation upon binding GTP, allowing effectors binding93. 
 
 
 
Figure 1.8 Sequence and structural mapping of characteristic segments of Rab 
proteins. All Rab proteins share a common structural fold, which is composed of five α-
helices and six β-strands connected by ten loops. Rab family-specific (RabF1-RabF5) 
sequence segments that are distinct for Rab GTPases and distinguish them from other small 
GTPases of the Ras superfamily (Pereira-Leal and Seabra, 2001) are mapped onto the crystal 
structure of the Rab5A GTPase from H. sapiens in an active conformation (Terzyan et al., 
2004) (displayed in orange-red). The nucleotide is shown in purple. The Switch I and II 
regions, which undergo large nucleotide dependent conformational transitions, are labelled. 
Adapted from Stein et al., Plos One (2012)94 
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1.3.2 Rab GTPase cycle 
Rab proteins cycle between the cytosol and the respective target membrane, acting as 
molecular switches that alternate between two conformational states: the GTP-bound “ON” 
form and the GDP-bound “OFF” form95. Figure 1.9 shows a schematic representation of 
Rab GTPase cycle. The newly synthesised Rab protein is recognised by a Rab escort protein 
(REP) that directs the Rab to a geranylgeranyl transferase (RabGTT) that catalyses the 
addition of one or, in most cases, two geranylgeranyl lipid groups to the COOH terminus of 
the Rab  in order to be able to bind to its target membrane. Next, REP delivers the Rab, in 
the GDP-bound form, to its target membrane. The nucleotide-bound state of the Rab 
influences its localisation and activity. Conversion of GDP-bound Rab into its GTP-bound 
form occurs through the exchange of GDP to GTP which is catalysed by a guanine 
nucleotide exchange factor (GEF). The high cytosolic concentration of GTP (~1 mM) 
ensures that GTP binds as soon as GDP has been released. The active Rab now interacts 
with effector proteins that specifically facilitate traffic in its respective pathway. The Rab is 
then converted back to its inactive state by a GTPase accelerating protein (GAP) binding to 
the Rab to catalyse hydrolysis of the bound GTP to GDP. The inactive Rab is then a 
substrate for a GDP dissociation inhibitor (GDI), which is able to extract the Rab in its 
GDP-bound conformation from the membrane and sequestered it in the cytosol. The Rab, 
bound to GDI, is now ready to be reinserted into a membrane and begin the cycle again. Re‐
delivery of Rab GTPase to a membrane requires displacement of Rab-GDI and this is 
proposed to be mediated by a GDI‐displacement factor (GDF)93. 
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Figure 1.9 The Rab GTPase cycle.  Newly synthesized Rab protein associates with Rab 
escort protein (REP) that present the Rab to the enzyme (RabGTT) that catalyses the 
addition of lipid tails. REP then delivers the Rab, in its GDP-bound state, to its target 
membrane where it can anchor to membranes via this geranyl-geranyl-group at the C-
terminus. The membrane-bound GDI displacement factors (GDF) regulate the targeting of 
Rab-GDI complex to specific membranes. A guanine nucleotide exchange factor (GEF) 
catalyses exchange of GDP for GTP. The GTP-bound Rab (with its cargo) interacts with 
different effector proteins. Hydrolysis of GTP to GDP is then mediated by GTPase 
activating protein (GAP).  The Rab then is removed from the membrane by guanine 
nucleotide dissociation inhibitor (GDI) in preparation for the next cycle.  In the cytosol, 
GDIs bind already geranylgeranylated, GDP-bound Rab proteins and thereby control the 
membrane cycle of Rabs. 
 
 
1.3.3 Rab GTPase regulation 
Despite the very similar overall structure characterising the members of the small Rab 
GTPase family, the proteins that interact with them, to either regulate their activity or carry 
out their downstream functions, are very distinct. 
 
1.3.3.1 GDI and REP 
GDI and REP proteins are crucial for the molecular function of Rabs. Although both REP 
and GDI are members of the GDI superfamily, they play different roles in the life cycle of a 
Rab protein93.  REP associates with RabGGT to facilitate the addition of geranylgeranyl lipid 
moieties to the COOH termini of Rabs while GDI extracts inactive, prenylated Rabs from 
membranes. The structures of Rab-GDI and Rab-REP show that both Rab-REP and Rab-
- 30 - 
 
GDI contain a two-site interface with Rab GTPases where one domain recognises the GDP-
bound Rab and the other domain interacts with Rabs geranylgeranylated C-terminus. Thus, 
they are structurally similar and related in function by their affinity for the GDP-bound form 
of Rabs. However, REP binds with high affinity to the GDP-bound Rab protein either 
prenylated or unprenylated, while GDI binds tightly to the Rab with its prenyl groups and 
binds poorly to the unprenylated Rab protein. The interaction of REP with unprenylated 
Rabs is consistent with its role in facilitating Rab prenylation by RabGGT, while the main 
function of GDI is to extract prenylated Rabs from membranes as part of the Rab cycle. The 
exact mechanism of Rab GTPase extraction from membranes by RabGDI has not been 
elucidated. However, the very high affinity of RabGDI for prenylated Rab GTPases indicates 
that another factor must facilitate RabGDI displacement and return of Rab GTPases to the 
membrane. This has led to the proposal that GDFs assist the correct membrane targeting of 
RabGDI complexed Rab GTPases. 
1.3.3.2 GAP proteins 
Small GTPases have a low intrinsic GTPase activity with the half-life of the active state being 
of the order of 30 min to several hours96. Therefore, to be turned off in a significant 
physiologically timeframe, additional proteins termed GTPase activating proteins (GAP) 
need to bind to the small GTPases and stimulate the hydrolysis. All characterised Rab GAP 
proteins to date contain a conserved TBC (Tre2/Bub2/Cdc16) domain that confers GAP 
activity97. The crystal structure of the catalytic TBC domain of a GAP in complex with a Rab 
GTPase shows that two conserved Arg and Gln ‘finger’ residues accelerate the catalytic 
activity of the Rab GTPase by stabilising the β-phosphate of GTP so that γ-phosphate of 
GTP easily hydrolyse and dissociate from Rab98. 
1.3.3.3 GEF proteins 
The rate-limiting step in GTPases activation is the exchange of bound GDP for GTP. 
Although GDP‐dissociation can occur intrinsically, this process is relatively slow and in cells 
is accelerated by Rab GEFs. GEFs catalyse the dissociation of the nucleotide from the G 
protein by modifying the nucleotide-binding site, in order to weaken the nucleotide affinity, 
thus, the nucleotide is released and subsequently replaced. In general, the affinity of the G 
protein for GTP and GDP is similar, however the resulting increase in GTP-bound over 
GDP-bound is due to the approximately ten times higher cellular concentration of GTP 
compared to GDP99. Unlike Rab GAP proteins, there are no clear motifs that define Rab 
GEF proteins. However, the structures of several GEF proteins indicate that they directly 
interact with the switch I domain, inducing a large conformational change which alters the 
Rab nucleotide or magnesium-binding site to cause displacement of the bound nucleotide. 
Rab GEFs can be subdivided into at least four types for their various functional domains100. 
The first large family of Rab GEFs identified were Vps9-domain containing proteins (at least 
9 members in humans) that are specific toward Rab5 family members and act in early 
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endocytic trafficking. The second large family of Rab GEFs, with 18 members in humans, 
are DENN domain GEFs, acting on several different Rab proteins. Besides these two major 
families of related Rab GEFs, several other proteins have been shown to possess GEF 
activity, including multi-subunit complexes such as the TRAPP I and II complexes (GEFs 
for Rab1 and Ypt31/32, respectively), the Mon1/Ccz1 complex (GEF for Rab7/Ypt7). 
Furthermore, several GEFs may act on a particular Rab protein with each GEF responding 
to distinct upstream stimuli, providing multiple avenues for signal regulation. 
Additionally, it has been shown that GEFs (together with other factors) play a major role in 
recruitment of Rabs to certain sites within cells. A Rab GEF cascade has been proposed for 
the class C vacuole protein-sorting/homotypic fusion and protein-sorting (VPS/HOPS) 
complex, an established GEF for Rab7, required for Rab5-to-Rab7 conversion within the 
transition from early to late endosomes101. The significance of Rab GEFs for correct Rab 
membrane targeting has also been demonstrated with Rab27A and its GEF Rab3 GEP 
involved in recruitment to melanocytes as well as with membrane recruitment of Rab5 by 
Rabex-5 GEF activity102. Therefore, Rab GEFs are also essential components for specific 
spatial and temporal recruitment of cognate Rab proteins. 
 
1.3.4 Function of Rab GTPase in membrane trafficking 
Different Rab GTPases regulate distinct stages in intracellular trafficking from vesicle 
formation at the donor membrane, trafficking along the cytoskeleton to vesicle fusion at the 
acceptor membrane (Figure 1.10). Rab proteins regulate their respective pathways by 
interacting with various effector proteins. Effectors are generally defined as proteins that 
preferentially interact with the GTP-bound form of their respective Rab. The role of Rab 
proteins is to recruit effectors such as motor proteins and tethering factors to facilitate 
downstream membrane traffic events. 
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Figure 1.10 Rab GTPase function in vesicles trafficking. Rab GTPases and its effectors 
can regulate distinct membrane trafficking steps. a) Rab GTPase can recruit sorting adaptors 
to sort receptors into budding vesicles. b) Following budding of vesicles from donor 
membranes, the coat is shed to allow the vesicles to fuse with their target membrane. c) Rab 
GTPases can mediate transport along microtubules, using motor proteins, and actin 
filaments. d) Rab GTPases can mediate membrane tethering by recruitment of tethering 
factors which can also interact with and regulate SNARE complex formation and subsequent 
fusion. e) Following membrane fusion the Rab GTPase is inactivated by Rab GAP, removed 
from the membrane by Rab GDI and recycled. Subsequent re‐insertion into the membrane 
is mediated by GDI‐displacement factor (GDF) and Rab GTPase is GTP‐loaded by Rab 
GEF.  
 
1.3.4.1 Cargo sorting 
Cargo selection into specific transport vesicles is a fundamental mechanism in intracellular 
trafficking. Central to the appropriate sorting of cargo is the recruitment of cytosolic coat 
complexes which specifically associate with distinct cargos95. In addition to the cargo itself, 
several other determinants, including membrane curvature, lipid composition and Rab 
GTPases, contribute to ensuring specific coat recruitment to distinct intracellular 
membranes. An example of a Rab GTPase involved in cargo-specific coat assembly is the 
late endosomal Rab9, which regulates membrane recycling of mannose-6-phosphate 
receptors (M6PRs) from late endosomes to the TGN. The cytosolic tail of M6PRs is 
recognised by the sorting adaptor TIP47, an effector of Rab9. The interaction of Rab9 with 
TIP47 enhances the interaction between the mannose-6-phosphate receptor and TIP47 
during the formation of the transport vesicle and maintains the recycling of M6PRs from the 
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late endosome to the TGN103. Similarly, the cargo‐selective subcomplex of retromer, which 
transports protein back to the TGN, has been shown to be recruited to late endosomes by 
Rab7104. Another Rab GTPase that is important for cargo sequestration is Rab5 which 
mediates assembly of clathrin-coated pits at the plasma membrane and clathrin-mediated 
endocytosis of transferrin receptors105. The emerging picture is that some Rab GTPases 
control several key events in vesicle budding from donor membranes, including coat 
assembly, cargo selection and physical budding. 
1.3.4.2 Vesicle uncoating 
Following budding of vesicles from donor membranes, the coat is shed to allow the vesicles 
to fuse with their target membrane. In addition to playing a role in coat formation, Rabs may 
also play a role in uncoating. A well-studied example is the clathrin coat and its cargo adaptor 
protein complex AP2 on endocytic vesicles, whose removal has proved crucial for proper 
membrane trafficking.  Clathrin-coated vesicles contain Rab5, and a recent study has shown 
that this GTPase and its GEF coordinate AP2 uncoating by promoting dephosphorylation 
of μ2 subunit and increasing PtdIns(4,5)P2 turnover
106. 
1.3.4.3 Vesicle motility 
Both the microtubule network and the actin filaments make essential contributions to local 
and long-range intracellular vesicle and organelle motility. Microtubules serve as tracks for 
transport via the motor protein dynein, which is implicated in retrograde motility, and kinesin 
which mediates movement towards the cell surface. Actin contributes to vesicle motility in 
distinct ways, for example functioning as a track for the myosin family of motor proteins. 
Attachment of motor protein to vesicles requires high specificity and there are several 
examples in which Rab GTPases and their effectors proofread these types of interactions107. 
A well-studied example involves Rab27a, which forms a complex with the motor Myosin‐
Va (MyoVa) and the adaptor protein, melanophilin, which is important for the peripheral 
actin association of melanosomes, lysosome related organelles108. MyoVa then shuttles these 
Rab27a positive vesicles towards the cell periphery, which is crucial for the proper 
functioning of melanocytes. A second Rab27a effector, MyRIP also recruits MyoVa forming 
a ternary complex in endothelial cells which is involved in linking WPB to the peripheral 
actin cytoskeleton70. Other examples include Rab8, Rab10 and Rab11, which can associate 
with MyoVa isoforms and transport cargo to the plasma membrane109–111. 
While actin is mostly involved in short-range movements of different vesicles, microtubules 
are mainly responsible for long-range anterograde and retrograde trafficking. Both types of 
microtubule-dependent motors are regulated by Rab GTPases. Kinesins can be direct 
effectors of Rab GTPases as first demonstrated by Echard et al., who described direct 
interaction between Rab6a and KIF20a (kinesin-6 subunit) required for correct cytokinesis112. 
However, published data from the literature indicate that Rab proteins more frequently 
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associate with their kinesin motors via adaptor/linker proteins that simultaneously bind the 
Rab and the kinesin motor107. For example, Rab27a and Rab27b regulate axonal transport of 
neurotrophin receptor-containing vesicles by association with KIF5/KLC1 (kinesin-1 
subunit) via two linker proteins, Slp1 (synaptotagmin-like protein-1) and CRMP-2 (collapsin 
response mediator protein-2)113. Molecular links with cytoplasmic dynein-1 complexes and 
members of the Rab6 subfamily are the most understood. Rab6a and Rab6b all directly bind 
the cytoplasmic dynein-1 Roadblock LC1 subunit and Rab6A also can associate with 
cytoplasmic dynein-1 via binding the dynactin p50/dynamitin and p150glued subunits114. 
Alternatively, indirect associations with dynein motors has been shown for the late 
endosomal Rab7115. The Rab7 effector Rab-interacting lysosomal protein (RILP) mediates 
minus-end-directed trafficking of late endosomes by recruiting a subunit of the dynactin 
complex, which is associated with dynein. Likewise, the Rab6 effector bicaudal D1 mediates 
attachment of Golgi vesicles to the dynein–dynactin complex in Golgi-to-ER transport. 
Another recent example is Rab11a which controls trafficking of recycling endosomes 
processes by linking to the cytoplasmic dynein-1 LIC1 and LIC2 subunits via the Rab11 
effector protein FIP3116. The multiple ways by which Rab GTPases associate with motor 
proteins probably reflect the important role these proteins have in attaching the right 
transport vesicle to the right motor. 
1.3.4.4 Vesicle tethering 
To ensure fidelity of transport, most membrane transport pathways require factors that 
“tether” the vesicles to the target membrane before they fuse117. These tethering factors fall 
into two categories: long coiled-coil tethers or multiprotein complexes. Members of both 
categories of tethers are Rab effectors. Thus, Rab GTPases mediate vesicle tethering by 
recruiting rod-shaped tethering factors that interact with molecules in the acceptor 
membrane. Such factors might interact with SNAREs and their regulators to regulate 
SNARE-mediated fusion of their respective vesicles to the target membrane.  
An example of coiled-coil tether protein is the early endosome antigen 1 (EEA1), an effector 
of Rab5 involved in tethering and homotypic fusion of early endosomes. In particular, 
formation of EEA1 homodimers tethers two Rab5 vesicles together, promoting homo‐
fusion118. Additionally, a number of Rab27a effectors have been implicated in vesicle docking 
of exocytic dense-core vesicles to the plasma membrane in a variety of cell types. Specifically, 
granuphilin tethers Rab27a‐positive vesicles at the plasma membrane before fusion through 
its interaction with the SNARE component syntaxin‐1 in a Munc18‐1 dependent or 
independent manner119,120.  Similarly, rabphilin3a, a Rab27a and Rab3a effector, binds 
SNAP25, another SNARE component, docking vesicle to the plasma membrane before 
fusion121. Furthermore, additional Rab27a effectors, as already mentioned, are responsible to 
tether WPBs to the actin cytoskeleton or to the SNARE protein before fusion with the 
plasma membrane (section 1.2.4.2). 
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1.3.4.5 Vesicle fusion 
The final step of vesicular transport is fusion with the acceptor membrane. Vesicle fusion 
occurs following the formation of a SNARE complex. Interactions between SNAREs on the 
target membrane (t-SNARE) and vesicle (v-SNARE) promote fusion by pulling the 
membranes together. Rab proteins also regulate the SNARE-dependent fusion of transport 
and target membranes. Rabs can either interact directly with SNARE proteins or with 
proteins that regulate SNARE function to perform this regulatory function122. On Rab5 
vesicles, EEA1 and rabenosyn-5 are Rab5 effectors that interact with the SNARE protein 
syntaxin-6 and the SNARE regulator protein VPS45, respectively123,124. Importantly, the 
reconstitution of Rab5-mediated fusion of proteoliposomes, supplemented with specific 
SNAREs and Rab5 effectors, has recently been achieved and directly demonstrates the 
coordination of SNARE-mediated fusion by a Rab and its effectors. As mentioned in 
previous section, Rab27a effector also bind to SNARE proteins (syntaxin‐1 and SNAP25) 
but how these interactions regulate fusion is still unclear125. Specificity of membrane fusion 
is determined by selection among the many SNARE and proteins which assist assembly of 
the SNARE-complex. For example, fusion of WPBs with the plasma membrane upon 
stimulation is highly regulated by the activation of the effector RalA. RalA mediates assembly 
of the exocyst complex and activation of phospholipase D1 inducing accumulation of 
fusogenic lipids that facilitate fusion of WPBs after the Munc18c-assisted assembly of the 
SNARE-complex29. 
 
1.3.5 Localisation of Rab GTPases in the cells 
The ability of Rab GTPases to tightly regulate membrane traffic is in part achieved by the 
specificity of their association with distinct intracellular membranes. Within cells, they are 
localised to the cytosolic face of distinct intracellular membranes. Zerial and coworkers were 
the first to provide evidence that each membrane compartment in the cytoplasm is likely to 
be decorated with distinct Rab proteins126. This was an incredibly important finding because 
Rabs became the first true molecular markers for different membrane compartments of the 
endocytic and secretory pathways. 
Rab GTPases are reversibly associated with membranes through the post-translation 
addition of two hydrophobic geranylgeranyl groups to two carboxy-terminal cysteine 
residues, and this is intrinsic to their role in regulating membrane traffic. The C-terminal 
hypervariable region has long been proposed to contain the targeting information required 
to direct Rab GTPases to their correct membrane; however, this domain is required but not 
sufficient for correct targeting of Rab proteins to their specific locations in the cell127,128. In 
most cases this membrane association is tightly linked with GTP loading and activation of 
Rab GTPase to stabilise Rab GTPase on the membrane. This ensures strict temporal and 
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spatial regulation of effector recruitment. The mechanism by which precise Rab GTPase 
targeting is achieved is yet to be elucidated.  
Each Rab protein is localized to the cytoplasmic surface of a distinct membrane bound 
organelle and appears to control a specific membrane transport pathway90. Some Rabs are 
expressed ubiquitously in human tissues, whereas others are more tissue-specific129. For 
example, Rab3A is a member of Rab protein family that is exclusively associated with the 
synaptic vesicle of neurons130, Rab17 is expressed in epithelial cells with Rab13 which 
regulates assembly of tight junctions,131 while Rab27a has been found to be predominantly 
expressed in hemopoietic cell lineages132. Rab18 is associated with lipid droplets with a role 
in releasing lipids in adipocytes133 whereas, active Rab32 is involved for the fission of 
mitochondria134. Rab12 is involved to transport from peripheral region of cell to perinuclear 
centrosomes to associate with centrosomes and maintains its integrity135. Rab proteins are 
present on all compartments of the endomembrane system (ER, Golgi, endosomes, 
lysosomes), the nucleus, the plasma membrane (including cell junctions and focal adhesions), 
mitochondria and centrioles. The sub-cellular localisation of Rab proteins defines the 
pathway that they regulate95,126. Several reviews summarise the relationship between Rab 
localisation and function. Stenmark (2009) described Rab GTPases as coordinators of a wide 
range of vesicles transport reactions (summarised in the Figure 1.11). For example, Rab1 and 
Rab2 are localized at the ER regulating ER-Golgi trafficking while the Golgi-localized Rab6, 
Rab33 and Rab40 mediate intra-Golgi trafficking. Rab8 mediates constitutive biosynthetic 
trafficking from the TGN to the plasma membrane and also participates in GLUT4 vesicle 
translocation (with Rab10 and Rab14) and ciliogenesis (with Rab17 and Rab23). Rab5, which 
is localised to early endosomes, phagosomes, caveosomes and the plasma membrane, 
mediates endocytosis and endosome fusion of clathrin-coated vesicles (CCVs), 
micropinocytosis (with Rab34 which also mediate lysosomes positioning) and maturation of 
early phagosomes (with Rab14 and Rab22). Rab21 mediates integrin endocytosis. Rab11 and 
Rab35 mediate slow endocytic recycling through recycling endosomes, whereas Rab4 
mediates fast endocytic recycling directly from early endosomes. Rab15 is involved in the 
trafficking from early endosomes to recycling endosomes and in the trafficking from apical 
recycling endosomes to the basolateral plasma membrane. Transport from early endosomes 
and late endosomes is mediated by Rab7 which mediates maturation of late endosomes and 
phagosomes, and their fusion with lysosomes. Another late endosomal GTPase, Rab9, 
mediates trafficking from late endosomes to the TGN. Secretory granules and vesicles are 
transported from TGN to apico-lateral membranes by Rab3, Rab26, Rab27, Rab37, and 
Rab38.  Rab27 also mediates the translocation of melanosomes and WPBs to the cell 
periphery. Rab32 and Rab38 are involved in the biogenesis of melanosomes. In this way, Rab 
GTPases regulate plasma membrane delivery, organelle biogenesis and degradative pathways 
(lysosomal and autophagic). 
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Characterisation of around half of the known Rab GTPases, highlighting the diversity of Rab 
proteins and their effectors, has revealed the extraordinary complexity of membrane 
trafficking circuits that are controlled by multiple Rab GTPases. Therefore, they truly deserve 
the name of “master regulator of membrane trafficking”136. 
 
 
Figure 1.11 Localisation and function of Rab GTPases. Schematic representation of a 
generic cell with its vesicle transport pathways. The localisation of selected mammalian Rab 
proteins in the membrane compartments participating in these transport processes is 
indicated. All of the organelles involved in biosynthetic/secretory and endocytic pathways 
carry at least one Rab protein on their cytoplasmic face. 
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1.3.6 Rab GTPases in endothelial cells 
A number of small GTP-binding proteins of the Rab subfamily which mediate vesicular 
transport along the secretory pathway have been found in endothelial cells. An early report 
in 1992 described for the first time the molecular cloning of an isoform of Rab5 from 
endothelial cells137. Subsequent studies about Rab proteins established the localisation of 
Rab1, Rab2, Rab3b, Rab4, Rab6, Rab7, Rab8, Rab9, Rab11, Rab13, Rab15, Rab22b, Rab30 
in endothelial cells138,139 (Table 1.5). Most of these Rabs are ubiquitously expressed and 
localise to specific endosomal structures which have been shown to have a conserved role in 
the endocytic and exocytic pathways in different cell types. For example, the small GTPase 
Rab5 has been well defined to control the vesicle-mediated plasma membrane protein 
transport to the endosomal compartment. Rab5, in endothelial cells, is involved in integrin 
endocytosis controlling cell adhesion as well as in the internalisation of vascular endothelial 
(VE)-cadherin, an important component of adherens junctions regulating the endothelial cell 
polarity and barrier function140. Furthermore, the small GTPases Rab4, Rab5, and 
Rab11 regulate the internalisation and intracellular trafficking of the endothelial cell protein 
C receptor (EPCR) and internalised FVIIa at different stages in endothelial cells141. A Rab-
dependent mechanism, involving Rab5a and Rab7a for regulating VEGFR2 trafficking and 
signalling toward early and late endosomes has also been proposed as specific regulator of 
endothelial cells migration142. 
The Rab27 and Rab3 subfamilies are specialised Rab GTPases for regulated secretion in a 
variety of cells. In endothelial cells, as mentioned previously (section 1.2.4.2), Rab27a has a 
central role in maturation and secretion of WPBs. Rab27a was the first WPB-associated Rab 
protein to be identified and Hannah et al., showed that this Rab is recruited to and regulates 
the peripheral distribution and secretion of WPB, ensuring it only occurs once the cargo 
VWF is fully multimerised. As all Rabs act through their effectors, Nightingale et al., 
described several of the Rab27 effectors expressed in Human Umbilical Vein Endothelial 
Cells (HUVECs), including myosin and Rab27a‐interacting protein (MyRIP), granuphilin 
(Slp4a), Slp3, Noc2, Munc13‐4, and Slp2a. They are all part of the exocytotic machinery 
which support appropriate WPBs exocytosis upon stimulation (section 1.2.4.2). 
The other Rabs associated with WPBs described by Bierings et al are Rab3D and Rab3B 
(representing 5% and 95% of expressed Rab3 isoforms, respectively), which indirectly 
regulate WPB exocytosis. A set of data from Zografou et al143 significantly complicates this 
picture as they reported three more Rab GTPases, Rab15, Rab33a and Rab37 targeted to 
WPBs. However, among these, only Rab15 has a functional role in WPB secretion.  More 
recently, a new study identified Rab35 and some potential downstream effectors as novel 
regulators WPBs exocytosis. 
This very large collection of Rabs is consistent with the notion that they play more than one 
role in endothelial cell secretion. However, the individual contribution of different Rab 
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GTPase as well as their cooperation and competition in regulation of endocytic and secretory 
pathways in endothelial cells is still an open and challenging area of research.  
 
Table 1.5. Rab GTPases identified in endothelial cells. 
Rab protein Localization/Function 
Rab1 Ubiquitously expressed, Golgi-ER trafficking  
Rab2 Ubiquitously expressed, Golgi-ER trafficking 
Rab3b-d WPBs, biogenesis and exocytosis 
Rab4 EPCR trafficking 
Rab5 
Early endosomes, integrin endocytosis, VE-cadherin 
internalization, EPCR and VEGFR2 trafficking 
Rab6 Golgi, post-Golgi vesicle trafficking 
Rab7 Late endosomes, VEGFR2 trafficking 
Rab8 Golgi, cell motility 
Rab9 VE-cadherin internalization 
Rab11 Recycling endosomes, EPCR trafficking 
Rab13 Autophagy 
Rab15 WPBs, exocytosis 
Rab22b Ubiquitously expressed 
Rab27 WPBs, maturation and exocytosis 
Rab30 Golgi, unknown function 
Rab33a WPBs, unknown function 
Rab35 WPBs, exocytosis 
Rab37 WPBs, unknown function 
 
 
1.3.7 Rab related diseases 
Considering the physiological importance of Rab GTPases in many cellular functions, it is 
not surprising that a number of human diseases can be associated with Rab GTPases and 
their regulators or effectors. Rab proteins work together with their effectors, coordinate the 
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dynamics of trafficking pathway and determine the cargo proteins’ destination in cells. 
Aberrant Rab GTPase functions caused by mutations or post-translational modifications will 
disrupt the regulatory network of vesicle trafficking, which have implications in many human 
diseases ranging from neurological disorders to cancer.  
There are a number of inherited Rab‐related disorders which have contributed to the 
understanding of the physiological function of Rab GTPases and their effectors. A summary 
of the various monogenic diseases caused by Rab proteins or Rab-associated proteins are 
listed in Table 1.6. 
 
Table 1.6. Inherited diseases caused by Rab proteins or Rab-associated proteins. 
Disease Rab protein/Rab 
associated  protein 
Description 
Griscelli syndrome 
type I 
Myo5a144 
Autosomal recessive, albinism, 
neurological impairment 
Griscelli syndrome 
type II 
Rab27a145 
Autosomal recessive, albinism, 
hemophagocytic syndrome 
Griscelli syndrome 
type III 
MLPH146 Autosomal recessive, albinism 
Choroideremia REP1147 X-linked, progressive loss of vision 
Non-specific mental 
retardation 
GDI1148 
X-linked, affected males show moderate 
to severe mental retardation 
Charcot-Marie-Tooth 
disease type IIb 
Rab7a149 
Autosomal dominant, peripheral 
sensory neuropathy 
Warburg Micro 
syndrome 
Rab3GAP1150 
Autosomal recessive, 
neurodevelopment defects 
 
In addition to mutations in Rabs and Rab-interacting proteins, increased or decreased Rab 
expression or activity is associated with diseases like cancer and neurological diseases such 
as Alzheimer's151, Huntington’s disease152 and Parkinson153.  
Membrane traffic plays a significant role in cancer biology, primarily in the loss of cell polarity 
and in the metastatic transformation of tumour cells154. Unlike Ras, no activating mutations 
in Rab GTPases have been found in any cancers thus far. However, most Rabs show altered 
expression levels in various types of cancers155. Many Rab GTPases have been proposed to 
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be involved in the progression of multiple cancer types156,157. Furthermore, Rab protein 
overexpression also increases the resistance of carcinogenic cells to chemotherapy158.  
There is also evidence that alterations in Rab function play an important role in the 
progression of multifactorial human diseases, such as infectious diseases (with role in 
counteracting bacterial159 and viral infections160) and type 2 diabetes. Abnormal trafficking of 
the insulin-sensitive glucose transporter 4 (GLUT4) has been described in patients with type 
2 diabetes. GLUT4 accumulates in the dense membrane compartments, suggesting that 
defects in membrane trafficking may be involved in insulin resistance161. Rab4 has been 
found to be implicated in GLUT4 biogenesis, sorting and movement but more studies are 
needed to define the exact role of this and other Rabs and Rab-associated proteins in GLUT4 
trafficking162.  
Recently, upregulation of several Rab family members has been shown  in a model of cardiac 
failure with specific increased myocardial Rab1a expression that can be profoundly 
deleterious to the heart163. 
 
In summary, Rab GTPases and associated regulatory factors are frequent targets of 
mutations which may cause altered expression and/or regulation in a variety of human 
diseases. In most cases, however, the cause-effect relationship in the pathogenesis is unclear, 
which opens new avenues for further research in the field. 
Although, it is of significant interest to consider the therapeutic potential of modulating Rab 
protein function, two main points have to be first considered164. The first issue is the 
requirement for cell- or tissue-specific targeting. This is an important consideration for 
ubiquitous Rab proteins, which may exhibit altered function only in distinct tissues as well 
as for Rab proteins expressed in a tissue-specific manner. The second issue pertains to 
transient versus a more permanent modulation of expression. For example, in the treatment 
of some cancers it may be sufficient to transiently downregulate Rab protein expression, 
while in the case of genetic loss of function diseases, it will be crucial to have sustained and 
permanent reconstitution of protein function. Finally, it is important to consider therapeutic 
interventions that can restore Rab protein function, as well as those that can block function, 
when the trafficking of specific cargo may need to be modulated. Rab proteins may be 
regulated at the level of expression or activation. Changes in expression or activation to 
restore normal function may be achieved either by gene therapy or by modulating specific 
signalling pathways via small molecule intervention. Due to the lack of clear binding pockets 
in the active conformation of small GTPases, the use of small molecules has been recently 
developed to modulate the activity of the small GTPase. To improve the therapeutic efficacy 
of inhibitors of small GTPases, new approaches have been developed by using different 
strategies (Figure 1.12), for example by targeting GEF and/or GAP proteins which can 
specifically modulate “oncogenic” GTPase proteins99. However, the generation of these 
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inhibitors is a challenging goal due to the fine regulatory roles assigned to each of the 
members of the small GTPases protein family. Most of the new drugs that hamper these 
strategies have only been proven successful in in vitro studies, while demonstrating some 
limitations at the in vivo model and clinical trial stages due to compensatory mechanisms that 
mask the effect of the inhibitor. Therefore, more studies are required to further validate 
GEFs and GAPs as therapeutic targets and to further evaluate the capability of these small 
molecules to specific achieved the desired GTPase modulation. 
 
Figure 1.12 New strategies to target small GTPases. Those include generation of new 
molecules that function as inhibitor of GEF-GTPase interaction or impair nucleotide 
attachment and small molecules that can enhance GAP activity. Given that most of small 
GTPases need to be attached to the organelle membrane to exert their actions, the 
development of novel molecules with the ability to abolish this binding has arisen recently 
as an innovative strategy to inhibit these molecules. Finally, the development of some drugs 
that interfere with effector binding could also be great to inhibit small GTPases. Adapted 
from Prieto-Dominguez et al., Cells Review (2019)165. 
 
 
Therefore, in-depth understanding of the molecular mechanisms of Rab proteins function 
and characterisation of Rab-interacting proteins will undoubtedly provide crucial insights 
into disease processes and it will ultimately lead to greater success in directing endocytosed 
drugs to their desired cellular and intracellular targets, geared toward restoring normal 
function or modulating pathways central to normal physiology. 
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1.4 CRACR2A-L: a new large Rab GTPase 
Most Rab proteins are 20–25 kDa, comprising primarily of a GTPase domain86. Recently a 
new putative Rab protein (CRACR2A-L: calcium-release-activated calcium (CRAC) 
regulator 2A) has been discovered in endothelial cells166 and in both human and murine T-
cells167. It is considered to be a non-canonical Rab protein as it has a molecular mass of 95 
kDa, larger than most of the other Rabs, due to the presence of additional Ca2+ sensing and 
coiled-coil domains. Structurally this new Rab is similar in size to Rab44 and Rab45, which 
have predicted masses of 108 and 83 kDa respectively. They all contain two EF hands at 
their N-termini, a mid-region containing a coil-coiled domain and a Rab domain at their C-
termini.  
Currently, Rab44 has only been investigated in one study which shows Rab44 localisation in 
the Golgi complex and lysosomes and suggests its role in regulation of osteoclast 
differentiation by modulating Ca2+ influx168.  
Shintani et al169 provide an initial characterisation of Rab45 as a self-interacting protein 
localized in the perinuclear area of Hela cells and a following linkage study identifies Rab45 
as a potential tumour-suppressor gene in uveal and cutaneous melanoma170. Moreover, 
investigating the signalling pathway of chronic myelogenous leukaemia, Nakamura and 
colleagues171 identified a role of Rab45 in mediating p-38 activation in apoptosis of chronic 
myeloid leukaemia progenitor cells. 
Human CRACR2A (alternatively EFCAB4B) gene encodes two transcriptional isoforms, 
CRACR2A-a (herein CRACR2A-L, NM_001144958.1) a long isoform with a predicted 
molecular weight of 95 kDa and CRACR2A-c (CRACR2A-S, NM_032680.3) a short isoform 
with a predicted mass of 46 kDa (Figure 1.13).  
The short isoform CRACR2A-S, which commonly exists in both human and mouse genome 
was previously identified to facilitate calcium-release-activated calcium (CRAC) channel 
function by stabilising Orai1-STIM1 interaction172. In particular, the Ca2+ release activated 
channel regulator 2A (CRACR2A), is Ca2+- binding protein that is reported to play a key role 
in store-operated Ca2+ entry (SOCE). In T-cells CRACR2A acts as a cytoplasmic Ca2+-sensor 
by regulating CRAC channel activation. It facilitates the clustering of Orai1 and STIM1 at 
the junctional regions between the plasma membrane and the ER at low intracellular Ca2+ 
concentration. This clustering facilitates the activity of CRAC channels, allowing entry of 
Ca2+ into the cells and thus increasing intracellular Ca2+ levels. Subsequent dissociation of 
Orai1 and STIM1 is then mediated by Ca2+ binding to CRACR2A and destabilising the 
ORAI1-STIM1 complex, preventing Ca2+ overload. Structurally, the short isoform contains 
two EF-hands and a coil-coiled domain and share 52% of similarity with the longer isoform 
which was first identified in endothelial cells by Wilson et al166 and next by Srikanth et al167 
in T-cells.  
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Figure 1.13 Schematic representation of CRACR2A-S (short isoform) and CRACR2A-
L (long isoform). Alternative splicing of EFCAB4B gene generates: i) a short isoform (45 
kDa) characterised by two EF-hands Ca2+-sensing domain and a coiled-coil domain; ii) a long 
isoform (95 kDa) characterised by an addition Rab domain at C-terminal.  
 
 
1.4.1 CRACR2A-L in endothelial cells 
CRACR2A protein, as mentioned previously, was initially described in T-cells as an EF-hand-
containing modulator of CRAC channels. Investigating CRACR2A in endothelial cells, 
Wilson et al., found no function of CRACR2A in endothelial cells. Unexpectedly, anti-
CRACR2A antibody failed to detect protein of 45 kDa, which is the expected mass of 
CRACR2A. However, a band around 95 kDa was labelled by the antibody. Moreover, short 
interfering RNA designed to deplete CRACR2A had no effect on SOCE in endothelial cells 
but reduced the abundance of a protein with about twice the mass of CRACR2A (Figure 
1.14).  To obtain an explanation for the larger mass, reference to genome sequence databases 
indicated that the gene encoding CRACR2A, EFCAB4B, is predicted to be alternatively 
spliced to give two variants: the short (CRACR2A) and long (CRACR2A-L) variants with a 
C-terminal Rab GTPase extension.  Full-length cloning demonstrated for the first time the 
expression of the long variant, designated as CRACR2A-L, in endothelial cells. Sequence 
analysis and construction of a dendrogram suggested CRACR2A-L to be a previously 
unrecognised member of the Rab GTPase family which is an EF-hand-containing Rab 
protein that lacks impact on CRAC channels. Therefore, CRACR2A-L was proposed as a 
novel protein with potential to couple changes in cytosolic Ca2+ to cellular trafficking events, 
thereby impacting endothelial cells responses. 
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Figure 1.14 CRACR2A expression in endothelial cells. (a) Western blot showing 
detection of long (L) but not short (S) CRACR2A in endothelial cells. (b) No effect of 
CRACR2A siRNA on CRAC channels in endothelial cells. TG: thapsigargin. From Wilson 
et al., BBRC (2015)166 
 
  
1.4.2 CRACR2A-L in T-cells 
Srikanth et al., validated the presence of CRACR2A-L in both human and murine immune 
cells and examined its functions compared to the short isoform167. Based on the amino acid 
sequence, CRACR2A-L contains a Rab domain with a predicted prenylation site at the C-
terminal in addition to the N-terminal domains shared with the short isoform (Figure 1.13).  
The Rab domain contains a characteristic P-loop, switch I and II regions of small G proteins. 
The P-loop and switch I region make contact with the γ-phosphate of GTP via Mg2+ ions 
while the switch II region plays a major role in hydrolysis of GTP by interaction with 
phosphates and water molecules. In this study they also proved the functional activity of the 
GTPase domain by showing the ability of WT CRACR2A-L to hydrolyse GTP. In contrast 
the nucleotide binding mutants (T559, Q604, and N658) showed a pronounced reduction in 
GTPase activity possibly due to defects in GTP binding (T559N and N658I) and hydrolysis 
(Q604L). Moreover, the amino acid sequence of the GTPase domain showed high similarity 
to that of Rab GTPases and three-dimensional homology modelling of the high-resolution 
crystal structure of Rab3a mapped to CRACR2A-L showed almost complete overlap (Figure 
1.15). 
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Figure 1.15 Homology modelling of CRACR2A-a GTPase domain (yellow) with 
Rab3a (red).  A zoomed-in view of the GPPNHP binding site (right). GPPNHP and side-
chains of residues important for GTP binding and hydrolysis, Thr559, Gln604 and Asn658 
are shown in stick representation. From Srikanth et al., Sci Signal. (2016)167 
 
 
In resting T-cells, CRACR2A-L is localised to the TGN and both C-terminal prenylation and 
GTP binding determine its localisation. Upon TCR stimulation, CRACR2A-L translocates 
via distinct subsynaptic vesicles from the Golgi to the immunological synapse (IS) where 
signalling molecules clustered to activate the Jnk pathway. Functionally, CRACR2A-L is 
necessary for both SOCE and Jnk signalling, whilst the role of the short isoform is limited 
to SOCE. Furthermore, to elucidate the mechanism of CRACR2A-L recruitment to the 
immunological synapse, Srikanth and co-worker showed that the interaction with Vav1, via 
the proline-rich domain of CRACR2A-L, is crucial for its recruitment to the IS after TCR 
stimulation. These data suggest that additional domains of CRACR2A-L are important to 
support its unique function to modulate T cell activation by bridging two important TCR 
signalling pathways: Ca2+-NFAT and Jnk. 
Recently, the role of CRACR2A-L in T-cell has been further characterised by Ron Vale’s 
group173. Based on the structural similarity between this large Rab GTPase and some well-
known dynein adaptors, they provided evidence indicating CRACR2A-L (and Rab45) as new 
adaptor proteins that activate dynein-dynactin motility. They also demonstrated that the 
dynein adaptor function of CRACR2A-L is regulated by Ca2+ in vitro, and that Ca2+ release 
after T cell activation results in up-regulation of CRACR2a–dynein–mediated trafficking. 
Consistent with Srikanth et al., they found that CRACR2a vesicles move toward the IS during 
Jurkat cell activation, likely due to the repositioning of the MTOC and the associated 
endomembrane system. However, Vale and co-workers also observed actin dependent 
formation of numerous CRACR2A-L cortical puncta at the cell membrane. During T-cell 
activation, CRACR2A-L activate the dynein-dynactin complex inducing the detachment of 
these cortical puncta (matured into endocytic vesicles) from the actin cortex and initiate 
- 47 - 
 
microtubule retrograde transport towards the MTOC. Thus, the study provides the first 
evidence about the novel Rab GTPase CRACR2A-L acting as dynein adaptor and mediating 
Ca2+-regulated endocytic trafficking in T-cells.  
 
1.4.3 CRACR2A-L associated diseases 
Various small G proteins of the Ras superfamily are known to play an important role in 
proximal TCR signalling with some Rab proteins involved in secretion of cytokines and 
chemokines174 and transport regulation of immune receptors175. The evidence of CRACR2A-
L function in activation of the vav1/Jnk signalling pathway necessary for secretion upon T-
cell activation suggested a potential contribution of CRACR2A-L to physiological and 
pathological mechanisms of immune cell related inflammatory diseases.  
A genome-wide association study (GWAS) study using histological data, revealed 
associations between a SNP in CRACR2A gene (EFCAB4B) and lobular inflammation 
evident in non-alcoholic fatty liver disease (NAFLD)176. As a previous GWAS study also 
showed EFCAB4B association with hypertension177, it may explain the genetic bases of co-
occurrence of hypertension among individuals with NAFLD. Interestingly, a recent study178 
identified EFCAB4B gene as a novel candidate gene involved in pulmonary arterial 
hypertension, a rare and severe disease affecting small pulmonary arteries and caused by 
abnormal proliferation of their smooth muscle cells and endothelial cells leading to an 
increase in pulmonary vascular resistance and heart failure. Consistent with Srikanth et al., 
EFCAB4B (CRACR2A) is highly expressed in the lung and the study from Barozzi et al178, 
suggested that disruptive variants at EFCAB4B gene could interfere with Ca2+ homeostasis 
of smooth muscle cells and/or endothelial cells in which intracellular levels are finely 
regulated to control vascular tone.  
Moreover, five single CRACR2A (EFCAB4B) nucleotide variations have been associated 
with rheumatoid arthritis, a complex autoimmune disease mediated by interactions between 
genetic and environmental exposures179. Recently, another GWAS study identified 
associations between variants in CRACR2A (EFCAB4B) gene and the chronic periodontitis 
suggesting a possible role of this gene in the inflammatory response underlying pathogenesis 
of periodontal disease180.   
Taken together these data suggest that genetic variations in CRACR2A gene may lead to the 
pro-inflammatory environment necessary for development of many human diseases which 
have a prevailing theme of chronic inflammation. Further investigations are required to 
understand the molecular mechanisms of the inflammatory response underlying these 
conditions and the role of CRACR2A-L in the onset and/or progression of these diseases. 
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1.5 Summary 
In summary, Rab proteins are implied in a variety of regulatory functions of membrane 
trafficking, protein secretion, endocytosis and vesicle trafficking. The ability of Rabs to 
perform these different tasks in a co-ordinated and regulated manner depend on their 
interaction with different Rab-associated proteins regulating Rab activation, post-
translational modification and intracellular localisation.  
The central role of these proteins has become clear during the past decade, as part of the 
progress that has been made in understanding in detail the mechanistic principles of 
intracellular transport, vesicle formation, movement, and fusion. Acting from organelle 
formation to exocytosis, Rab proteins have been reported as essential components of the 
endothelial exocytotic machinery which regulates WPB secretion. Multiple layers of this 
cellular machinery act together at different stages, leading to differential release of cargo from 
WPBs. Therefore, a highly regulated secretory system controls the on-demand release of 
WPB content allowing differentiated endothelial cell responses. However, a fully and detailed 
picture of how such a complex process acts in an integrated and physiologically responsive 
way still need to be drawn. 
Recently, the identification of a novel large G protein, CRACR2A-L in both endothelial cells 
and T-cells reveals novel functions of Rab GTPases. Unlike the canonical role of small Rab 
GTPases, CRACR2A-L contains multiple functional domains and plays an unexpected role 
in regulating intracellular signalling pathways important for T-cell activation.  
The expression of this large GTPase in endothelial cells suggests it could couple Ca2+ 
signalling events to cellular trafficking of specific endothelial secretory granules which 
respond to changes in intracellular Ca2+; thus, contributing to the molecular mechanisms 
which control the broad range of endothelial cell functions.  
Identification of CRACR2A-L as an EF-hand-containing Rab protein led to the addition of 
a new Rab family member. Therefore, hereafter, I will refer to the long CRACR2A-L isoform 
as Rab46 to distinguish from the short non-Rab isoform: CRACR2A.  
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1.6 Aims and Objectives  
 
Aim 
Rab46 may play a role in coupling cytosolic Ca2+ elevation to protein trafficking in endothelial 
cells. The presence of an EF-hand domain raises the possibility that this Rab may be involved 
in vesicle trafficking in response to alterations in intracellular [Ca2+], thus making it a potential 
candidate in regulation of WPB trafficking and vWF secretion. 
Understanding the function and mechanisms of this novel putative Ca2+-regulated Rab 
GTPase in physiologically relevant endothelial cells will lead to define new events in vascular 
physiology and pathologies, contributing for example to the discovery of new targets to 
manipulate WPB secretion in athero-thrombotic disease. 
 
Hypothesis 
Rab46 is a Ca2+-regulated Rab GTPase with important roles in endothelial cells that include 
regulation of WPB trafficking and secretion of vWF. 
 
Objectives 
1. Establish the cellular localisation of Rab46 in endothelial cells;  
2. Determine the role of Rab46 in stimuli-dependent WPB trafficking ; 
3. Explore the contribution of Rab46 nucleotide-binding domains to regulation of 
trafficking and localisation; 
4. Investigate the molecular machinery necessary for Rab46-dependent WPB 
trafficking;   
5. Identify Rab46 protein partners; 
6. Develop a method to investigate direct interactions; 
7. Characterise Rab46 global knock-out mice for future studies.
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Chapter 2 Material and Methods 
 
2.1 Chemicals and Reagents 
All general salts and solutions were purchased from Sigma unless otherwise stated. Other 
chemicals are summarised in Table 2.1. 
 
Table 2.1. List of reagents 
Product Solvent Stock 
Working 
concentration 
Supplier 
Thrombin H2O 1000 U/ml 2.5 U/ml Sigma 
Histamine H2O 100 mM 30 µM Sigma 
Nocodazole DMSO 50 mM 1 µM Merck Millipore 
Ciliobrevin D DMSO 50 mM 40 µM Merck Millipore 
 
2.2 Cell culture 
2.2.1 Human Umbilical Vein Endothelial Cells 
Pooled HUVECS (Human Umbilical Vein Endothelial Cells) purchased from Lonza or 
PromoCell were maintained in Endothelial Cell Basal Medium (EBM-2) supplemented with 
a bullet kit (Cell Media CC-3156 and Bullet Kit, Lonza, CC-4176). Cells were maintained at 
37°C and 5% CO2 in a humidified incubator. Cells were grown to 95% confluency before 
passage and used from passage 2 to passage 5. 
2.2.2 Human Microvascular Cardiac Endothelial cells 
Human Cardiac Microvascular Endothelial Cells (HCMEC) purchased from PromoCell were 
grown in Endothelial Cell Growth Medium MV2 (EGM MV2). HCMEC were maintained 
at 37°C and 5% CO2 in a humidified incubator and used between passage 2 and 7. 
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2.2.3 COS-7  
Cos-7 cells were purchased from the American Type Culture Collection (ATCC) and 
maintained in Dulbecco Modified Eagles Media (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS) and 100 U/ml penicillin + 100 µg/ml streptomycin. Cells were 
maintained at 37°C and 5% CO2 in a humidified incubator and used between passage 2 and 
20. 
2.2.4 Mouse Liver Endothelial Cells 
Animals were sacrificed at 12 weeks, then dissection and removal of the whole liver was 
performed. Samples placed into EBM-2 were transferred on ice to the tissue culture 
laboratory, with all subsequent steps being performed in a laminar flow hood. Mouse liver 
sinusoidal endothelial cells were isolated using an immunomagnetic separation technique. A 
whole mouse liver was added to a Petri dish containing dissociation solution consisting of 9 
ml 0.1% collagenase II, 1 ml 2.5 U ml−1 dispase, 1 μM CaCl2 and 1 μM MgCl2 in PBS solution 
and then minced with 2 scalpel blades. The tissue-dissociation mix was then transferred into 
15 ml centrifuge and incubated at 37°C for 50 mins on a MACSmix rotator. At the end of 
enzymatic digestion, the sample was passed through 100 and 40 μm cell strainers to remove 
any undigested tissue. Cells were washed twice in PEB buffer consisting of PBS, 2 mM 
EDTA and 0.5% BSA, pH 7.2. The washed pellets were resuspended in 1 ml PEB buffer 
and 30 μl CD146 microbeads (Miltenyi Biotec) and incubated at 4 °C for 15 mins with 
continuous agitation. CD146 is a specific membrane protein marker for endothelial cells and 
is highly expressed in mouse endothelial cells.  
After incubation, cell suspension was passed through an MS column, set on a magnetic stand 
and primed with 1 ml of PEB buffer. CD146 positive cells were retained in the column and 
CD146 negative cells (non-endothelial cell fraction) passed through as eluate. Columns were 
rinsed twice with PEB buffer, then removed from the magnetic stand and placed into 15 ml 
centrifuge tubes. 500 μL PEB buffer (x3) were added then the plunger from the kit was 
applied forcibly through the column to extract the endothelial cells. Samples were centrifuged 
for 5 mins at 1000 g then resuspended in 500 μL PEB buffer and applied to MiniMACS 
columns as previously described. The final endothelial samples were centrifuged at 1000 g 
for 5 mins then resuspended in EGM-2 before being plated onto 6 well plate coated with 
0.1% poly-D-Lysine. Cells were incubated in a 5 % CO2 incubator at 37°C and a full media 
change was performed 2 hours following isolation to remove cell debris, with half media 
changes every day thereafter. Purity of mLECs was assessed by phase contrast microscopy 
and CD31 immunostaining has been shown in previous papers form our lab using the same 
protocol (Rode B et al., 2017). 
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2.3 Transfection 
2.3.1 cDNA 
HUVECs were plated either into Ibidi μ-slide 8-well (7*104 cells/ml) or into a 10 cm Petri 
dish (10*105 cells/ml) and after 24 hours they were transfected using LipofectamineTM 2000. 
A 3:1 ratio between Lipofectamine and cDNA (100 ng and 6 µg respectively) was used. 1 
hour after transfection the medium was removed and fresh cell culture medium added. 
Experiments were performed 24 hours post-transfection.  
COS-7 cells were plated into a 10 cm Petri dish (2*106 cells/petri dish) and transfected after 
24 hours as described above. 
2.3.2 Short-interfering RNA (siRNA) 
HUVECs were plated in a 6-well plate (2*105 cell/well) and after 24 hours they were 
transfected using Lipofectamine 2000 with 1 ul of EFCAB4B (Rab46) siRNAs or control 
non-targeting siRNA 50 µM (final concentration of 50 nM) (Table 2.2). Per well of a 6-well 
plate: 1 μl siRNA was added to 100 μl Opti-MEM in tube 1 and 3 μl LipofectamineTM2000 
was added to 100 µl Opti-MEM in tube 2. The tubes were incubated at room temperature 
for 5 mins. After this time, 100 μl of tube 1 was added to 100 μl of tube 2 and the mixture 
was incubated at room temperature for 20 mins. The 200 μl transfection mixture was added 
to 90% confluent HUVECs/well plus 1 ml of cell culture medium. After 5 hours, the 
medium was removed and replaced with fresh cell culture medium. Experiments were 
performed 48-72 hours post transfection. Knockdown efficiency was assessed by western 
blot as described in section 2.6. 
 
Table 2.2. siRNA sequence 
siRNA target Sequence (5’-3’) Supplier 
siRNA-1 EFCAB4B GUGUGAAGGUCAAAAGAGAtt Ambion 
siRNA-2 EFCAB4B GGAGUUCACUACUGGAUUUtt Ambion 
Control siRNA UGGUUUACAUGUCGACUAA Dharmacon 
Control siRNA Unknown Ambion 
 
 
 
- 53 - 
2.4 Mutagenesis 
A site-directed mutation encoding single amino acid change (T559N) was introduced into 
the CRACR2A-L gene. Substitution of a threonine (T) residue for an asparagine (N) residue  
was generated. Mutagenic primers are shown in Table 2.3. Phusion DNA polymerase was 
used for the reaction. PCR reaction was run for 18 cycles. PCR products were treated with 
the enzyme Dpn1 (2 µl) to digest any (parental) methylated DNA strands. The mutated 
plasmid DNA was transformed in E.coli competent cells as per manufacturer’s protocol and 
isolated using the Mini-prep kit (Qiagen). The presence of each desired mutation was 
confirmed by sequencing (GENEWIZ) and results analysed with ApE software. After 
sequence analysis, Maxiprep (Qiagen) was performed as per the manufacturer’s protocol. 
 
Table 2.3. List of primer for Rab46 mutagenesis 
Mutation Primer (5’-3’) 
Rab46_T559N 
F: 5’ GGTGGGGAAGAATTCCTTCCTGAGG 3’ 
R: 5’ CCTCAGGAAGGAATTCTTCCCCACC 3’ 
 
 
 
Figure 2.1 Sequence alignment of WT-Rab46 and T559N mutant.  Highlighted ACA 
codon (blue) codes for a Threonine in WT sequence of Rab46. Site directed mutagenesis, 
highlighted in red, changed the codon to AAT coding for an Asparagine. 
 
 
2.5 Quantitative Polymerase Chain Reaction of RNA samples 
2.5.1 RNA isolation 
2.5.1.1 RNA isolation from cells 
HUVECs were grown to confluence in 6-well tissue culture plates and total RNA was 
extracted from fresh cells using high pure isolation kit (Roche) as per manufacturer’s 
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instruction. Briefly, medium was removed, the cells were washed with PBS and harvested. 
Cells pellet was resuspended in 200 μl PBS and 400 μl of lysis buffer was added. After 
vortexing, the sample was transferred to a filter tube and centrifuged. For each sample 90 μl 
of DNase incubation I and 10 μl of DNase was added to the tube and centrifuged again. 
Following three washing steps the RNA was eluted, quantified using the Nanodrop and 
stored at -80°C for later analysis. 
2.5.1.2 RNA isolation from tissues 
Samples were harvested by myself and Mrs Katarina Miteva with RNA extraction, Reverse 
Transcriptase PCR and qPCR on liver and spleen tissues performed by myself and heart and 
lung by Mrs Katarina Miteva. 
Samples were harvested from 12 weeks old mice following sacrifice by appropriate Schedule 
1 procedure. The tissues were immediately snap-frozen in liquid nitrogen. In order to process 
the samples, tissues were placed in a tube with a metal lysis bead and 1 ml Trizol Reagent 
was added to each sample. Tubes were then placed in a tissue lyser and agitated at 26 Hz for 
3 x 1 min sessions. The resultant liquid was transferred to 1.5 ml centrifuge tubes, 200 μl of 
phenol-chloroform were added and left to settle for 3 mins at room temperature, then spun 
at 12000g (4°C) for 15 mins. The supernatant (top aqueous phase) was transferred to new 
tubes and 500 μl of isopropanol were added to each tube and gently mixed before being left 
to stand for 10 mins. The samples were then spun for 15 mins at 12000g (4°C), and the 
supernatant discarded. The pellets were resuspended in 1 ml of 75% ethanol (in dH2O) 
before a further spin at 8000g (4°C) for 5min. The supernatant was removed carefully, the 
pellet dried and then 20-50 μl of RNA-free dH2O was added to each sample which were then 
stored at -80°C. RNA was quantified using a NanoDrop®.  
2.5.2 Reverse Transcriptase PCR  
Complimentary DNA (cDNA) was synthesised using a High Capacity RNA-to-cDNA RT 
kit (Applied Biosystems). 1 μg of RNA was mixed with 5 μl 2x RT buffer, 0.5 μl 20x enzyme 
mix and nuclease-free water to make a 10 μl total reaction volume. Non-reverse transcribed 
(-RT) control solutions were prepared and tested in parallel. The solutions were mixed, 
centrifuged and incubated for 1 hour at 37°C followed by 5 mins at 95°C. This produces 
cDNA that is ready for use in real-time qPCR application or short-term storage at 4°C. 
2.5.3 qPCR 
RT-qPCR was carried out using SYBR Green I (Bio-Rad) on a LightCycler (Roche). SYBR 
Green I intercalates with double stranded DNA and fluoresces when excited at 470 nm. Each 
reaction had a 10 μl total volume and contained the following components: 5 μl of 2x iTaq™ 
Universal SYBR® Green Supermix (containing antibody-mediated hot-start iTaq DNA 
polymerase, dNTPs, MgCl2, SYBR® Green I dye, enhancers and stabilizers), 0.75 μl of 
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forward primer (0.375 μM), 0.75 μl of reverse primer (0.375 μM), 1 μl cDNA and 2.5 μl 
nuclease-free water. Real-time PCR primers were designed using the Primer3-BLAST tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and the primer sequences and 
information are displayed in Table 2.4. All the primers were obtained from Invitrogen. DNA 
amplification started with 10 mins at 95°C, followed by 40 cycles with 10 seconds at 95°C 
and 60 seconds at 60°C. The relative abundance of target genes amplified by RT-qPCR were 
calculated relative to the housekeeping genes, β-actin and GAPDH. 
 
Table 2.4. RT-qPCR primers 
Target Primer sequence (5’-3’) 
h-vWF 
F: 5’ TTCCCGACAAGGTGTGTGTC 3’ 
R: 5’ GCCTTCATGCAGAACGTAAGTG 3’ 
h-Rab46 
F: 5’ GGTCATCCTTGCCTACG 3’ 
R: 5’ GCTCGCATGAGATCAAGT 3’ 
h-Rab44 
F: 5’ TCTGAGAGGAGGCCAGGTTC 3’ 
R: 5’ATTCTTCCAGCGACAGGTGG 3’ 
h-Rab45 
F: 5’ CAGCTGGTCAGGAAGTTCA 3’ 
R: 5’ GCAGTGTCACGAATGTCAGC 3’ 
h-Rab27a 
F: 5’ AGTTGATGGAGCGAACTGCT 3’ 
R: 5’ ACATGTCCTCTTCAGGAAGGTT 3’ 
h-Rab7a 
F: 5’ TTAAGCAGGAAACGGAGGTGG 3’ 
R: 5’ GGCCTACGTGTGTTCTTGGT 3’ 
m-Cracr2a 
F: 5’ CTGGAGCGACTCAATCAGAAGC 3’ 
R: 5’ GAGGCAAGCTGAGTTGGAAGAG 3’ 
m-Rab46 
F: 5’ GGGCAGCCTGTTGGAAAAGA 3’ 
R: ACTCGGTAGTCGATGCCCAC 
m-Cracr2a + mRab46 
F: 5’ GATGGACAGACTTGGAGCCC 3’ 
R: 5’ CAGCAATTTTCTTTCTGAGGGCA 3’ 
m-Rab44 
F: 5’ GCTGAGCAGACAGTGACCTC 3’ 
R: 5’ CTGAACCTGGCCTCCTCTC 3’ 
m-Rab45 F: 5’ GGAGATCTGGAGTTACGGTGA 3’ 
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R: 5’ AACACGACTAAGCAGCCACA 3’ 
 
 
2.6 Western Blot 
Cells grown in 6-well plates or 10 cm petri dishes were washed in PBS and harvested in 
respectively 70 and 300 µl of lysis buffer (NP-40 supplemented with protease and 
phosphatase inhibitor cocktail (Sigma). Lysates were centrifuged at 12000g for 10 mins at 
4°C. The supernatant containing the soluble fraction was collected and pellet containing 
nuclei and cell debris was discarded. For quantitative experiments, the protein concentration 
in each sample was measured using a Bio-Rad Assay (Bio-Rad Laboratories) as per the 
manufacturer’s protocol. Protein concentrations in each sample were estimated by 
comparison against a BSA protein standard curve.  
Equal amounts (10-20 μg) of samples were mixed with a 4x sample loading buffer and boiled 
for 5 mins at 95°C to fully denature the proteins. The protein samples were loaded alongside 
with a molecular weight ladder (Bio-Rad or HiMarkTM - ThermoFisher) either on a 4-20% 
gradient gel for protein up to 200 kDa or 7.5% SDS polyacrylamide gel (Bio-Rad) for proteins 
bigger than 200 kDa. Samples were resolved by SDS-PAGE: low voltage (70V) was applied 
until proteins migrate into the resolving gel and then higher voltage (120V) for about 1hour 
was applied to carry on the electrophoresis.  
The separated proteins in the gel were then transferred onto PVDF membranes (Millipore) 
by using wet transfer system for 50 mins at 100 V, except for high molecular weight proteins 
(such as dynein heavy chain) which were transferred for 90 mins at 90 V with ice pack to 
reduce the heating. The membrane was then incubated in 5% non-fat milk in TBS-T for 1 
hour at room temperature to block non-specific binding sites. Subsequently, membranes 
were incubated overnight at 4°C with primary antibodies (Table 2.6 primary antibodies with 
respective dilution). After three washes, 10 mins each, in TBST-T membranes were 
incubated with horse radish-peroxidase (HRP) donkey anti-mouse or rabbit secondary 
antibodies (1:5000) (Jackson ImmunoResearch) for 1 hour at room temperature in 5% milk. 
Membranes were washed 4 times with TBS-T before visualization with SuperSignal Femto 
Detection Reagents (ThermoScientific) using GeneSys software. If membranes were re-
probed, stripping buffer (RestoreTM- Stripping Buffer) was applied for 20 mins at room 
temperature and the protocol was repeated from the blocking stage. 
Data were analysed using ImageJ Fiji. Bands intensity was compared by drawing a rectangle 
around each band to generate profile plots which represent the relative intensity of the 
content of the rectangle per each lane (ex. higher peaks represent darker bands). As western 
blots will always have some background signal, so the peaks do not reach down to the 
baseline of the profile plot. Therefore, it is necessary to close off the peak, using a straight 
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line, so that the size can be measured. When each peak has been closed off at the base with 
the straight line selection tool, select the wand tool to highlight each peak and get the mean 
intensity values of each band. These values are then expressed as relative values normalized 
to a corresponding housekeeping gene (GAPDH or vinculin). 
 
Table 2.5. Western blotting solutions 
Solutions Composition 
Sample (loading) buffer 
(4x) 
200 mM Tris pH 6.8, 8% SDS, 40% glycerol, 8% 
mercaptoethanol, 0.1% bromophenol blue 
Running buffer 25 mM Tris, 192 mM glycine and 0.1% SDS, pH 8.3 
Transfer buffer 48 mM Tris, 39 mM glycine, 0.5% SDS and 20% methanol 
TBS-T 145 mM NaCl, 20 mM Tris-base, 0.5% Tween 20, pH 7.5. 
 
 
Table 2.6. Primary antibodies used for Western Blot 
Primary antibody Species Dilution Supplier Cat. # 
Anti-human vWF Mouse 1:500 DAKO MO6016 
Anti-human 
EFCAB4B 
Rabbit 1:800 Proteintech 15206-I-AP 
Anti-mouse 
EFCAB4B 
Rabbit 1:200 ThermoFisher PA5-21060 
Anti-DYNC1H1 Rabbit 1:1000 Proteintech 12345-I-AP 
Anti-vinculin Mouse 1:1000 Bio-Rad MCA465GA 
Anti-p150 Mouse 1:2000 BD Biosciences 610473 
Anti-Na+/K+-
ATPase α1 
Mouse 1:500 Santa Cruz sc-21712 
Anti-GFP Mouse 1:1000 ThermoFisher PA5-15256 
Anti-Histidine Mouse 1:1000 Bio-Rab MCA13964GA 
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2.7 Pull-down  
2.7.1 GFP-trap 
HUVECs plated in 10 cm Petri-dishes were transfected with the appropriate GFP plasmids 
for 24 hours. Cells were washed with PBS and lysed with 250 µl NP-40 lysis buffer. Lysates 
were left on ice for 20 mins and then centrifuged at 12000g for 10 mins at 4°C. The 
supernatant was then collected and the protein content was quantified using a Bio-Rad assay. 
GFP trap is a matrix coupled to agarose beads. These beads are advantageous as they avoid 
contaminations by heavy and light chain on the western blot, they have a very high affinity 
binding even to low abundant proteins and they only need a short incubation time with lysate. 
25 μl GFP-Trap bead 50% slurry (Chromotek) was used and all wash steps were performed 
with washing buffer containing 10 mM Tris/Cl pH 7.5, 150 mM NaCl and 0.5 mM EDTA. 
GFP-Trap beads were washed 3x with dilution buffer prior to addition to cell lysate. Beads 
were incubated with cell lysate at 4°C for 2 hours following another wash step (x3). To elute 
the proteins off the beads 40 μl sample buffer (Table 2.5) was added and samples were boiled 
at 95°C for 5 mins. Western blotting was used for analysis (section 2.6). 
2.7.2 His-tagged protein interaction pull-down 
Cos-7 cells were plated in a 10 cm Petri dish and transfected with WT-Rab46 cDNA. 24 
hours after transfection cells were washed with ice cold PBS and lysed with 400 μl EDTA-
free lysis buffer (BOSTER) plus protease/phosphates inhibitor cocktail EDTA-free 100x 
(ThermoFisher). Cell lysate was left on ice for 20 mins and then centrifuged at 4°C 12000 g 
for 10 mins. Supernatant was collected and protein quantified as described. 20 μg of total 
lysate was used to incubate with pre-equilibrated beads. 100 μl of His Mag Sepharose® Ni 
beads (GE Healthcare) were equilibrated with equilibration buffer containing 20 mM sodium 
phosphate, 500 mM NaCl, 20 mM imidazole. Immediately after equilibration, total lysate was 
added and incubated for 1 hour at 4˚C, rotating. The pre-cleared lysate was collected and the 
beads discarded. At this point, 10 µg of recombinant his-tagged dynein heavy chain 
(DYNC1H1-CloudClone) were mixed with the cleared lysate and incubated for 1 hour. After 
incubation, the mixture containing the complex (WT-Rab46 + His6DYNC1H1), was added 
to 100 μl of pre-equilibrated His Mag Sepharose® Ni beads and incubated for 1 hour at 4˚C, 
rotating. At this point, the his-tagged protein should be bound the Ni2+ beads, thus, the 
supernatant could be discarded and a linear gradient of imidazole (up to 90 mM) was applied 
to the beads to reduce unspecific binding. Following these washing steps, elution was 
performed with elution buffer containing 20 mM sodium phosphate, 500 mM NaCl, 500 
mM imidazole. The eluted samples were collected and analysed by western blot (2.6) 
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2.8 Immunoprecipitation 
2.8.1 Immunoprecipitation of exogenous proteins 
HUVECs were plated and transfected with cDNA in 10 cm Petri-dishes (3 per condition). 
24 hours after transfection cells were washed with ice cold PBS and lysed with 300 µl of NP-
40 lysis buffer supplemented with protease and phosphates inhibitors (Sigma). Lysate were 
left on ice for 20 mins and then centrifuged at 12000 g for 10 mins at 4°C. 20 ug of lysates 
were saved in order to be used as total input during western blot analysis and the rest 
incubated with 1 µg of anti-GFP antibody for 4 hours at 4˚C, rotating. The mixture was then 
added to pre-equilibrated Protein G-Sepharose beads (GE Healthcare) and incubated 
overnight. The next day the beads were pelleted and following removal of the supernatant, 
washed 3 times with ice-cold lysis buffer and then eluted with 20 µl of sample buffer (4x). 
The samples were boiled at 95°C for 3 mins and the immunoprecipitated fraction analysed 
by western blot. 
2.8.2 Immunoprecipitation of endogenous proteins 
HUVECs plated in 10 cm Petri-dishes were grown for 72 hours. Before harvesting, cells 
were washes with PBS and cross-linked using 1% PFA for 1 min. Thus, washed with ice cold 
PBS once and harvested with NP-40 lysis buffer. Lysates were left on ice for 20 mins and 
then centrifuged at 12000 g for 10 mins at 4°C. Supernatant was quantified (as per section 
2.6) and 0.5 mg of total lysate was used to incubate with 2 µg of respective antibody or 
control IgG from the same species of the primary antibody for 4 hours at 4°C, rotating. 40 
µl of washed Protein G-Sepharose beads were added to the lysate/antibody mix and 
incubated overnight rotating at 4°C. The following day the beads were pelleted, washed 3 
times with ice-cold lysis buffer and then eluted with 4x sample buffer. The samples were 
boiled at 95°C for 3 mins and the immunoprecipitated fraction was analysed by western blot. 
 
2.9 Immunocytochemistry 
Cells were seeded (8*104cells/ml) into Ibidi µ-slide 8 well (IbiTreat). HUVECs were grown 
for 72 hours before the experiments and the medium was changed every day. Cells, after 
treatments, were fixed with 4% paraformaldehyde (PFA) for 10 mins at room temperature, 
washed 3 times with PBS and then permeabilised with 0.1% Triton-X solution for 10 mins 
at room temperature. Cells were incubated in primary antibody (in PBS) for 1 hour followed 
by three washes in PBS and incubated with the relevant species-specific fluorescent dye-
conjugated secondary antibodies for 30 mins (see Table 2.7 and Table 2.8). Cells were washed 
three times in PBS and briefly incubated in HOECHST (nuclear stain) before being mounted 
with Ibidi mounting medium. Cells were imaged on either the DeltaVision microscope 
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(Applied Precision) or confocal microscope (Zeiss) with Airyscan system as described below. 
Images were processed using ImageJ software. 
 
Table 2.7. Primary antibodies used for immunofluorescence 
Primary antibody Species Working 
dilution 
Supplier Cat.# 
Anti-vWF Mouse 1:200 DAKO MO6016 
Anti-vWF Rabbit 1:400 DAKO A0082 
Anti-vWF Sheep 1:200 GeneTex GTX74137 
Anti-EFCA4B Rabbit 1:100 Proteintech 15206-I-AP 
Anti-pericentrin Rabbit 1:1000 Abcam ab4448  
Anti-pericentrin Mouse 1:100 Abcam ab28144 
Anti-calnexin Mouse 1:100 Santa Cruz sc-46669 
Anti-58K Golgi 
protein 
Mouse 1:100 GeneTex GTX26284 
Anti-Lamp1 Mouse 1:200 DSHB H4A3-C 
Anti-tPA Mouse 1:100 Santa Cruz sc-515562 
Anti-GM130 Mouse 1:100 BD Biosciences 51-9001978 
Anti-Rab11 Mouse 1:100 Santa Cruz sc-166912 
Anti-α-tubulin Mouse 1:200 Santa Cruz sc-32293 
 
Table 2.8. Secondary antibodies used for immunofluorescence 
Secondary antibody Species Working dilution Supplier 
Alexa Fluor 488 anti-
rabbit IgG 
Rabbit 1:300 
Jackson 
ImmunoResearch Labs 
Alexa Fluor 594 anti-
mouse IgG 
Mouse 1:300 
Jackson 
ImmunoResearch Labs 
Alexa Fluor 594 anti-
goat IgG 
Goat 1:300 
Jackson 
ImmunoResearch Labs 
Alexa Fluor 647 anti-
mouse IgG 
Mouse 1:300 
Jackson 
ImmunoResearch Labs 
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2.10 Microscopy 
2.10.1 DeltaVision 
DeltaVision is a wide field microscope that uses an iterative algorithm to restore out of focus 
light (deconvolution) from one plane of a Z stack to another. For each of the imaging 
experiments 10 focal planes at 0.2 µm per z stack were taken using a Roper CoolSNAP HQ 
CCD camera. The filter sets used were DAPI (excitation 360/40 and emission 457/50); 
FITC/GFP/Cy2 (excitation 490/20 and emission 528/38); 
TRITC/Rhodamine/Cy3/DsRed (excitation 555/28 and emission 617/73) and Cy5 
(excitation 632/22 and emission 685/40). The objectives used were 40x/1.35 oil, 60x/1.4 oil 
or 100x/1.4 oil, as stated in the figures. Image acquisition and processing was performed 
using SoftWoRx software. 
2.10.2 High-resolution  
Images were taken on an inverted confocal laser scanning microscope Zeiss LS880 with 
AiryScan system delivering a resolution of imaging beyond that of a classic confocal point 
scanning microscope as it can resolve 140 nm laterally and 400 nm axially. This improvement 
in resolution is achieved by the use of a multichannel area detector with 32 elements –each 
detector element functions as a single pinhole and allows more light to be collected (Figure 
2.2). This differs from a classical confocal microscope, which illuminates one spot on the 
sample and employs a single pinhole to reject out of focus light. Images were captured using 
a 63x/1.4 oil objective and 405 nm Diode; Argon/2 (458, 477, 488, 514 nm); HeNe 543 nm 
and HeNe 633 nm lasers. Images were taken with 2x zoom and Z-series were taken setting 
the upper and lower limit along with the optimal sectioning suggested. All the images were 
acquired and processed with Zen software. 
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Figure 2.2. Zeiss LSM880 + Airyscan Inverted Confocal Microscope. Microscope and 
Zen software used for image acquisition with beam path Airyscan diagram. Light from 
samples is projected onto 32 channel GaAsP detector and the hexagonal design (5) allows to 
detect the Airy orders in one snap without losing any signal. A better signal-to-noise, 
resolution and speed is achieved. 
 
2.11 Image analysis 
Maximum intensity projections and 3D surface rendering images performed using 
DeltaVision Softworx or Zeiss Zen accordingly and analysed in ImageJ Fiji. In ImageJ the 
channels were split, then vWF and Rab46 channels subjected to background subtraction 
depending of the noise level. The noise estimated using a region of interest in the background 
for measurement and the mean subtracted to the entire image. Pixels whose intensity values 
are similar to the background were replaced with the mean background intensity value.  
2.11.1 WPBs counting  
For WPBs counting, segmentation of WPBs was applied. A local threshold algorithm 
(Bernsen method) with 15 radius applied and a binary image was created. The numbers of 
particles (WPBs) were calculated according to their size in every image and normalized to 
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the numbers of nuclei per image. Number of vWF positive cells and the number of nuclei 
was determined using cell counter plugin. 
2.11.2 Colocalization analysis  
 WPBs marked with vWF antibody and endogenous Rab46 fluorescent structures quantified 
using ICY software (Spot detector plugin). WPBs and Rab46 vesicles were delineated by ~ 
14 px and 4-7 px spot size respectively. Detection of Rab46 (green spot) only over WPBs 
structures (red spot) was performed selecting the red channel as driver channel and the ROI 
module to detect the green spots.   
2.11.3 Analysis of the cellular distribution of Rab46 Mutants  
Pixels intensity of Rab46 mutants in the perinuclear area was measured using Oval profile 
plugin in ImageJ (https://imagej.nih.gov/ij/plugins/oval-profile.html). At first step, an oval 
was drawn around the nucleus, enlarged by 20% and then the plugin, with the option radial 
sum, was executed to create a pixel intensities profile plot per each cell. 
2.11.4 WPBs and Rab46 cellular distribution  
The first analysis of vWF and Rab46 distribution in the perinuclear area was obtained using 
the RGB profiler plugin in ImageJ (https://imagej.nih.gov/ij/plugins/rgb-profiler.html). 
Pixels intensity was measured along a straight line across different nuclei and the obtained 
plot profile shows the pixel intensity on the y-axis and the distance along the line is on x-
axis.  
Cellular distribution and particle intensity were determined using Fiji (Figure 2.3). I designed 
a customised macro (see Appendix) to automate the analysis. Briefly, a 16-bit image was 
loaded in Fiji. The channels were split and a binary mask was created using a Default 
threshold on the DAPI channel. Noise was reduced using a median filter and if required 
adjacent sites split using the watershed algorithm. A distance map was generated. Green and 
red channels were duplicated to sample the original pixel intensities of WPBs and Rab46 
structures. Each channel was segmented using a threshold algorithm (Max Entropy) and the 
distance and intensity of each particles from the nucleus was measured. The macro 
automatically exports results tables with distance and intensity values per each particle, binary 
images of the distance map and .tiff images of each channel per analysed image. 5 to 10 
widefield images (40x) were analysed per experimental group.  Distance (Min) and integrated 
intensity (IntDen) values imported in OriginPro as X and Y values respectively. Distance 
values range from 0 px (nucleus) to 255 px (Periphery). This list of numerical values was 
binned into three areas: Perinuclear (x< 2 µm) – Intermediate (2 µm < x > 5 µm) – Periphery 
(x > 5 µm) where x is the distance from the nucleus to cells periphery. The integrated 
intensity normalized by the total fluorescence intensity of the image. The mean values were 
calculated for each area and averaged among all analysed images. The mean values averaged 
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among all the biological repeats were presented as bar-plots with mean ± SEM where Y-axis 
denoting “Normalized (integrated) intensity” and the X-axis denoting the distance from the 
nucleus indicated the average distribution of the analysed signal based into the three areas in 
the analysed cell population.  
 
Figure 2.3 Image analysis workflow to quantify Rab46 and vWF cellular distribution. 
Raw images were uploaded on Fiji as input. The channels were separated and thresholded 
individually to get an accurate binary mask. A distance map was generated on the DAPI 
channel were each pixel is replaced with a grey value equal to that pixel distance from the 
nearest background pixel (nucleus: black = 0). Distance from the nucleus of each segmented 
particle on the red or green channel, with their respective intensities was measured. 
Therefore, the outputs (distance and intensity measurements) of the summarised workflow 
were analysed and plotted in OriginPro. The distance is on the x-axis and the mean 
normalized intensity is on the y-axis. 
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2.12 Data analysis 
All average data is represented by mean ± S.E.M. Paired t-test performed as appropriate 
when comparison among two data groups was sought. For comparison among three or more 
mean values, one- or two-way ANOVA performed to determine whether significant 
differences exist amongst groups, coupled with Bonferroni post hoc test. Statistical 
significance was considered to exist at probability (p) ≤ 0.05 (* ≤ 0.05, ** ≤ 0.01, *** ≤ 
0.001). Where comparisons lack an asterisk, they were not significantly different and/or 
marked as not significant, n.s. OriginPro 2017 software (USA) used for data analysis and 
presentation. n/N represents number of independent biological repeats/number of technical 
repeats. 
 
2.13 Mice studies 
2.13.1 General 
Murine work was carried out in accordance with The Animals (Scientific Procedures) Act 
1986 (Amended 2012). Mice were kept in the University of Leeds animal facility under 
standard conditions, including a 12-hour sleep/wake cycle, with access to water and chow 
diet ad libitum. Experiments were conducted under Home Office Project License 
P606230FB. All studies were approved by the University of Leeds Ethics Committee. Male 
and female animals were ear notched at weaning, with these samples being used for 
genotyping (see section 2.13.3).  
2.13.2 Cracr2a -/- mice 
The Cracr2a mouse strain used for this research project was created from ES cell clone 
15424A-C4, generated by Regeneron Pharmaceuticals, Inc. and obtained from the KOMP 
Repository (www.komp.org). The colony C57BL/6N-Cracr2atm1.1(KOMP)Vlcg is generated 
following the strategy illustrated in Figure 2.  
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Figure 2.4. Velocigene CREed Deletion allele strategy. Mice that contained the 
reporter-tagged null allele, (tm1) were bred to Cre-expressing mice.  This resulted in removal 
of the B-actin promoter and the Neomycin gene it activated. The tm1.1 allele remains a lacZ 
reporter and is a NON-conditional knock-out of the gene. 
 
The litter we received from the KOMP repository was a mix of a few heterozygous mice 
with C57BL/6N wildtype mice. Therefore, for the first round of breeding, we first increased 
the numbers of heterozygous mice to ensure a stronger breeding colony prior to setting up 
het x het matings. The latter strategy illustrated in Figure 6.1 led to generation of some 
homozygous mice as well as control wild-type. Genotyping was performed and homozygous 
and wild-type mice were selected for breeding (hom x hom and WT x WT) to generate a 
strong homozygous and wild-type colony. At this point genotyping was not needed anymore. 
As for a preliminary study littermate controls were not used at the moment. Littermate 
controls will be used for future studies. 
2.13.3 Genotyping 
Mouse genotyping was performed by taking ear notches at weaning age. The samples were 
sent for automated genotype PCR service (Transnetyx – Cordova, TN) using specific primers 
designed by the company.   
2.13.4 Phenotyping 
Both female and male mice between 8 and 12 weeks were used for the initial phenotyping 
studies. Physical appearance, fertility and mortality rate was observed at the beginning. Next 
metabolic phenotyping was performed. 
2.13.4.1 Body weight 
Both Cracr2a -/- knockout and control WT mice were weighed at 8 weeks and 12 weeks until 
they were sacrificed for further experiments. 
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2.13.4.2 Organ weight 
Animals at 12 weeks were sacrificed following schedule 1 procedure. Body weight was 
measured prior to organ collection. The heart, pancreas, kidneys, spleen and subcutaneous 
and visceral fat were dissected and weighed prior to being snap frozen in liquid nitrogen and 
stored at -80°C for mRNA/protein analysis for subsequent analysis. Liver and lungs were 
weighed as well and either snap frozen for PCR analysis or fixed in 4% PFA for histological 
analysis. Organ-to-body weight ratios were calculated normalising the weight of each organ 
with its respective body weight. 
2.13.4.3 Histological analysis 
Liver samples were fixed overnight and then kept in 70% ethanol until further analysis. Liver 
tissues from female Cracr2a -/- and control mice were processed at the St. James’s hospital 
histology facility (Leeds). H&E staining was performed by the histology department at St. 
James’s hospital and imaged slices were sent and opened with Aperio ImageScope for 
analysis. 
 
2.13.5 Metabolic phenotyping 
2.13.5.1 GTT 
Animals were fasted overnight with access to water ad libitum. The following morning, the 
mice were weighed before being placed under conscious restraint. A small incision was made 
in the distal part of the tail of each animal in order to obtain a tail vein blood sample of 1-2 
μl that was analysed with a glucometer and testing strips. Fasting glucose was measured first 
and then mice were treated with 200 mg/mL glucose solution (1 mg per gram of body 
weight) administered via intraperitoneal injection. Repeat tail vein blood samples were taken 
at 30 min intervals until 120 mins after the initial injection. Between measurements animals 
had free access to water and were not restrained. 
2.13.5.2 ITT 
This experiment was conducted in similar fashion to the GTT (section 2.13.5.1) except that 
animals were fasted for two hours, rather than overnight. Fasting glucose was measured and 
mice then underwent intraperitoneal injection of insulin at a dose of 0.75 IU/Kg of body 
weight with tail vein blood glucose measurements taken at the same time intervals as for 
GTT. Animals were monitored closely for any signs of hypoglycaemia throughout the 
experiment. No mice required injection of glucose to correct hypoglycaemia. 
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Chapter 3 Rab46 is a novel Rab GTPase that localises 
to Weibel-Palade bodies 
 
3.1 Introduction 
CRACR2A isoform-a (Rab46) is a unique Rab GTPase with multiple functional domains. 
The existence of  CRACR2A-a was discovered and validated in endothelial cells by Wilson 
et al166. CRACR2A protein (CRACR2A-c) was initially described as a 45 kDa protein involved 
in Ca2+ channel dynamics in immune cells172 . However, in endothelial cells, Wilson et al using 
a validated anti-CRACR2A antibody in western blot only detected a band at 95 kDa. 
Molecular cloning and sequence analysis revealed this 95 kDa protein to be the proposed 
CRACR2A isoform-a, a longer isoform than CRACR2A-c, that contains an additional highly 
conserved Rab domain. In endothelial cells, CRACR2A-a has no effect on Ca2+ channels so 
we hypothesize that the additional C-terminal Rab GTPase sequence affects the location and 
function of this protein. We have since named CRACR2A-a Rab46, which is how I will 
reference it going forward. 
Srikanth et al. validated the presence and function of Rab46 in murine and human immune 
cells167. Rab46 localises to TGN in resting T-cells and its localisation is strictly dependent on 
the intrinsic GTPase activity of the Rab domain.  The sequence of the GTPase domain shows 
several conserved residues with other small Rab GTPases. Moreover, mutations which 
impair the nucleotide binding activity show a reduction in the GTPase activity indicating high 
similarity with already characterized functionally active G-proteins. Besides its intracellular 
localisation being influenced by the nucleotide binding activity of the Rab domain, other 
domains contributed to activation-dependent Rab46 translocation to the immunological 
synapse and its subsequent activation of Ca2+ dependent-NFAT and JNK signalling. 
The main aim of this chapter is to gain insight into the endogenous localisation of Rab46 in 
endothelial cell in resting conditions. Identifying its intracellular distribution will help us 
determine its role in endothelial cell trafficking. Super-resolution imaging was used for more 
precise Rab46 localisation and single point mutations were introduced into the Rab domain 
to study the effect of the GTPase activity on Rab46 localisation. Moreover, siRNA 
specifically targeting Rab46 was used to investigate the effect of protein silencing on 
endothelial cell function. This chapter reveals that endogenous Rab46 is primarily targeted 
to a subpopulation of Weibel-Palade bodies (WPBs) suggesting a potential role of Rab46 in 
regulating WPB trafficking and vWF secretion. 
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3.2 Rab46 localisation in endothelial cells 
First, in order to study Rab46 localisation in endothelial cells, I validated a commercially 
available antibody raised against Rab46 using western blot analysis.  A first indication of the 
antibody specificity was given by Wilson et al., showing the presence of a single band at 95 
kDa in HUVEC lysate. For further validation, Rab46 was depleted in endothelial cells using 
two siRNAs targeting different regions of Rab46 mRNA and the antibody specificity 
analysed with western blot (Figure 3.1a). A single band at the known molecular weight (95 
kDa) was observed in the mock and control siRNA transfected cells whereas a reduced band 
intensity was observed in Rab46 siRNA transfected cells. As a single band of the correct 
molecular weight was only identified in the endothelial cells expressing Rab46, this 
encouraged the use of this antibody for immunofluorescence imaging studies. Here, 
overexpression of Rab46 was used as positive control to further test antibody specificity 
(Figure 3.1b). Wild-type Rab46 (WT-Rab46) was overexpressed in endothelial cells and 
immunostained after 24 hours for Rab46. Immunostaining depicts cells with small rod-
shaped vesicles which resemble endothelial specific WPBs, therefore vWF was used as a 
marker of WPBs to co-stain endothelial cells transfected with Rab46. Merged images show 
specific localisation of exogenous expressed Rab46 (green) to WPBs (red). However, some 
cells displayed a strong cluster in the perinuclear area, most likely due to a slow intrinsic GTP 
hydrolysis typical of many Rab proteins (data not shown).   In order to observe the suitability 
of the antibody in detecting endogenous Rab46, endothelial cells transfected with Rab46 
siRNA or control siRNA were fixed and immunostained. Control cells immunostained for 
Rab46 using anti-Rab46 antibody (green) revealed an evenly distributed vesicle-like pattern 
similar to the overexpressed protein. Despite the presence of some non-specific 
fluorescence, green intensity was greatly reduced in Rab46 depleted cells confirming 
suitability of the antibody to detect endogenous Rab46 in endothelial cells (Figure 3.1c). 
Validation of commercially available anti-Rab46 antibody for both western blot analysis and 
immuno-fluorescence assays in endothelial cells lays the foundation for all the next 
investigations. 
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Figure 3.1 Validation of Rab46 antibody.  (a) Representative western blots depicting 
specificity of Rab46 antibody. Rab46 depleted cells, transfected with two different siRNAs, 
show reduced intensity bands compared to control siRNA. (b) Immunofluorescent 
DeltaVision imaging of HUVECs transfected with wild-type Rab46 (green: anti Rab46) show 
Rab46 is localised to WPBs (red: anti vWF). DAPI (blue) shows nuclei. Scale bar = 30 µm. 
(c) Immunofluorescence showing endogenous Rab46 (green) in control and Rab46 depleted 
endothelial cells. Scale bar = 20 µm 
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3.3 Endogenous Rab46 localises to Weibel-Palade bodies 
In order to establish the role of Rab46 in endothelial cells, subcellular localisation of 
endogenous Rab46 was investigated. HUVECs were grown for 72 hours into Ibidi μ-slides 
and immunostained for Rab46. As overexpressed Rab46 localised to endothelial WPB rod-
shaped vesicles, cells were co-stained for vWF, a marker for WPBs, in addition to Rab46.  
Endothelial cells were first imaged using a DeltaVision deconvolution microscope (Figure 
3.2a) and  then  an inverted confocal laser scanning microscope Zeiss LS880 with AiryScan 
system to increase the resolution (Figure 3.3). Immunofluorescent staining of Rab46 (green) 
shows a cytoplasmic vesicular-like pattern characteristic of WPBs which was similar to the 
vWF staining (red). Indeed, merged images of cells stained for both vWF and Rab46 revealed 
co-localisation of Rab46 to WPBs in HUVECs (Figure 3.2a). HUVECs are a model system 
for studying WPB regulation. However, to confirm Rab46 specific localisation in endothelial 
cells from different vascular beds, human cardiac microvascular endothelial cells (HCMECs) 
were also stained for Rab46 and vWF (Figure 3.2b). Immunofluorescent imaging confirms 
that Rab46 (green) localises to WPBs (red) in cardiac microvascular endothelial cells, 
indicating this is not specific to HUVECs. 
To further investigate Rab46 association with WPBs, high resolution microscopy was used 
to achieve a better understanding of the association. Endothelial cells stained for vWF (red) 
and Rab46 (green) were imaged using a confocal microscope with AiryScan system, z-stacks 
were acquired and maximum intensity projections were shown as representative images 
(Figure 3.3a).  The cigar-shaped morphology of WPBs represented by vWF staining (red) 
was closely associated with the green Rab46 intensity as showed in the merged image. 
Moreover, the increased resolution allowed visualisation of single WPBs. Figure 3.3b shows 
representative single WPBs (red) associated with Rab46 (green) with their respective 3D 
reconstructions (bottom). High-resolution imaging revealed Rab46 was juxtaposed to vWF 
on the outside of WPBs, suggesting a role in WPB regulation. 
High-resolution imaging permitted quantitative measurement to evaluate the extent of Rab46 
localisation to WPBs.  Multichannel images were processed to detect and count WPBs (red 
particles), Rab46 (green particles) and particles that were both green and red. Quantification 
of high-resolution images using Spot Detector algorithm revealed that not all WPBs are 
associated with Rab46, only 49% ( ± 13%) of  particles were positive for both vWF and 
Rab46 (Figure 3.4). Therefore, Rab46 does not colocalise to a full population of WPBs. This 
data suggests that Rab46 regulates a subpopulation of WPBs which may contain specific 
cargo. 
WPBs are endothelial-specific organelles and the main storage granules; nevertheless, other 
granules are present in the endothelial cells’ cytoplasm. In order to confirm that Rab46 
localised specifically to WPBs, co-staining with markers for secretory granules (Tissue 
Plasminogen-activator), lysosomes (Lamp1) and recycling endosomes (Rab11) was 
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performed (Figure 3.5). Immunofluorescent images revealed distinct localisation of Rab46 
vesicles from all the other granules, suggesting that WPBs are the primary localisation of 
Rab46 in endothelial cells.  
 
 
 
 
Figure 3.2 Endogenous Rab46 localises to Weibel-Palade bodies. Immunofluorescent 
images showing subcellular localisation of endogenous Rab46 (green) and vWF (red) in 
HUVECs (a) and HMCEC (b). DAPI (blue) shows nuclei. Merged images on the right to 
show colocalisation of Rab46 with vWF. Maximum intensity projections from DeltaVision 
z-stack are shown. Scale bar = 30 µm. 
 
 
  
vWF Rab46
a
b
vWF
Rab46
b
- 73 - 
 
   
Figure 3.3 Specific Rab46 localisation to Weibel-Palade bodies in endothelial cells. 
(a) High-resolution Airyscan imaging showing detailed localisation of cigar-shaped WPBs 
(red) and Rab46 (green) in HUVECs, merged image showing colocalisation of Rab46 with 
vWF. Scale bar = 20 µm. (b). Zoomed-in and cropped high-resolution image (top) and 3D 
reconstruction (bottom) showing single WPBs (vWF: red) where Rab46 (green) is juxtaposed 
to vWF. 
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Figure 3.4 Rab46 localised with a subpopulation of WPBs. Representative high-
resolution image stained for vWF and Rab46 and quantified using Spot detector plugin in 
ICY. The insets represent cropped single WPB either with no Rab46 (top) or with Rab46 
localisation (bottom). Scale bar = 1 μm. The graph below shows the number of WPBs 
(counted as red spots as per methods) which colocalise with Rab46 vesicles (green spots). 
49% (± 13%) of WPBs per cell localise with Rab46. n/N = 3/15 
 
 
 
 
 
Figure 3.5 Rab46 does not localise to other endothelial granules. HUVECs co-stained 
with Rab46 (green) and tissue plasminogen activator (tPA: red) (left), lysosomal marker 
(Lamp1: red) (middle), recycling endosomes (Rab11: red) (right), show distinct localisations 
in endothelial cells. Scale bar = 30 μm. 
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3.3.1 Nucleotide binding to Rab46 influence its intracellular localisation 
Srikanth et al., demonstrated that the GTPase domain of Rab46 is functionally active and the 
GTP/GDP switching regulates its association with the Golgi in T-cells167. Therefore, the 
importance of a functional GTPase domain was equally assessed in endothelial cells. The 
amino acid sequence of Rab46 GTPase domain contains conserved residues which are 
important for the GTPase function167. To confirm the role of these conserved residues, 
mutants with predicted impaired GTPase activity were generated. Single point mutation, 
involving the substitution of a threonine (T) to an asparagine (N) residue in the P-loop of 
the GTPase domain was introduced to generate a mutant (T559N) which is preferentially 
GDP-bound. Moreover, a GTP-bound (constitutively active) mutant (Q604L) and a 
nucleotide-free inactive mutant (N658I) were previously generated to assess whether GTPase 
activity influences the subcellular localisation of Rab46. The T559N, Q604L and N658I 
mutants were over-expressed in endothelial cells and localisation observed by 
immunofluorescence after 24 hours.  Localisation of GTP/GDP binding defective mutants 
showed that mutants impaired in GTP binding have a predominant cytosolic localisation 
whereas defects in the hydrolysis of GTP cause a strong perinuclear localisation, at times 
similar to the exogenous expressed WT-Rab46. Quantitative measurement of Rab46 
intensity around the perinuclear area was obtained from analysis of immunofluorescent 
images of Rab46 nucleotide-binding mutant. Both N658I and T559N show an even cytosolic 
distribution with impaired co-localisation to vWF. In contrast, constitutively active mutant 
Q604L shows a green intensity peak next to the nucleus driving localisation of vWF in the 
same area (Figure 3.6). These findings confirm that the GTPase domain of Rab46 is 
functionally active and that the conserved GTP-binding motif is important for Rab46 
localisation to WPBs in endothelial cells. 
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Figure 3.6 Subcellular localisation of Rab46 nucleotide binding mutants. 
Representative images of HUVECs expressing constitutively active form of Rab46 (Q604L: 
top) stained for vWF (red) with its respective Rab46 (green) intensity plot on the right side 
where the peak indicates a cluster in the perinuclear area. Representative images of the 
nucleotide-free mutant (N658I) and the inactive GDP-bound form of Rab46 (T559N) 
expressed in HUVECs and their representative intensity plots showing homogenous green 
distribution indicated a cytosolic localisation (middle and bottom respectively). All the plots 
were generated using the Oval profile method in ImageJ. n/N=3/28  
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3.4 Rab46 depletion increases vWF protein content 
Rab proteins are known to orchestrate the dynamics of various intracellular and secretory 
vesicles by controlling vesicle biogenesis, motility and fusion events95. The identity and 
function of some Rab GTPases associated with WPBs in regulating their biogenesis and 
modulation of vWF exocytosis has been recently investigated181.    
To determine the role of Rab46 in WPB function, its expression was reduced using two 
siRNAs targeted against Rab46 or control siRNA (see methods). Downregulation of Rab46 
in endothelial cells after 48 –72 hours was confirmed by western blot and quantified by 
densitometry analysis (Figure 3.7a). 70% and 64% of Rab46 protein knockdown was 
achieved using Rab46 siRNA-1 and siRNA-2 (respectively) compared to control siRNA 
(Figure 3.7b). Rab46 siRNA-1 was used throughout unless otherwise specified. 
Next, the role of Rab46 in WPB biogenesis was questioned. WPB formation is driven by 
vWF content and tubulation182. Therefore, in order to look at the effect of Rab46 siRNA on 
WPB formation, mRNA and protein level of vWF was measured by qPCR and western blot. 
Firstly, mRNA expression of vWF was analysed after siRNA transfection. Figure 3.7c shows 
that siRNA-mediated knockdown of Rab46 does not affect vWF mRNA level, suggesting 
Rab46 does not have a role in vWF expression. However, western blot analysis shows that 
the amount of intracellular vWF protein increases by 2.3 fold  (+/- 0.6) in Rab46 depleted 
endothelial cells compared to control siRNA (Figure 3.7d), suggesting a role for Rab46 in 
WPB trafficking.  
To further investigate the increased abundance of vWF protein in response to Rab46 
depletion, vWF expression and the number of WPBs per cell was analysed by 
immunostaining for vWF. Randomised images of endothelial cells transfected with Rab46 
siRNA or control siRNA were taken with DeltaVision system. The images were then 
analysed and the number of vWF positive WPBs were counted using ImageJ. Representative 
images of WPBs population in transfected endothelial cells are showed in Figure 3.8a. Mean 
data (Figure 3.8b) showed an average of 95 ± 6 WPBs per cell in controls samples, versus a 
significant higher count (128 ± 8 WPBs/cell) in cells where Rab46 is depleted. Moreover, 
the number of vWF positive cells did not change after downregulation of Rab46, so siRNA 
transfection had no significant effect on the number of cells that contain WPBs (Figure 3.8c).  
These results together suggest that Rab46 does not play a positive role in biogenesis. 
However, aforementioned downregulation of Rab46 results in a potential detention of vWF 
in the cell, probably leading to a reduction of vWF secretion. Thus, we propose Rab46 as a 
new Rab protein involved in vWF exocytosis and trafficking of WPBs. 
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Figure 3.7 Rab46 depletion increases vWF protein content. (a) Representative western 
blots for Rab46 and vWF expressed in HUVECs transfected with two Rab46 siRNAs (si.1 
and si.2) or control siRNA. (b) Quantification of Rab46 band intensity is shown as fold 
change relative to vinculin (n = 6). (c) qPCR ΔCT analysis of HUVECs transfected with 
Rab46 siRNA-1 demonstrate no difference in the expression of vWF mRNA as compared 
to cells transfected with control siRNA (n = 3). (d) Densitometry analysis from a western 
blot of vWF band intensity in HUVECs transfected with 2 different siRNAs specific for 
Rab46 is shown as fold change relative to housekeeping genes (siRNA Rab46-1, 1.63 ± 0.23 
and siRNA Rab46-2, 1.49 ± 0.22) (n = 6) 
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Figure 3.8 Rab46 depletion increases the number of WPBs per cell. (a) Example images 
used to quantify cells stained for vWF as a marker for WPBs in the presence or absence of 
Rab46 (siRNA-1). (b) The number of WPBs per cell as quantified as WPB counting 
(described in materials and methods) where cells were depleted of Rab46 versus siRNA 
control (control 95 ± 6, siRNA Rab46-1 128 ± 8). n/N = 3/18. (c) Quantification of cells 
that contain WPBs was performed counting the number of cells positive for vWF in 
HUVECs when cells were depleted of Rab46 by targeted siRNA (siRNA Rab46-1) or a 
control siRNA (n/N = 3/18). Graphs show mean ± SEM.  n.s. not significant. *p-value < 
0.05 **p-value < 0.01 from Student’s t-test. 
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3.5 Rab46 depletion does not affect the expression of 
structurally and functionally related Rab GTPases 
Rab46 is a non-conventional Rab protein as its GTPase domain is associated with a coil-
coiled domain and two EF-hand domains which results in a large Rab GTPase. High 
similarity in the overall structure with Rab46 is presented by two other large GTPases: Rab44 
and Rab457. Both Rab44 and Rab45 have not been described in endothelial cells therefore, 
their relative mRNA expression was examined. In contrast several studies have already 
shown the role of other Rab proteins in endothelial cells trafficking events, such as Rab27a 
in trafficking of mature WPBs69 or Rab7a in retrograde lysosomal trafficking184. In order to 
ascertain that Rab46 depletion does not result in an overall cellular imbalance, relative 
expression of Rab44, Rab45, Rab27a and Rab7a was first quantified in endothelial cells. Next, 
their mRNA abundance was measured in Rab46 depleted cells and control endothelial cells 
(Figure 3.9). Figure 3.9a shows mRNA relative expression of the indicated Rab proteins in 
endothelial cells demonstrating that the two structural related Rab44 and Rab45 are 
expressed at very low levels. In contrast, mRNA abundance of Rab27a is similar to Rab46 
whereas, as expected, Rab7a mRNA has an increased expression as compared to other Rab 
proteins in endothelial cells. No change in the expression of the selected genes was observed 
(Figure 3.9b) when comparing mRNA abundance between non transfected endothelial cells 
and Rab46 siRNA transfected cells.    
These data exclude the possibility of some off-target effects, such as genetic compensation 
by other related Rabs in response to Rab46 knockdown in endothelial cells, suggesting a 
specific role of Rab46 in regulating trafficking of a subpopulation of WPBs.    
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Figure 3.9 Rab46 depletion does not affect the expression of other related Rab 
proteins. (a) qPCR ΔCT analysis of total HUVECs lysate showing mRNA expression of 
Rab46, Rab44, Rab45, Rab27a and Rab7a normalized to housekeeping genes in endothelial 
cells. (b) qPCR ΔCT analysis of HUVECs transfected with Rab46 siRNA-1 showing mRNA 
expression normalized to housekeeping genes and compared to control siRNA. No 
difference in the mRNA expression of the indicated Rab proteins was measured as compared 
to HUVECs transfected with control siRNA (n = 3).    
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Chapter 4  Rab46 regulates Weibel-Palade body 
trafficking in response to histamine 
 
4.1 Introduction 
WPBs provide a dynamic storage pool in endothelial cells whose contents can be regulated 
and released by inflammatory or thrombotic mediators present in the vascular micro-
environment59. Upon vascular perturbation, a rapid and immediate release of bioactive 
components from an intracellular storage pool is necessary to maintain vascular haemostasis. 
WPB contents can be released from endothelial cells in response to several different 
secretagogues, such as histamine and thrombin which act by raising intracellular Ca2+ or 
epinephrine and vasopressin which increase cAMP level in the cell56. Ca2+ raising agonists 
like histamine and thrombin are expected to induce a more rapid and vigorous response 
where release of pro-inflammatory and pro-thrombotic mediators from WPBs provide the 
vasculature with an emergency kit for wound repair. However, thrombin and histamine have 
distinct physiological roles. Thrombin, as part of the response to vascular injury, necessitates 
release of both pro-thrombotic and pro-inflammatory mediators whereas histamine 
stimulates release of mainly pro-inflammatory factors. In order to achieve an appropriate 
response to these physiologically distinct stimuli there must exist discrete cargo-restricted 
WPB populations whose trafficking and exocytosis is highly controlled. Regulated exocytosis 
of WPBs is a multistep process requiring translocation of mature WPBs from the cytoplasm 
toward the cell surface, docking and fusion with the plasma membrane181. Recent studies 
have unravelled the role of some Rab GTPase and their effectors in regulation of WPB 
trafficking and exocytosis181. However, it is unclear if subpopulations of WPBs are 
differentially trafficked in response to stimuli and how this is regulated. 
In this chapter the function of Rab46, a novel Rab protein associated with a subset of WPBs 
is investigated. The presence of the Ca2+ binding sites together with a GTPase domain in the 
Rab46 sequence suggested a possible coordination by Rab46 of G-protein and Ca2+ signals 
in regulating WPB trafficking. Histamine and thrombin were used to induce mobilization 
and secretion of WPBs as both agonists induce intracellular Ca2+ mobilization but have 
distinct outcomes. Understanding how WPBs are able to recognise different stimuli, inducing 
differential release, will provide new insight into endothelial cells fine-regulation of different 
physiological responses. To study the role of Rab46 in WPB trafficking upon acute histamine 
and thrombin stimulation, siRNAs targeting Rab46 were used. In addition, chemical 
inhibitors of cellular proteins were used to unravel the mechanisms underlying Rab46-
dependent WPB trafficking and a customised automated imaging analysis was designed for 
image quantification.   
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This chapter reveals that Rab46, a new Rab GTPase associated with a subset of WPBs, 
regulates histamine, but not thrombin, WPB trafficking. Acute histamine stimulation induces 
Rab46-dependent WPB clustering to the microtubule organizing centre (MTOC), moving 
along the microtubular network with the dynein motor protein.   
 
4.2 Differential Weibel-Palade body trafficking 
In basal conditions, WPBs are evenly distributed in the cytoplasm of endothelial cells. In 
order to establish WPB response and the role of Rab46 in WPB trafficking, cellular 
localisation of vWF and Rab46 was investigated in response to different stimuli. The two 
major agonists of WPB trafficking and vWF exocytosis are histamine and thrombin. They 
both act via increasing intracellular Ca2+ inducing a rapid depletion of WPBs.  
HUVECs were grown for 72 hours in order to have a confluent monolayer and a full 
population of WPBs, representing a physiological condition. To mimic an on-demand 
response, cells were stimulated for 10 mins with histamine (30 µM) or thrombin (2.5 U/ml). 
WPB cellular distribution to these two different stimuli was examined by immunostaining. 
Endothelial cells fixed and immunostained for vWF show a clear difference in WPB cellular 
redistribution upon acute stimulation. Imaging of histamine stimulated endothelial cells 
reveals a striking perinuclear clustering of vWF, in contrast to thrombin treated cells which 
exhibited a more typical vWF patches on the cell surface, indicating vWF exocytosis (Figure 
4.1). 
Next, Rab46 under stimulated conditions was also examined together with vWF. Stimulated 
endothelial cells were co-stained for vWF and Rab46 to observe the distribution of WPBs 
and Rab46 elicited by the two agonists (Figure 4.2). Interestingly, whilst vehicle and 
thrombin-treated cells displayed an even distribution of Rab46 and WPBs throughout the 
cytoplasm, acute histamine stimulation induces a redistribution of Rab46 (green) as well as 
vWF (red) towards a perinuclear area.  To better understand the difference in the distribution 
of WPBs and Rab46 under different conditions, pixels intensity across nuclei was measured 
(Figure 4.3a). Linear plot profiles on RGB images showed the presence of red (vWF) and 
green (Rab46) peaks only on one side of the nuclei (blue line) for histamine treated cells 
whereas more uniform or irregular profiles belong to non-treated or thrombin treated cells. 
To analyse the overall change in WPBs and Rab46 cellular distribution upon acute 
stimulation, I designed a customised macro using ImageJ that analysed the intensity of green 
and red particles and their distance from the nucleus (see methods 2.11.4). Briefly, each image 
was separated in 3 different channels and each channel processed separately. A binary mask 
was created using a default threshold on the DAPI (nuclear stain) channel and a distance 
map was generated. Green and red channels were duplicated to sample the original pixel 
intensities of WPBs and Rab46 structures. Each channel was segmented using a threshold 
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algorithm (Max Entropy) and the distance and intensity of each particles from the nucleus 
measured. Distance and normalized integrated intensity values were plotted as X and Y 
values respectively. Distance values (x), which range from 0 px (nucleus) to 255 px 
(periphery) were binned into three areas: Perinuclear (x< 2μm) – Intermediate (2μm < x > 
5μm) – Periphery (x > 5μm). Figure 4.3b and c show the average distribution of vWF (red 
signal) and Rab46 (green signal) into the three indicated cellular areas in control and 
stimulated cells. This method confirmed that the accumulation of vWF and Rab46 in the 
perinuclear area upon histamine stimulation is highly significant (p-value ≤ 0.01).  
These data show differential WPB trafficking in response to different physiological stimuli 
suggesting a role for Rab46 in regulating acute histamine stimulation. 
 
 
 
 
Figure 4.1 Histamine but not thrombin induces perinuclear trafficking of Weibel-
Palade bodies. Immunofluorescent images showing endothelial cells fixed and stained for 
vWF (red) in resting condition (left) and upon acute stimulation (10 mins) with histamine 30 
µM (middle) or thrombin 2,5 U/ml (right). DAPI (blue) shows nuclei. Scale bar = 30 µm. 
n/N=3/36   
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Figure 4.2 Weibel-Palade bodies and Rab46 traffic to a perinuclear area upon acute 
histamine stimulation. (a) Immunofluorescent images showing endothelial cells fixed and 
stained for vWF (red) and Rab46 (green) in resting condition (top) and upon 10 mins 
stimulation with histamine 30 μM (middle) or thrombin 2,5 U/ml (bottom). White arrows 
indicate perinuclear clusters of vWF and Rab46. DAPI (blue) shows nuclei. Scale bar = 30 
µm  
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Figure 4.3 Quantification of  the cellular distribution of WPBs and Rab46 upon 
histamine or thrombin stimulation. (a) HUVECs immunostained for vWF and Rab46 in 
resting condition (top) or after stimulation with histamine (middle) or thrombin (bottom) 
and their representative RGB profiles showing pixels intensities traces from different images 
measured according to a straight white line randomly drawn throughout different nuclei per 
images. Scale bar = 10 µm.  Quantification of cellular distribution of vWF (b) and Rab46 (c) 
intensity in basal and histamine (30 µM) or thrombin (2,5 U/ml) acute 10 mins stimulation. 
Results were grouped into three areas: perinuclear, intermediate and periphery. The plot 
shows vWF or Rab46 signal intensity of each particles in the respective area where the mean 
(± SEM) was noted as percentage of the total signal intensity. n/N=3/36. **p-value < 0.01 
from one-way ANOVA. 
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4.3 Histamine-induced WPB perinuclear trafficking is Rab46-
dependent  
Seeking the function of Rab46 in WPB trafficking, HUVECs were transfected with either 
Rab46 targeted siRNA or control siRNA and after 72 hours stimulated as above. 
Interestingly, imaging analysis showed that the depletion of Rab46 with specifically targeted 
siRNAs (Figure 4.4b siRNA-1 and Figure 4.4c siRNA-2) had no effect on the distribution of 
WPBs in basal conditions (Figure 4.4a image top right and mean data Figure 4.4b-c). 
However, histamine failed to induce perinuclear clustering of vWF in cells depleted of Rab46 
(Figure 4.4a bottom right and mean data Figure 4.4b-c) suggesting that histamine-evoked 
clustering of a subpopulation of WPBs to the perinucleus is dependent on Rab46.  
In contrast, depletion of Rab46 had no effect on WBP trafficking upon thrombin stimulation 
(Figure 4.5a). Quantification of cellular distribution in Figure 4.5b shows a slight non-
significant increase in vWF accumulation in the perinuclear area, however uniform cellular 
distribution of vWF signal  confirm no significant difference in thrombin-stimulated cells 
upon Rab46 depletion.    
These results show that in resting cells WPBs are distributed in an apparently random manner 
throughout the cytosol, but differential trafficking was observed upon stimulation with the 
two agonists. Although exocytosis of WPBs is induced by two Ca2+-raising agents such as 
histamine and thrombin, these data indicate that WPBs are able to distinguish two 
physiologically distinct  stimuli and elicit a differential response. Whilst thrombin stimulation 
is Rab46-independent, acute histamine stimulation induces a directed movement of WPBs 
towards a perinuclear area in a Rab46-dependent manner. 
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Figure 4.4 Histamine induced Rab46-dependent perinuclear clustering of WPBs. (a) 
Representative images of HUVECs transfected with Rab46 siRNA-1 or control siRNA in 
control conditions (vehicle) or after 10 mins histamine treatment (30 μM). Immunostaining 
of Rab46 (green) and vWF (red) shows perinuclear cluster of Rab46 and vWF in siRNA 
control cells upon histamine stimulation (bottom left). Perinuclear trafficking of WPBs is 
completely abolished in Rab46 depleted cells (bottom right). Scale bar = 30 µm and applies 
to all images. Quantitative analysis of vWF cellular distribution in siRNA control cells and 
Rab46 depleted cells with two different siRNAs, siRNA-1 (b) and siRNA-2 (c) upon 
histamine stimulation. Results were grouped into three areas: perinuclear, intermediate and 
periphery. The plot shows vWF signal intensity of each particles in the respective area where 
the mean (± SEM) was noted as percentage of the total signal intensity. n/N=3/36. *p-value 
< 0.05 from 2-way ANOVA. 
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Figure 4.5 Thrombin-evoked trafficking of WPBs is independent of Rab46. (a) 
Representative images of HUVECs transfected with Rab46 siRNA-1 or control siRNA in 
control conditions (vehicle) or after 10 mins thrombin (2,5 U/ml) stimulation. 
Immunostaining of Rab46 (green) and vWF (red) shows that Rab46 depletion does not have 
affect WPB trafficking upon thrombin stimulation. Scale bar = 30 µm and applies to all 
images. (b) Quantitative analysis of vWF cellular distribution in siRNA control cells and 
Rab46 depleted cells upon thrombin stimulation. Results were grouped into three areas: 
perinuclear, intermediate and periphery. The plot shows vWF signal intensity of each 
particles in the respective area where the mean (± SEM) was noted as percentage of the total 
signal intensity. n/N=3/36. n.s. not significant 
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4.4 Histamine evokes WPBs and Rab46 redistribution to the 
Microtubule-Organising Centre 
WPBs undergo retrograde transport to the perinuclear area by a Rab46-dependent 
mechanism when triggered by acute histamine stimulation. The region around the nucleus 
contains different compartments, such as the Golgi apparatus, endoplasmic reticulum (ER) 
and the MTOC. 
Therefore, in order to exactly identify WPBs and Rab46 localisation upon acute histamine 
stimulation, immunofluorescence and super-resolution imaging was performed. Firstly, 
histamine-treated endothelial cells were co-stained for vWF (or Rab46) and pericentrin, a 
marker for the MTOC (Figure 4.6a-b). High-resolution imaging revealed a clear re-
orientation of WPBs (red) towards the MTOC (green), and Rab46 (green) clusters were co-
localised with pericentrin (red). In contrast, WPBs (vWF) and Rab46 failed to co-localise 
with the Golgi apparatus or the ER before and after histamine stimulation (Figure 4.7). 
Separate intracellular localisation of both Rab46 and vWF with those cellular compartments 
was revealed by super-resolution imaging. 
These data identify the MTOC, an intracellular structure from which microtubules of the 
cytoskeleton radiate, as the perinuclear compartment where Rab46 clustering occurs upon 
histamine stimulation. 
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Figure 4.6 Histamine evokes redistribution of WPBs and Rab46 to the Microtubule 
Organising Centre (MTOC). (a) Airyscan images of HUVECs stained with vWF (red) and 
pericentrin (green). Control cells on the left and 30 µM histamine treated cells on the right 
showing reorientation of WPBs towards the MTOC. (b) High-resolution AiryScan image of 
cells treated with 30 µM histamine (10 mins) then immunostained with Rab46 (green) and 
pericentrin (red) showing Rab46 clustering at the MTOC. Maximum intensity projection 
from confocal microscopy z-stack are shown. DAPI (blue) shows nuclei. Scale bar = 20 µm  
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Figure 4.7 Subcellular distribution of WPBs and Rab46 following histamine 
stimulation. (a) High-resolution images of endothelial cells stained for vWF (red) and 58-k 
Golgi protein, a Golgi marker (green) before and after histamine treatment (left and right 
respectively). Maximum intensity projection from confocal microscopy z-stack are shown. 
Scale bar = 20 µm (b) HUVECs stained for vWF (red) and Calnexin (green) as marker for 
the ER, control cells on the left and histamine treated on the right. (c) Endothelial cells 
treated with histamine and stained for Rab46 (green) and GM130 (red) as a Golgi marker 
(left) and calnexin (red) as marker for the ER (right). Representative images to show no 
Rab46 colocalisation with these subcellular compartments.  Maximum intensity projections 
from DeltaVision microscope z-stack are shown. DAPI (blue) shows nuclei. Scale bar = 10 
µm 
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4.5 Nucleotide-binding is necessary for Rab46-dependent 
trafficking 
As shown previously (3.3.1) Rab proteins contain highly conserved nucleotide binding sites 
that dictate GTPase membrane localisation and function185. Srikanth et al. have previously 
demonstrated that WT-Rab46 has the intrinsic ability to hydrolyse GTP whilst nucleotide 
binding mutants have no GTPase activity, suggesting that the GTPase domain is functionally 
active167. Therefore, whether the nucleotide binding to the GTPase domains of Rab46 would 
be necessary for histamine induced retrograde transport of WPBs was considered. Consistent 
with endogenous Rab46 localisation, exogenous expressed WT-Rab46 localised to WPBs. 
However, some of these Rab46-positive WPBs localise to a perinuclear region probably due 
to an effect of overexpression which could drive a GTP-bound state as many Rab proteins 
have slow intrinsic GTP hydrolysis rate. I have previously shown (3.3.1) that the 
constitutively active Rab46 mutant (Q604L) localised to the perinuclear region supporting 
the Rab46 motility to the perinucleus being dependent on GTP-binding. Here, the data 
suggest that GTP-bound Rab46 is necessary for WPB motility, as vWF (red) co-localised 
with Q604L Rab46 (green) at the MTOC, labelled with pericentrin (white), even in the 
absence of stimulation (Figure 4.8). In contrast, histamine failed to induce redistribution of 
Rab46 or perinuclear clustering of WPBs in cells overexpressing the N658I inactive Rab46 
mutant (Figure 4.9).  
The data suggest that GTP binding status governs the perinuclear localisation of WPBs, 
therefore GTPase activity regulates Rab46 localisation to WPBs as well as its function. 
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Figure 4.8 Constitutively active (Q604L) Rab46 localises vWF to the MTOC in the 
absence of stimulation. DeltaVision images of HUVECs immunostained for Rab46 
Q604L (green), vWF (red) and pericentrin (white) as a marker of the MTOC in control 
conditions. vWF localises to the perinucleus (arrows) in cells expressing Q604L in the 
absence of stimulation. Scale bar 30 μm.  
 
 
 
Figure 4.9 Rab46 GTPase activity is needed for WPB retrograde trafficking. 
Endothelial cells transfected with the inactive N658I Rab46 mutant treated with vehicle 
control (top) or 30 µM histamine (bottom) and immunostained for Rab46 (green), vWF (red) 
and pericentrin (white) as a marker of the MTOC. Histamine does not induce vWF 
perinuclear clustering of cells overexpressing the inactive N658I Rab46 mutant. Example 
cells outlined in yellow. n/N = 3/15. Scale bar = 50 μm. 
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4.6 Intact microtubule network is necessary for Rab46-
dependent WPB trafficking to the MTOC 
Intracellular transport of organelles along microtubules is a fundamental process essential to 
many cellular functions. The role of cytoskeleton in WPB motility has previously been 
studied. Microtubules are required for long-range movement of WPBs to the cell 
periphery186. Questioning how WPBs move back to the MTOC, the role of the microtubule 
network in Rab46-dependent WPB trafficking, following histamine stimulation, was 
evaluated.  Endothelial cells were pre-treated with 1 μM nocodazole, a microtubule-
disruptive agent, for 30 mins and then stimulated with histamine (30 μM) for 10 mins (Figure 
4.10a). α-tubulin staining (small insets bottom right) reveals complete disassembly of 
microtubules in nocodazole-treated cells compared to non-treated cells. Moreover, to assess 
cell viability a washout experiment was performed where nocodazole was removed and cells 
were re-incubated with normal medium. Microtubules re-polymerization was monitored and 
after 2 hours microtubules were able to regenerate a complete network (data not shown). 
Immunofluorescent staining and imaging analysis show that disruption of microtubules 
inhibited histamine induced WPB and Rab46 perinuclear clustering. Rab46 intensity in the 
perinuclear area following histamine stimulation is indeed significantly reduced in 
nocodazole treated cells (Figure 4.10b). 
The data show that microtubule integrity is required for Rab46-dependent WPB retrograde 
transport to the MTOC in response to histamine. 
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Figure 4.10 The integrity of microtubules is necessary for Rab46-dependent 
trafficking of WPBs to the MTOC. (a) Non-treated and histamine treated endothelial cells 
(top) compared with (bottom) endothelial cells pre-treated with nocodazole (1 µM) 
stimulated with 30 µM histamine for 10 mins and then fixed and stained for vWF (red) and 
Rab46 (green). Panels (bottom right) showing tubulin staining of endothelial cells before and 
after nocodazole treatment. (b) Mean data showing the cellular distribution of Rab46 upon 
histamine stimulation in cells pre-treated with nocodazole (b) and respective control cells. 
The plots quantify Rab46 signal intensity in the respective area where the mean (± SEM) was 
noted as percentage of the total signal intensity. n/N=3/18, *p-value < 0.05 **p-value < 
0.01 from 1-way ANOVA. 
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4.7 Retrograde WPB trafficking is dynein-dependent  
Microtubule-based transport of cargo is mainly directed by cytoskeletal-associated motor 
proteins which regulate spatio-temporal trafficking of different organelles. Bidirectional 
movements along the radially organized microtubules is driven by two main intracellular 
motor proteins: kinesin and dynein, which move in two opposite directions. Kinesin is a 
plus-end motor protein moving cargos to the cell periphery, whereas cytoplasmic dynein is 
a minus-end motor protein responsible for retrograde trafficking. Considering WPB 
retrograde trafficking upon histamine stimulation, the role of cytoplasmic dynein was 
investigated. Ciliobrevin D is an inhibitor of dynein ATPase activity, preventing the cycling 
activity of the motor protein necessary for dynein movement. Therefore, endothelial cells 
were pre-treated with ciliobrevin D (45 μM) for 45 mins to inhibit dynein activity and then 
treated with histamine for 10 mins. Rab46 and WPB localisation was observed by co-staining 
for Rab46 and vWF (Figure 4.11a). Representative images show typical Rab46 and WPBs 
clusters at the MTOC in histamine-treated cells in contrast with ciliobrevin pre-treated cells 
where histamine failed to induce Rab46-dependent WPB retrograde trafficking.  Moreover, 
quantification of Rab46 cellular distribution in ciliobrevin-treated cells reveals significant 
reduction in Rab46 signal at the perinuclear area when compared to histamine-treated cells 
(Figure 4.11b).  
These results show that dynein activity is necessary for Rab46-dependent trafficking of 
WPBs along the microtubules to the MTOC. 
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Figure 4.11 Dynein activity is necessary for Rab46-dependent trafficking of WPBs to 
the MTOC. (a) Histamine treated endothelial cells (left) compared with (right) endothelial 
cells pre-treated with ciliobrevin D (45 µM) stimulated with 30 µM histamine and then fixed 
and stained for vWF (red) and Rab46 (green). (b) Mean data showing the cellular distribution 
of Rab46 upon histamine stimulation in cells pre-treated with ciliobrevin and respective 
control cells. The plots quantify Rab46 signal intensity in the respective area where the mean 
(± SEM) was noted as percentage of the total signal intensity. n/N=3/18, *p-value < 0.05 
**p-value < 0.01 from 1-way ANOVA. 
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Chapter 5  Mechanisms underlying Rab46-dependent 
WPB trafficking 
 
5.1 Introduction 
To understand the molecular mechanism underlying Rab46-regulated WPB trafficking, it is 
essential to identify cellular Rab46 partners which may temporally and spatially control its 
activity. Although there is a high degree of Rab domain sequence conservation, the functional 
diversity of all the Rab family members arises from their interaction with a wide variety of 
effectors. To this extent, Rab-family members acquire particular features that allow them to 
perform specific cellular functions. By interacting with a wide variety of effectors, they play 
a key regulatory function in coordinating the consecutive stages of intracellular trafficking.  
The characterization of the protein–protein association mechanisms is crucial to 
understanding how biological processes occur. Srikanth et al., identified Vav1 as a new Rab46 
interacting protein in T-cells. Interaction with Vav1 is crucial for recruitment and 
accumulation of Rab46 vesicles at the immunological synapse. A recent paper from the Vale 
lab also identifies the dynein protein as a new Rab46 interacting partner in immune cells, 
presenting Rab46 as a novel dynein adaptor protein. Despite these two studies in immune 
cells, the mechanisms underlying Rab46 function in endothelial cells is unknown.   
The aim of this chapter is to identify putative Rab46-interacting proteins in order to gain 
insight the molecular machinery which coordinate WPB trafficking. It has already been 
shown that most of the already known Rab effector proteins preferentially interact with the 
active GTP-bound form of the Rab GTPase as conformational change expose the binding 
sites allowing their specific cellular function. In order to identify potential Rab46 effectors, 
the constitutive active mutant (Q604L) was compared with the inactive (N658I) in proteomic 
analysis and immunoprecipitation assays, followed by western blots validation of potential 
candidate proteins.    
This chapter establishes two new Rab46-interacting proteins in endothelial cells. The Na2+ 
/K+ ATPase subunit 1α (ATP1α) and the Dynein Heavy Chain (DHC) interact with the 
active form of Rab46 in addition to endogenous Rab46 upon histamine stimulation. 
Interestingly, and in agreement with (the Vale paper)173, my data suggest Rab46 interacts 
directly with the dynein-dynactin complex.   
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5.2 Identification of Rab46 binding partners 
To identify Rab46 interacting partners, pull-down assays with recombinant Rab46 mutants 
followed by mass spectroscopy were used. Figure 5.1 illustrates a graphical representation of 
the pull-down workflow for protein identification by mass spectrometry. Briefly, GFP-
tagged Rab46 active (Q604L) and inactive (N658I) forms were overexpressed in endothelial 
cells, expression of a GFP empty vector was used as a negative control. High affinity binding 
and high specificity of ChromoTek GFP-trap beads allowed purification and specific elution 
of any protein complex bound to the beads. 20% of the elution fraction from three biological 
replicates was analysed by western blot (Figure 5.2) to confirm efficient pull-down.  
Immunoblot with anti-GFP antibody shows a single band at the expected molecular weight 
(120 kDa) in the total lysates as well as the elution fractions of both Q604L and N658I, 
indicating that the GFP-Rab46 mutants successfully bound to the GFP-beads. All the 
interacting proteins which co-purified with the two Rab46 mutants were subsequently 
identified using mass spectroscopy (LC-MS/MS).  
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Figure 5.1 Pull-down experiment workflow for endothelial cells proteomics. The 
flowchart demonstrates the major steps for the purification of tagged proteins along with 
their interactors. Endothelial cell transfected with GFP-tag protein were lysed and incubated 
with GFP-trap beads. After incubation the beads were sedimented and a small fraction of 
the unbound supernatant was taken for subsequent western blot analysis. Following several 
washing steps the protein complex bound to the beads was eluted with appropriate buffer. 
10% of the beads were used for SDS-PAGE/Coomassie staining and western blot analysis. 
The inset illustrates how the bait protein, tagged with GFP, binds to an affinity bead via 
direct interaction with a GFP-binding domain. Proteins interacting with the bait protein co-
purify on the affinity beads and are subsequently identified using mass spectrometry.  
 
 
Figure 5.2 Pull-down of Rab46 binding mutants. (a) GFP-tagged active and inactive form 
of Rab46 (Q604L and N658I respectively) were overexpressed in HUVECs. Cells lysates 
were incubated with GFP-trap beads (ChromoTek) and pulled down proteins were subjected 
to SDS-PAGE and western blot. Anti-GFP antibody was used to check successful pull-
down. Input represents total lysate, FT represents flow-through after incubation and GFP-
trap represents pull-down proteins.  n=3.   
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5.2.1 Proteomic analysis 
LC-MS/MS was the method of choice for analysing the components of the final eluted 
samples from GFP-trap pull-down. The three groups of analysis (QL: active, NI: inactive 
and GFP: control) generates four different datasets: i) QLvsGFP ii) NIvsGFP (control 
datasets) iii) QLvsNI and iv) NIvsQL (datasets of interest). These comparisons give a fold 
change value which is calculated by comparing the peak areas and a p-value for significance 
between the technical and biological triplicates.  
The MS analysis, performed by Gemini Biosciences, identified a large number of peptides 
from proteins that had been significantly (p≤ 0.05) pulled down by the Rab46 mutants. In 
order to narrow the number of candidate proteins for further investigation, a list of criteria 
was established. Firstly, a 1.5-fold change cut-off was set and p-value ≤ 0.05 was considered 
the significant threshold. Figure 5.3 shows the distribution of quantified proteins according 
to the set criteria. The first sorting, considering fold change values ≥ 1.5 (vertical line), 
highlights 10% of all the proteins identified in the QL sample by mass spectroscopy and 20% 
of the one identified in the NI (blue data points). It also shows that proteins with high fold 
changes do not necessarily have low p-values. Therefore, to further narrow the investigations, 
an extra selection step was applied to previously sorted proteins based on the significance of  
p-values. Proteins with fold change ≥ 1.5 and p-value ≤ 0.05 (red data points) result to be 
5% of the total proteins identified by mass spectroscopy. In order to prevent missing out 
any potential trusted candidates, the mean and the median values were also taken into 
consideration for proteins with fold change ≥ 1.5 but non-significant p-value. Co-purified 
impurities such as keratin and trypsin were ignored. These criteria were applied to all the 
datasets. 
Next, control datasets were compared to their respective dataset of interest, i.e. QLvsGFP 
compared to QLvsNI. Venn diagram in Figure 5.4 shows comparisons between all the 
datasets revealing the percentage of proteins in common between them. Proteins identified 
in both datasets were highlighted as positive candidate proteins together with the ones 
uniquely present in the dataset of interest with significant p-value and fold change greater 
than 1.5. A final list of candidate proteins, sorted by fold change, was compiled (Figure 5.5 
and  Figure 5.6) and the biological significance in the context of membrane trafficking of the 
selected proteins was evaluated. 
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Figure 5.3 Visualization of proteomic data. Scatter plots showing the distribution of 
proteins that co-precipitated with GFP-tagged Rab46 nucleotide binding mutants or GFP 
control. Proteins identified from mass spectrometry analysis were plotted according to p-
value (-log10  transformed) on the y-axis and fold change (log2  transformation) on the x-axis. 
Significance level is indicated with a horizontal straight black line (p-value < 0,05) and fold 
change threshold with vertical black line (fold change ≥ 1.5). Representative scatter plot from 
control dataset (a) and dataset of interest (b) where a first sorting filter was applied to 
highlight proteins with a fold change greater than 1,5 and significant p-values. 
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Figure 5.4 Comparison between the datasets illustrate proteins that are uniquely 
present in one condition and not in others. Venn diagram comparing the accession 
numbers of proteins identified in four different conditions: QL vs GFP and NI vs GFP 
(control datasets), QL vs NI and NI vs QL (datasets of interest) illustrating the intersections 
between the proteomes (Venny, http://bioinfogp.cnb.csic.es/tools/venny). 
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5.2.2 Candidate protein selection 
The proteomic analysis led to a list of candidate proteins for both the active and inactive 
forms of Rab46 (Figure 5.5a and Figure 5.6a). The PANTHER classification system was used 
to classify proteins by function in order to identify those functional categories, and respective 
pathways, which were overrepresented in the two groups. A functional classification was 
performed using the gene list analysis tool within PANTHER. This tool returns the results 
in a pie chart, which displays an overview of all ontology terms at the first (or most general) 
level within the same ontology. When a slice of the pie chart, which represents an ontology 
term, is clicked, a new pie chart will appear that contains its child ontology term. Analysis of 
the list of proteins identified for the inactive form of Rab46 (NI) generates the protein 
function pie chart in Figure 5.5b. 72% of the gene hits were classified as having a nucleic 
acid binding function which include structural molecular activity and transcription or 
translation regulation. The other proportion is divided into different protein classes with a 
very low representation hits which are mainly involved in the apoptosis or autophagy 
signalling pathway.  On the other hand, the gene classification regarding the active form of 
Rab46 (QL) returns a pie chart (Figure 5.6b) where different protein classes were identified. 
The most abundant protein classes are the membrane traffic protein class and the hydrolase 
class. However, to further seek a biological explanation, classification according to the 
biological process to which a protein contributes was performed. More than 40% of the hits 
have a role in cellular components organisation and localisation. Interestingly, the second 
level of classification shows that the most represented function is the establishment of 
organelle localisation and transport. The most relevant proteins which were often highlighted 
were vesicle-mediated transport protein (BCAP31, CLTC and COPA), regulatory membrane 
traffic protein like LAMP1 and MYO9, transporter protein (ATP1α) and (DYNCH1) as 
proteins involved into establishment of organelles localisation and transport along the 
microtubules. 
To select candidate proteins with possible biological relevance to Rab protein regulation, I 
performed a literature review and an overview of available resources and tools (i.e. antibody, 
siRNA) for the proteins highlighted by the panther analysis. Although all highlighted proteins 
represent interesting candidates, two recent publications173-187 drove the attention to the Na2+ 
/K+ ATPase subunit 1α (ATP1α) and the cytoplasmatic dynein heavy chain (DYNCH1 or 
DHC). The relevance of the ATP1α  arises from its new role in regulating Rab27a localisation 
and activation in melanocytes proposed by Booth et al187. Rab27a is one of the most 
characterised Rab GTPases associated with WPBs, thereby suggesting a role of the ATP1α 
in regulating Rab46 and WPBs. Very recently,  the identification of Rab46 as a new dynein 
adaptor protein in immune cells by Wang et al.173 as well as our previous knowledge about 
the role of dynein activity in Rab46-depedent WPB trafficking, advocates DHC as a 
candidate for investigation.  
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Consequently, ATP1α and DHC were chosen to further characterise Rab46 interactions. 
 
 
Figure 5.5 Analysis of Rab46 binding mutants interactome. (a) Proteins co-precipitate 
with GFP-N658I and identified by mass spectrometry analysis, in reference to GFP-Q604L, 
were sorted by fold change and p-value and then ranked by decreasing fold change. Bubble 
plots show proteins with Fold change greater than 1,5 and p-value < 0,05. Circled area is 
proportional to the fold change. (b) Panther Pathway Analysis and classification of the GFP-
N658I hits into the most relevant protein classes. 
b
a 
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Figure 5.6 Analysis of Rab46 binding mutants interactome. Proteins co-precipitate with 
GFP-Q604L identified by mass spectrometry analysis in reference to GFP-N658I, were 
sorted by fold change and p-value and then ranked by decreasing fold change. Bubble plots 
show proteins with Fold change greater than 1,5 and p-value < 0,05. Circle area is 
proportional to the fold change. Relevant proteins for this thesis are highlighted (red). (b) 
Panther Pathway Analysis and classification of the GFP-Q604L hits into the most relevant 
protein classes. (c) Panther Analysis of the candidate proteins contributions to the 
highlighted biological process.   
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5.3 Validation of Rab46 interacting proteins 
The GFP-trap pull-down and the mass spectrometry analysis identified a selection of putative 
Rab46-interacting proteins. In particular, the ATP1α and the DHC proteins were selected 
due to their potential relevance in terms of organelles trafficking and localisation. In order 
to validate the presence of ATP1α and DHC in the same complex with the constitutively 
active Rab46, co-immunoprecipitation (co-IP) experiments were performed. The GFP-
Rab46 active and inactive constructs (Q604L and N658I, respectively) were overexpressed 
in endothelial cells. A GFP immunoprecipitation (IP) was performed and immunoblotting 
was utilised to detect whether the two selected candidates co-precipitated. Firstly, the 
interaction between GTP-bound Rab46 (Q604L) and the dynein heavy chain was examined. 
Immunoblotting using a GFP antibody reveals the presence of a specific band at the expected 
molecular weight (120 kDa) in the input lysate showing the transfection efficiency of the 
active (GFP-QL) and inactive (GFP-NI) Rab46 in the total lysate. The GFP antibody used 
for the IP was able to pull-down both the GFP constructs as indicated by the single band in 
the IP lanes and immunoblotting for the dynein heavy chain confirms its presence in the 
same sample with the active form of Rab46 (Figure 5.7). These results validated the mass 
spectrometry analysis suggesting that both GTP-Rab46 (Q604L) and the dynein heavy chain 
interact in the same complex. 
The result was similar when the expression of ATP1α was validated by IP and 
immunoblotting. Probing with a GFP antibody shows expression of the Rab46 constructs 
in the input as well as after IP. Immunoblotting for ATP1α shows single band at the expected 
molecular weight (110 kDa) in the total lysate and in the IP samples. Notably, the ATP1α 
preferentially interacts with the active GTP-Rab46 (Figure 5.8). These results propose two 
new Rab46 interacting proteins; both the dynein protein and the ATP1α preferentially 
interact with the active form of Rab46 when the GFP-construct is overexpressed in 
endothelial cells.  
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Figure 5.7 Immunoprecipitation of Rab46 nucleotide binding mutants to confirm 
proteomic analysis. GFP-tagged active and inactive form of Rab46 (Q604L and N658I 
respectively) were overexpressed in HUVECs and immunoprecipitation performed using an 
anti-GFP antibody. Input represents lysate before immunoprecipitation and IP denotes 
samples after GFP immunoprecipitation. Western blot using anti-GFP and anti-dynein heavy 
chain antibodies shows that the dynein heavy chain co-precipitates with the active form of 
Rab46 (Q604L). n=3 
 
 
Figure 5.8 Immunoprecipitation of Rab46 nucleotide binding mutants to confirm 
proteomic analysis. GFP-tagged active and inactive form of Rab46 (Q604L and N658I 
respectively) were overexpressed in HUVECs and immunoprecipitation performed using an 
anti-GFP antibody. Input represents lysate before immunoprecipitation and IP denotes 
samples after GFP immunoprecipitation. Western blot using anti-GFP and anti-ATP1α 
antibodies shows that the ATP1α co-precipitates with the active form of Rab46 (Q604L). 
n=2 
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5.3.1 Validation of endogenous Rab46 protein-protein interaction 
High concentrations of proteins can potentially interfere with cellular function in several 
ways, for example by activating or overloading certain biological pathways, disrupting their 
regulation, upsetting the balance in protein complexes or by aggregating together188. 
Ultimately, overexpressing any protein will be destructive because it exhausts the resources 
of the cell to make and transport proteins189. 
It is evident that the concentration of a protein can be a major driving force for any protein 
interaction; hence, when artificially raising cellular protein concentrations, non-interactors 
might be forced to associate190.  In order to avoid side effects of unequal gene dosage causing 
unbalanced stoichiometry leading to artificial results, it is important to evaluate biologically 
meaningful interactions under native conditions. This approach should allow spatiotemporal 
resolution of interactions distinguishing from artefacts caused by overexpression. 
Highlighting these points, the IP protocol was adapted for the endogenous Rab46 protein. 
The anti-Rab46 antibody bound to sepharose beads was used to immunoprecipitate 
endogenous Rab46 from endothelial cell lysate. The ratio between antibody and protein 
lysate was optimized to avoid saturation and non-specific binding. Figure 5.9 shows 
successful IP of endogenous Rab46 using 1 μg of antibody and 0.5 mg of total lysate. 
The ability to pull-down endogenous Rab46 prompts further more biologically relevant 
investigations to examine Rab46 protein interactions in endothelial cells under both resting 
and stimulated conditions. 
 
 
Figure 5.9 Immunoprecipitation of endogenous Rab46. Representative western blot 
showing successful immunoprecipitation of endogenous Rab46 using sepharose beads 
conjugated with anti-Rab46 antibody. Input represents HUVECs lysate before the IP and 
co-precipitated samples after elution are denoted as IP. Anti-rabbit IgG are used as control. 
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5.3.1.1 Endogenous Rab46 interacts with the ATP1α 
Heterologous expression of Rab46 mutants suggests ATP1α interaction with the active form 
of Rab46. To validate this result for the native protein, endogenous Rab46 IP was repeated 
and ATP1 co-immunoprecipitation assessed by immunoblotting. I have previously shown 
(section 3.3.1 and Figure 4.8) that the constitutively active form of Rab46 (Q604L) localises 
to the perinuclear area which is mimicked by histamine stimulation of endogenous Rab46. 
Therefore, to mimic GTP-driven Rab46 localisation in native condition, endothelial cells 
were treated with histamine prior to IP of endogenous Rab46. Cell lysates were incubated 
with anti-Rab46 antibody or control IgG and pulled down with sepharose beads. Eluted 
samples were analysed by western blot (Figure 5.10a). Immunoblotting for Rab46 shows a 
band at 95 kDa confirming positive IP for non-treated and treated cells in contrast with no 
signal in the negative IgG control. To examine the existence of the ATP1α in the same 
sample, immunoblotting for the ATP1α was performed. The Na2+ /K+ ATPase subunit 1α 
has a predicted molecular weight of 110 kDa, which was confirmed  via immunoblotting by 
the presence of a specific band at the exact molecular weight in the total lysate as well as the 
IP fractions. Although a faint band is present into the non-treated IP fraction, a stronger 
band is visible in the histamine-treated sample.  To further validate the interaction between 
Rab46 and the ATP1α, a reverse co-IP was performed using an antibody against the novel 
target (ATP1α) and immunoblotting for the original “bait” (Rab46).  Similarly, the reverse 
co-IP shows the presence of Rab46 in both the ATP1α IP fractions with a stronger band 
corresponding to the histamine stimulated IP fraction (Figure 5.10b). The specificity of this 
interaction is supported by the use of control IgG as negative control showing no interaction 
between the IgG and the target proteins.  
These results suggest that Na2+ /K+ ATPase subunit 1α is a Rab46-interacting protein and 
that this interaction is enhanced after histamine stimulation. 
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Figure 5.10 Endogenous Rab46 interacts with the Na+/K+ ATPase subunit α1. (a) 
Immunoprecipitation of endogenous Rab46 in HUVECs stimulated with 30 μM histamine 
or vehicle control was performed using an anti-Rab46 antibody and co-precipitation of 
ATP1a1 was assessed by immunoblotting. Input represents total lysate before the IP and 
samples after the IP are denoted as IP. (b) Reverse co-immunoprecipitation of endogenous 
Rab46 performed using anti-ATP1a1 antibody, co-precipitation was assessed by 
immunoblotting for Rab46. Input represents total lysate before the IP and samples after the 
IP are denoted as IP. Anti-rabbit and anti-mouse IgG were respectively used as negative 
controls. Blots are representative of 3 independent experiments.  
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5.3.1.2 Endogenous Rab46 interacts with the cytoplasmic dynein  
Heterologous expression of Rab46 mutants also suggests DHC interaction with the active 
form of Rab46. To validate this result and better characterise the nature of the interaction, 
endogenous Rab46 IP was performed and DHC co-IP assessed by immunoblotting. As 
described above, to mimic GTP-bound active Rab46, endothelial cells were stimulated with 
histamine and co-IP was performed. Western blot analysis confirmed similar levels of Rab46 
expression in the total lysates and the IP. DHC is a large protein with a predicted molecular 
mass of 500 kDa, therefore a suitable western blot protocol for large proteins was performed. 
Immunoblotting for DHC successfully revealed a specific band at the correct molecular 
weight (500kDa) in the total lysates as well as in the IP corresponding to the non-treated and 
histamine treated samples (Figure 5.11a).  In addition, a reverse co-IP using an anti-DHC 
antibody to pull-down endogenous dynein and immunoblotting to seek for Rab46 co-IP was 
performed. Similarly, dynein was pulled down with Rab46 in both the vehicle and histamine 
treated cells. No cross-reaction was observed in the negative IgG control, suggesting specific 
interaction between endogenous Rab46 and the DHC in both the tested conditions but with 
a potential enhanced interaction upon histamine treatment (Figure 5.11b). 
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Figure 5.11 Endogenous Rab46 interacts with the dynein motor protein. (a) 
Immunoprecipitation of endogenous Rab46 in HUVECs stimulated with 30 μM histamine 
or vehicle control was performed using an anti-Rab46 antibody and co-precipitation of DHC 
was assessed by immunoblotting for dynein heavy chain. Input represents total lysate before 
the IP and samples after the IP are denoted as IP. (b)  Reverse co-IP of endogenous Rab46 
performed using anti-dynein heavy chain antibody, co-precipitation was assessed by 
immunoblotting for Rab46. Rab46 is shown at an increased exposure and overlaid on the 
blot. Input represents total lysate before the IP and samples after the IP are denoted as IP. 
Anti-rabbit IgG or Sepharose beads were used as negative controls. Blots are representative 
of 3 independent experiments. 
  
- 115 - 
 
5.4 The cytoplasmic dynein-dynactin motor complex interacts 
with Rab46 
Cytoplasmic dynein-1 is a large protein complex that drives long-range retrograde transport 
along microtubules. Dynein works together with another protein complex called dynactin 
which is an essential co-factor for all dynein function including dynein motility. To further 
characterise the interaction between Rab46 and the DHC, I investigated the interaction 
between Rab46 and the dynactin complex. The largest component of the dynactin complex 
is p150Glued which binds to dynein and mediates direct association between dynactin and 
microtubules. Co-immunoprecipitation assays were carried out to ascertain whether Rab46, 
DHC and p150 co-immunoprecipitate with each other in endothelial cells before and after 
histamine stimulation. First of all, endogenous Rab46 was pulled-down and immunoblotted 
for both DHC and p150Glued (Figure 5.12a). Rab46 was equally pulled down before and after 
histamine stimulation and co-IP of DHC was confirmed by the presence of a single band at 
500 kDa in both conditions. Furthermore, probe for p150 revealed a single band at 120 kDa 
in the total lysate as well as the IP fractions. To confirm this association, the interaction was 
further investigated by performing the reverse IP. Endothelial cells were lysed and incubated 
with anti‐p150 antibody or anti-DHC antibody. The IP was assessed by immunoblotting for 
p150, Rab46 and DHC. Probing for these proteins simultaneously revealed a band at the 
expected molecular weight of endogenous Rab46 (95 kDa) in both the DHC and p150 IP 
samples (Figure 5.12b-c).  
The presence of Rab46, DHC and p150 in the same IP sample suggested the existence of a 
Rab46-dynein-dynactin motor complex.  
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Figure 5.12 Endogenous Rab46 interacts with the dynein-dynactin complex. (a) 
Immunoprecipitation of endogenous Rab46 in HUVECs stimulated with 30 μM histamine 
or vehicle control was performed using an anti-Rab46 antibody and co-precipitation of DHC 
and p150, subunit of dynactin, was assessed by immunoblotting for dynein heavy chain and 
p150. (b)  Reverse co-immunoprecipitation of endogenous Rab46 and p150 subunit was 
performed using anti-dynein heavy chain antibody, co-precipitation was assessed by 
immunoblotting for Rab46 and p150. (c) Reverse co-immunoprecipitation of endogenous 
Rab46 and dynein heavy chain was performed using anti-p150 antibody, co-precipitation was 
assessed by immunoblotting for Rab46 and DHC. Input represents total lysate before the IP 
and samples after the IP are denoted as IP. Corresponding IgG were used as negative control. 
Blots are representative of 3 independent experiments.   
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5.5 Regulation of dynein-Rab46 interaction by calcium 
Rab46 contains two functional Ca2+ binding motifs (EF-hands) in the C-terminal167. Wang et 
al173 recently reported that Ca2+ binding to the EF-hands was necessary for the interaction 
between Rab46 and dynein in T-cells. Therefore, I investigated the role of Ca2+ binding to 
Rab46 in the interaction between dynein and Rab46 in endothelial cells. Ca2+ was unable to 
bind to Rab46 when the EF-hands were mutated (Rab46EFmut) regardless of Ca2+ 
concentration172 (Figure 5.13a). Imaging of Rab46EFmut overexpressed in endothelial cells 
revealed a strong perinuclear clustering, suggesting anchoring of Rab46EFmut to the MTOC 
(Figure 5.13b). We have previously shown that Ca2+ is necessary for dissociation of Rab46 
clustered at the MTOC by histamine stimulation, evoking subsequent dispersal191. According 
to proteomic analysis (5.2.1) and western blot (Figure 5.7), the inactive nucleotide-free Rab46 
does not bind to the DHC. Therefore, in order to investigate the effect of Ca2+ on Rab46 
interaction with dynein, a co-IP was performed.  GFP-tagged Rab46EFmut, inactive GFP-NI 
Rab46 construct or a GFP only vector were overexpressed in endothelial cells and an IP 
performed using anti-GFP antibody. The IP was validated by immunoblotting for GFP and 
co-IP of dynein assessed by DHC probing (Figure 5.14). Similar levels of expression of all 
the constructs were observed in the total lysates (input) and successful IP of GFP-tagged 
Rab46 confirmed by a band at approximately 120 kDa. The use of GFP antibody for the IP 
rather than GFP-trap and the use of the same antibody for immunoblotting highlighted non-
specific bands (asterisks*) corresponding to the IgG heavy (50 kDa) and light chains (25 
kDa) but this had no effect on the detection of both Rab46 and DHC. Although the level of 
Rab46EFmut in the IP fraction is lower than the inactive GFP-NI mutant, immunoblotting for 
DHC shows a distinct band, at the correct molecular weight, in this fraction as compared to 
the NI mutant or GFP control. Surprisingly, these results suggest that the interaction 
between Rab46 and the dynein heavy chain is Ca2+-independent. 
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Figure 5.13 Rab46 calcium-binding defective mutant.  (a) Schematic representation of 
Rab46 structure showing mutations in the two EF-hands which abolish calcium binding. (b) 
Super-resolution imaging of endothelial cells expressing Rab46 EF-hand mutant (green). 
Deficiency in calcium binding shows Rab46EFmut clustering in the perinuclear area. DAPI 
(blue) for the nuclei. Scale bar = 30 μm  
  
* *
Ca2+
a
b
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Figure 5.14 Rab46 and dynein interaction is calcium-independent. 
Immunoprecipitation of Rab46 binding mutants (GFP-NI and GFP-EF hand mutant) in 
HUVECs was performed using an anti-GFP antibody and co-precipitation of DHC was 
assessed by immunoblotting for dynein heavy chain. Input represents total lysate before the 
IP and samples after the IP are denoted as IP. Empty GFP vector was used as negative 
control. Blots are representative of 2 independent experiments.  
   
kDa 
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5.6 Characterisation of Rab46 and dynein interaction 
Cytoplasmic dynein is a minus end-directed motor, composed of two globular heads, each 
formed from a single dynein heavy chain (DHC) and a base from intermediate (DIC) and 
light chains (DLC). Dynein binds to microtubules through dimerization of its two heavy 
chains: the C-terminal of the heavy chain constitute the motor domain with ATP-binding 
activity (six ATPase subunits) and a stalk domain which link the motor to the microtubules, 
whereas the N-terminal constitute the tail domain where the association of the DIC and the 
DLC form a cargo-binding complex192. The association of dynein with many membrane 
cargos or target sites requires the accessory dynactin protein complex, which interact with 
DIC though the p150 glued subunit.192 (Figure 5.15a-b). 
On one side, the complex dynein structure provides a dynamic interaction with the 
microtubules through the catalytic heavy chains, on the other side the tail complex is 
responsible for linking the dynein motor complex to different cargos, directly or through 
adaptors. Because the tail region links the motor to a cargo, understanding the interactions 
within this portion is important in determining how dynein is targeted and regulated.  
To this end, a commercially available purified protein corresponding to the N-terminal of 
the dynein heavy chain (Figure 5.15-box) was used to identify whether this sequence directly 
interacts with Rab46.  
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Figure 5.15 Schematic representation of the overall structure of a cytoplasmatic 
dynein and dynactin complex.   (a) Structural organization of a dynein complex: the dynein 
heavy chain consists of a head region and a tail region which recruits the dynein intermediate 
chains and light chains. The dynactin complex interacts with dynein and mediates the 
interaction with cargo membrane. (b) Domain composition of the N-terminal stem region: 
dynein heavy chain (HC: grey) with interaction site for dimerization in red, dynein 
intermediate (IC) and light chains (LIC) interaction sites in blue and green respectively. The 
C-terminal region includes the motor domain with AAA1-6 and a stalk domain. The box 
below shows the sequence of the purified his-tag DYNC1H1 which is used in the following 
experiments.       
AAA1 AAA2 AAA3 AAA4 AAA5 AAA6Stalk
IC LICHC
(N) (C)
Motor domainStem: tail domain + linker
Ala20≈Leu285
Head
Tail
b
a
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5.6.1 Optimization of His-tag pull-down assay 
The recombinant dynein heavy chain protein contains N-terminal His-tags (His-DYNCH1) 
for purification and identification. Unfortunately, recombinant Rab46 was not available for 
me to examine if the two proteins had a direct interaction in vitro. Therefore, in order to get 
some insight into this interaction, I ectopically expressed the human WT-Rab46 in monkey 
Cos-7 cells and designed a pull-down experiment using His-DYNCH1. 
A pull-down assay is based on a bait protein captured on a solid support (beads) used to 
isolate potential binding proteins (prey) from a complex mixture. One of the most common 
tags used for purification or binding of expressed proteins is a short sequence of six histidine 
residues which has a unique ability to bind to divalent cations such as nickel, cobalt or copper. 
A powerful system to bind and immobilize His-tagged proteins is the use of solid support 
like beads where Ni2+ or Co2+ ions are immobilized. Here, we hypothesized that His-tagged-
DYNCH1, could be used as a bait to identify binding partners (prey) obtained from Cos-7 
cell lysate (transfected with human-Rab46), where monkey Rab46 may not be expressed or 
interact with human Rab46.  
The main steps of the pull-down workflow (obtained after a long optimization process) are 
shown in Figure 5.16. First, human WT-Rab46 was overexpressed in Cos-7 cells and cells 
were lysed after 24 hours. Cell lysate was pre-cleared with plain Ni2+ beads, to reduce non-
specific binding and then incubated with purified His-DYNCH1. This incubation permitted 
the formation of interacting complexes partners. Next, pre-equilibrated magnetic Ni2+ beads 
were mixed with the cell lysate containing the His-DYNCH1 and the WT-Rab46 proteins. 
After incubation the beads were washed with a gradient of washing buffer containing 
increasing amounts of imidazole to wash away unbound protein and impurities. Finally, the 
proteins were eluted with 500 mM imidazole elution buffer and the elution fraction analysed 
by SDS-Page and western blot. 
For validating biologically significant results, negative controls were used. Total lysates (no 
pull-down) from Cos7 cells were used to indicate if endogenous Rab46 (if expressed in Cos7 
cells), was similar to human Rab46 (Rab46 polyclonal antibody recognises 395 amino acid 
sequence of Rab46), thereby confounding any possible direct interaction.  A WT-Rab46 
control alone (minus His-DYNCH1) helps identify and eliminate false positives caused by 
non-specific binding of proteins to the Ni2+ beads. A bait control (plus His-DYNCH1, minus 
WT-Rab46) helps identify and eliminate false positives caused by non-specific binding of 
Cos-7 proteins to the bait protein. This control also serves as a positive control that verifies 
successful capture of the His-tag protein to the Ni2+ beads.  
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Figure 5.16 Schematic representation of pull-down assay.  The flowchart demonstrates 
the major steps of the purification of histidine tagged proteins along with their interactors. 
Cos-7 cells transfected with WT-Rab46 construct were lysate after 24hours. Pre-cleared cell 
lysate was mixed with purified his-tag dynein heavy chain and the mixture added to pre-
equilibrated magnetic nickel beads. After 1 hour incubation the beads were washed using a 
magnetic rack and the protein complex bound to the beads eluted with imidazole buffer and 
analysed by SDS-PAGE and western blot. Proteins interacting with the bait protein (His-tag 
DYNC1H1) co-purify on the affinity beads and are subsequently identified by western blot.   
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5.7 Rab46 directly interacts with dynein 
To detect whether the purified DHC and the ectopically expressed Rab46 interact with each 
other and the complex co-precipitate together, a western blot was performed. Following pull-
down, the elution samples were loaded on a gel and immunoblotted for Rab46 and His-
tagged DHC. The recombinant portion of the dynein tail domain has a predicted molecular 
weight of 37 kDa. Its capture and elution from the Ni2+ beads was verified using an anti-
Histidine antibody. Western blot in Figure 5.17 shows a band at 37kDa in the first elution 
corresponding to the recombinant dynein in the positive control as well as into the elution 
fraction where it was mixed with WT-Rab46. Probing for Rab46 revealed a single band at 
the expected molecular weight (95 kDa) in the total Cos-7 lysate used as input but most 
importantly in the same elution fraction with the His-tagged dynein. No Rab46 was detected 
in cells not expressing human Rab46 and no cross-reactivity was observed in the negative 
control where WT-Rab46 was incubated with the Ni2+ beads but in absence of His-DHC.  
These results show that the interaction between Rab46 and the dynein heavy chain occurs 
through the specific tail domain of the dynein heavy chain suggesting a direct interaction 
between the two proteins.  
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Figure 5.17 Direct interaction of the dynein heavy chain with Rab46.  Pull down of 
human WT-Rab46 overexpressed in Cos7 cells (monkey cells) using purified his-tag dynein 
heavy chain (His-DHC) bound to Ni2+ beads. Non-transfected cells (-) and cells transfected 
with WT-Rab46 (+) were mixed with (+) or without (-) 10 μg of His-DHC. Magnetic 
sepharose Ni2+ beads were used to pull-down His-tag DHC complexes: the beads were 
incubated with the mixture of His-DHC + WT-Rab46 (or non-transfected cell as control) or 
WT-Rab46 only as control to show non-specific binding to the beads. Imidazole buffer (500 
mM) was used for elution. 15 μl of the elution fractions were loaded on a gel and co-
precipitation of Rab46 with his-DHC assessed by western blot using anti-Rab46 and anti-
histidine antibodies.  Representative western blot of 3 independent experiments. 
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5.8 Identification of Rab46-DHC binding sites 
Cytoplasmic dynein is a minus end–directed microtubule motor that transports intracellular 
cargos. The molecular basis by which each cargo is linked to dynein and its cofactor dynactin 
has started to emerge. A central role for this process is fulfilled by a set of coiled-coil proteins 
— ‘activating adaptors’ — which both recruit dynein–dynactin to their cargos and activate 
dynein motility. Thus far, eight adaptors have been demonstrated to directly bind and activate 
dynein: BicDL1, BicD2, Hook1, Hook3, Rab11FIP3, Spindly, Ninein, and Ninein-like 
proteins193,194. Recruitment of the dynein–dynactin adaptor complex to specific membrane 
organelles is often mediated by the interaction between a dynein adaptor and a Rab GTPase, 
which associates with intracellular membrane compartments through C-terminal prenylation. 
A common feature of the dynein adaptor proteins is the presence of long coiled-coil domains 
with conserved residues important for dynein interaction. 
Rab46 is an unconventional Rab GTPase that contain a pair of EF-hand, a coiled-coil domain 
and a Rab GTPase domain (Figure 5.18).  The domain architecture, as already suggested by 
Wang et al., resemble the well-known dynein adaptor Rab11FIP3116 with two EF-hand 
followed by coiled-coils domains. Wang et al demonstrated that Rab46 and Rab45 are new 
dynein adaptor protein in T-cells173.  
This structure similarity raises the question about the presence of conserved residues in 
Rab11FIP3 sequence which could be shared with Rab46.   Comparing the sequence of Rab46 
and Rab11FIP3 by a global sequence alignment, 13.6% of identity and 22.9% of similarity 
was shown (Figure 5.19). Interestingly, the two proteins have high similarity especially within 
the Ca2+ binding motif, in the conserved coiled-coil domain and in a specific Rab-binding 
domain at the C-terminal called FIP-RBD domain.  In particular, two conserved alanine 
residues responsible for dynein binding in the Rab11FIP3 sequence were highlighted in red 
as they appear to be in common with Rab46 sequence. The A435 in the coiled-coil domain 
and the A709 in FIP-RBD domain are also conserved in other dynein adaptors and mutations 
of these alanine residues to valine abolished dynein interaction. Identification of the A227 at 
the very beginning of Rab46 coiled-coil domain and the A555 within the Rab domain which 
perfectly matched the two alanines previously identified in the Rab11FIP3 sequence suggest 
the possibility that these residues may be important in binding the N-terminal of the dynein 
heavy chain.  
As previously mentioned, a common feature of all the dynein adaptors is the presence of 
long coiled-coil domain, in particular a short region at the very beginning called CC1 box 
found in the BICD family, the spindly protein and some candidate dynein activator, is 
involved in the interaction with dynein. Therefore, comparison between the coiled-coil 
domain of Rab46 (I226-Q313) and the coiled-coil domains of other dynein adaptors such as 
BICD2, BICDR2, Spindly and HAP1  was examined (Figure 5.20). Remarkably, a common 
feature within the CC1 box was observed. Two alanines were also found within the Rab46 
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coiled-coil domain which are conserved among the already characterized dynein adaptors as 
they are responsible for the interaction with dynein. However two alanines are present in the 
Rab46 CC domain, the alignment shows that only the A227 matches with the others.   
These preliminary results highlight common features between Rab46 and some dynein 
adaptors, identifying two putative binding sites. Mutations of the two identified alanines 
would indicate whether the Rab46 interaction with the dynein heavy chain is disturbed.   
   
 
 
 
 
 
Figure 5.18 Domain organization of structural related Rab GTPases compared to 
Rab11FIP3, Spindly and BICR1 (dynein activators and adaptors). EF-hand domains 
(blue): calcium binding sites. Coil-coiled domain (CC: black): protein interactions sites. Rab 
(red): GTP/GDP binding site. CC1 (grey): coiled-coil segment shared by some dynein 
binding proteins. Spindly motif (S: purple): conserved features of some dynein activators. 
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Figure 5.19 Sequence alignment of Rab46 and Rab11FIP3 sequences showing 
conserved residues involved in dynein binding.  Sequence alignment using Clustal Ω 
shows a conserved region in the first coiled-coil segment of the dynein adaptor Rab11FIP3 
(CC1 box) and Rab46 coil-coiled domain. The alignment also shows a second conserved 
residue in the spindly motif of RFIP3 (708-712) which is shared within the Rab46 sequence. 
The two alanines (A435 and A709 in RFIP3) important in the interaction with dynein and 
the conserved alanines in Rab46 sequence (A227 and A555) are marked with red asterisks.  
  
CLUSTAL O(1.2.4) multiple sequence alignment
RFIP3 MASAPPASPPGSEPPGPDPEPGGPDGPGAAQLAPGPAELRLGAPVGGPDPQSPGLDEPAP 60
Rab46 ------------------------------------------------------------
RFIP3 GAAADGGARWSAGPAPGLEGGPRDPGPSAPPPRSGPRGQLASPDAPGPGPRSEAPLPELD 120
Rab46 --------------------------------MAAPDGRV-------------------- 8
:.* *::
RFIP3 PLFSWTEEPEECGPASCPESAPFRLQGSSSSHRARGEVDVFSPFPAPTAGELALEQGPGS 180
Rab46 ------------------VSR-----------------------------PQRLGQGSGQ 21
*                                 * ** *.
RFIP3 PPQPSDLSQTHPLPSE--------PVGSQEDGPRLRAVFDALDGDGDGFVRIEDFIQFAT 232
Rab46 GPKGSGA-CLHPLDSLEQKETQEQTSGQLVMLRKAQEFFQTCDAEGKGFIARKDMQRLHK 80
*: *.    *** *           *.     : : .*:: *.:*.**:  :*: :: .
RFIP3 V--YGAEQVKDLTKYLDPSGLGVISFEDFYQGITAIRN--GDPDGQCYGGVASAQDEEPL 288
Rab46 ELPLSLEELEDVFDALDADGNGYLTPQEFTTGFSHFFFSQNNPSQEDAGEQVAQRHEEKV 140
. *:::*: . ** .* * :: ::*  *:: :    .:*. :  *  .: :.** :
RFIP3 ACPDEFDDFVTYEANEVTDSAYMGSESTYSECETFTDEDTSTLVHPELQPEGDADSAGGS 348
Rab46 --------YLS---RGDEDLGDMGEDEEA----QF------RMLM---------DRLGAQ 170
:::   .   * . **.:.       *       ::          *  *..
RFIP3 AVPSECLDAMEEPDHGALLLLPGRPHPHGQSVITVIGGEEHFEDYGEGSEAELSPETLCN 408
Rab46 KVL----E--DESDVKQLWLQLKKEEPHLL---------SNFEDFLTRIISQLQEAHEEK 215
*     :  :* *   * *   : .**           .:***:     ::*.     :
RFIP3 GQLGCSDPAFLTPSPTKRLSSKKVARYLHQSGALTMEA---LEDPS-------PELMEGP 458
Rab46 NELECALK-------------RKIAAYDEEIQHLYEEMEQQIKSEKEQFLLKDTERFQAR 262
.:* *:               :*:* * .:   *  *    ::. .        * ::.
RFIP3 EEDIADKVVFLE--------------RRVLELEKDTAATGEQHSRLRQENLQLVHRANAL 504
Rab46 SQELEQKLLCKEQELEQLTQKQKRLEGQCTALHHDKHETKAENTKLKLTNQELA------ 316
.::: :*::  *               :   *.:*.  *  ::::*:  * :*.
RFIP3 EEQLKEQELRACEMVLEET----RRQKELLCKMEREKSIEIENLQTRLQQLDEENSELRS 560
Rab46 -R-----ELERTSWELQDAQQQLESLQQEACKLHQEKEMEVYRVTESL------------ 358
.     **. .   *:::    .  ::  **:.:**.:*: .:   *
RFIP3 CTPCLKANIERLEEEKQKLLDEIESLTLRLSEEQENKRRMGDRLSHER-HQFQRDKEATQ 619
Rab46 ------------QREKAGLLKQLDFLRERNK-----------HLRDERDICFQKNKAAKA 395
:.**  **.::: *  * .           :* .**   **::* *.
RFIP3 ELIE-----------DLRKQLEHLQLLKLEA-----EQRRGRSSSMGLQEYHSRARESEL 663
Rab46 NTAASRASWKKRSGSVIGKYVDSRGILRSQSEEEEEVFGIPRRSSLGLSGYPLTEEEPGT 455
:               : * ::   :*: ::          * **:**. *    .*
RFIP3 ---------EQEVRRLKQDNR-NL-------------------KEQNEELNGQIITL--- 691
Rab46 GEPGPGGPYPRPLRRIISVEEDPLPQLLDGGFEQPLSKCSEEEEVSDQGVQGQIPEAPPL 515
: :**: . :.  *                   : .:: ::***
RFIP3 ----------------------SIQGAKSLFSTAFSESLAAEISS----VSRDELMEAIQ 725
Rab46 KLTPTSPRGQPVGKEALCKEESSPSAPDRLFKIVFVGNSAVGKTSFLRRFCEDRFSPGMA 575
* .. . **. .* .  *.  :*    ...*.:  .:
RFIP3 KQEEINFRLQD---------------------------YI---DRIIVA-IMETNPSILE 754
Rab46 ATVGIDYRVKTLNVDNSQVALQLWDTAGQERYRCITQQFFRKADGVIVMYDLTDKQSFLS 635
*::*::                            ::   * :**   :  : *:*.
RFIP3 VK---------------------------------------------------------- 756
Rab46 VRRWLSSVEEAVGDRVPVLLLGNKLDNEKEREVPRGLGEQLATENNLIFYECSAYSGHNT 695
*:
RFIP3 ------------------------------------
Rab46 KESLLHLARFLKEQEDTVREDTIQVGHPAKKKSCCG 731
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Figure 5.20 Multiple motif alignment of some dynein adaptors and Rab46 coil-coiled 
domain.  Sequence alignment using Clustal Ω shows a conserved region (CC1 box) in the 
first coiled-coil segment of the dynein adaptors BICD2, Spindly, BICDR2, HAP1 and Rab46 
coil-coiled domain. Within the conserved region the alanine important in the interaction with 
dynein and the conserved alanine in Rab46 sequence (A227) are marked in red with red 
asterisks.   
  
CLUSTAL O(1.2.4) multiple sequence alignment
BICD2    ------------------------------------------------------------
spindly  --------------------------------------------------------EADI 4
BIDR2    MSSPDGPSFPSGPLSGGASPSGDEGFFPFVLERRDSFLGGGPGPEEPEDLALQLQ----- 55
HAP1     ------RFVFQGPFGSRATGRG-TGKAAGIWKTPAAYVGRRPGVSGPERAAFIRELEEAL 53
CC_Rab46 ------------------------------------------------------------
BICD2    --------------EVKRLSHELA----------------ETTREKIQAAEYGLAVLEEK 30
spindly  ITN-------------------------------LRCRLKEAEEERLKAAQYGLQLVESQ 33
BIDR2    ----------------------------------------QKEKDLLLAAELGKMLLERN 75
HAP1     CPNLPPPVKKITQEDVKVMLYLLEELLPPVWESVTYGMVLQRERDLNTAARIGQSLVKQN 113
CC_Rab46 ------------------------------------------------IAAYDEEIQHLY 12
* . : .
BICD2    HQLKLQFEELEVDYEAIRSEMEQLKEAFGQAHTNHKKVAADGESREESLIQESASKEQYY 90
spindly  NELQNQLDKCRNEMMTMTESYEQEKYTLQREVE------------LKSRMLESLSCECEA 81
BIDR2    EELRRQLETLSAQH-LEREE------RLQ--QENH----------ELRRGLAAR--GAEW 114
HAP1     SV-------------------------LM--EENS----------KLEALLGSAKEEILY 136
CC_Rab46 EEMEQQIKSEKEQFLLKDTE------RFQ--ARSQ----------ELEQKLL-------- 46
:
BICD2    VR--------------------KVLELQTELKQLRNVLTNTQSENERLASVAQELKEINQ 130
spindly  IKQQQKMHLEKLEEQLSRSHGQEVNELKTKIEKLKVELDEARLSEKQLK----------H 131
BIDR2    EA--------------------RAVELEGDVEALRAQLGEQRSEQQDSGR---ERARALS 151
HAP1     LR--------------------HQVNLRDELLQLYSDSDEEDEDEEEEEE---E-KEAEE 172
CC_Rab46 ------------------------------------------------------------
BICD2    NVEIQRGRLRDDIKEYKFREARLLQDY--SELEEENISLQKQVSVLRQNQVEFEGLKHEI 188
spindly  QVDH----QKELLSCKSE-ELRVMSERVQESMSSEMLALQIELT-------EMESMKTTL 179
BIDR2    ELSEQNLRLSQQLAQASQ-----TEQ----ELQRELDALRGQCQ-------AQA------ 189
HAP1     EQEE--EEAEEDLQCAHP-----CDAP--KLISQEALLHQHHCP-------QLEALQEKL 216
CC_Rab46 --------------CKEQ-----ELE----QLTQKQKRLEGQCT-------ALH------ 70
: :     . .
BICD2    KRLEEETEYLNSQLEDAIRLKEISERQLE---EALETLKTEREQKNSLRKELSHYMSIND 245
spindly  KEEVNELQYRQEQLELLIT-------NLM---RQVDRLKEEKEERE---KEAVSYYNALE 226
BIDR2    ----L------------------AGAELR---TRLESLQGENQ------------MLQSR 212
HAP1     RLLEE------------------ENHQLREEASQLDTLEDEEQ------------MLILE 246
CC_Rab46 ----H------------------DKHETK---AENTKLKLTNQ----------------- 88
:          *:  .:
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5.9 Summary 
In brief, through these last three chapters qualitative and quantitative data have been 
generated to suggest Rab46 is a novel WPB-associated Rab GTPase which mediates acute 
histamine, but not thrombin, response in endothelial cells. Histamine stimulates activation 
of Rab46 thus promoting Rab46 interaction with dynein and retrograde trafficking, along the 
microtubules, of a sub population of WPBs to the MTOC (Figure 5.21).  
Further investigations on the mechanisms regulating Rab46-dependent WPBs trafficking 
revealed the dynein-dynactin complex as the most promising interacting partner. Direct 
interaction between the tail domain of the dynein heavy chain and WT-Rab46 and high 
similarity with already known dynein adaptors suggested Rab46 as new dynein adaptor 
protein.  
All together these data described for the first time a fundamental mechanism by which 
physiologically diverse agonists coordinate intracellular signals in order to discriminate 
between cargo-restricted populations of WPBs.  
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Figure 5.21 Proposed model of Rab46-dependent WPB trafficking. Histamine acts 
upon its receptor to stimulate the trafficking of WPBs in two opposite directions: WPBs 
which are negative for Rab46 but contain vWF and P-selectin (data not shown in this thesis) 
are directed to the cell surface for WPBs exocytosis. Simultaneously, histamine stimulates 
nucleotide binding of Rab46 thus promoting Rab46 interaction with dynein and trafficking 
of a sub population of WPBs contain other cargo (e.g. angiopoietin-2) to the microtubule 
organising centre (MTOC)191. 
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Chapter 6 Characterization of Cracr2a knock-out mice 
 
6.1 Introduction 
Human CRACR2A gene encodes two validated transcriptional isoforms: a short variant 
CRACR2A-c and a long variant CRACR2A-a (Rab46). Although the current mouse genome 
database shows presence of only CRACR2A-c, Srikanth et al validated presence of the long 
isoform, named Rab46 in this thesis, in murine tissues such as mouse lymphoid organs167.  
A global Cracr2a knockout mice, with global elimination of the gene’s function, was available 
from the KOMP Repository which adopted a definitive null allele design, resulting in deletion 
of the entire protein-coding sequence of the target gene. Thus, both the short and the long 
isoforms were deleted in whole body. This line is also a non-conditional knockout; thus, we 
were not able to generate an endothelial specific Rab46 knock out mice. 
Therefore, in order to start the investigation of Rab46 in vivo, characterization of this global 
Cracr2a knockout mice line has been used as just the beginning for further studies which will 
aim to establish the role of Rab46 in the whole organism. 
This chapter presents data that is additional to my thesis where I aim to give a purely 
phenotypic description of Cracr2a knockout mice. qPCR analysis is used to confirm 
knockout of both the long and short isoform in the selected organs and the relative effect 
on expression of structural related Rab proteins. A phenotypic characterization including 
body weight and organs weight at 12 weeks is presented as preliminary data.  
Here, I demonstrate that Cracr2a knockout mice are viable and do no present major 
phenotypic differences compared to control wild-type mice at the considered time points. 
Interestingly, a significant difference was observed in liver weight between the two 
genotypes, therefore a first H&E staining and GTT/ITT tests were performed.   
However, all together the preliminary results presented in this extra chapter are still at an 
early stage to be able to draw significant conclusions about the contribution of Rab46 in vivo. 
 
6.2 Validation of Cracr2a -/- mice  
The knockout mouse strain Cracr2a tm1.1(KOMP)Vlcg generated from cryo-recovery was obtained 
from the KOMP repository containing a litter of heterozygous (Het +/-) and wild-type (WT 
+/+) mice. After a first round of  Het +/- x WT +/+ cross to increase the numbers of 
heterozygous mice, ensuring a stronger breeding colony, a breeding strategy (Het +/- x Het 
+/-)  was set in order to generate a homozygous knockout mouse strain (Figure 6.1). The litter 
was genotyped after 2 weeks by ear notching and qPCR results obtained from the automated 
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genotyping Transnetyx service. To create an inbred homozygous and WT mice colony, 
homozygous (Hom -/-)and WT mice were selected and crossed as indicated by the breeding 
scheme (Hom -/-  x Hom -/- or WT +/+ x WT +/+). The offspring is 100% Hom -/- or WT+/+ 
and further genotyping is not required. 
The Hom -/- Cracr2a knockout mice did not show any viability or fertility issues, therefore, 
after establishing a strong colony of both Hom-/- and WT+/+ mice to perform the 
experiments, the heterozygous colony was sacrificed.  
Mice with disrupted Cracr2a expression and respective WT+/+ control were sacrificed at 12 
weeks and gene knockout was validated from different tissues. Quantitative RT-PCR analysis 
of mRNA abundance in the liver, lung, spleen and heart from Cracr2a -/- and control mice 
was performed (Figure 6.2). As this transgenic mouse line is designed to delete both the short 
and the long isoform of Cracr2a (EFCAB2B) gene, three sets of primers were designed to 
assess the distinct expression of only the short variant (Cracr2a), only the long (Rab46) and 
both together (Cracra2a + Rab46) in both control and knockout mice. qPCR analysis showed 
reduced mRNA expression of both the isoforms in all the selected organs, confirming global 
knockout of Cracr2a gene.  
Moreover, Cracr2a knockout was also confirmed at protein level in mouse liver endothelial 
cells (mLECs). Immunoblotting using anti-Cracr2a antibody, recognizing mouse target, 
showed a specific band at the expected molecular weight (95 kDa) corresponding to the 
longer isoform (Rab46) in control mLECs and reduced intensity in knockout mLECs (Figure 
6.3). Unfortunately, it was not possible to confirm this result by immunostaining and observe 
Rab46 localisation in mLECs as the antibody was not optimized for immunofluorescence. 
These results confirm Rab46 deletion in mLECs as well as confirm that, similar to human 
endothelial cells, the short isoform (Cracr2a) is not expressed in mLECs. 
Genetic compensation in response to gene knockout is a widespread phenomenon, 
upregulation of related genes following a gene knockout may be a direct consequence of the 
loss of protein function. Considering the unique structure of Rab46, which is shared by only 
other two large GTPases namely Rab44 and Rab45, mRNA abundance of these structurally 
related Rab proteins was measured in WT+/+ mice (Figure 6.4). Firstly, mRNA expression 
relative to the mean of two housekeeping genes was measured from liver, spleen, lung and 
heart tissues. Rab46 appears to be relatively highly expressed as compared to other Rabs in 
all the organs analysed, with a great extent in the lung tissues, which is also consistent with 
previous observation by Srikanth et al (2010). Rab44 demonstrates very low expression 
compared to Rab46 in all the organs, quite low expression was detected by qPCR analysis. 
In contrast, qPCR analysis was not able to detect mRNA expression of Rab45 in any of the 
selected organs (Ct values ≥ 34). Therefore, in order to exclude upregulation of Rab44 
following Cracr2a knockout, its mRNA abundance was measured in Cracr2a knockout mice 
and compared to control WT+/+ mice (Figure 6.5). Expression of Rab44 mRNA is not 
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changed in the liver, lung and heart of knockout mice, only a slightly increase is observed in 
the spleen of Cracr2a knockout mice compared to control. 
 
 
 
 
 
 
Figure 6.1 Generation of Cracr2a homozygous knockout mice line. Cracr2a 
heterozygous mice obtained from KOMP Repository were crossed and the litter was 
genotyped. In order to create an inbred homozygous and WT mice colony, homozygous and 
WT mice were selected and crossed as indicated by the breeding scheme (Hom -/-   x Hom -
/- or WT +/+ x WT +/+). The offspring is 100% homozygous or WT.   
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Figure 6.2 Validation of Cracr2a gene knockout in Cracr2a -/- mice. qPCR ΔCt analysis 
of Cracr2a gene expression relative to HG and normalized to control WT in the liver, lungs, 
spleen and heart of Cracr2a knockout mice and WT control mice. (a) mRNA expression of 
Cracr2a short isoform, Rab46 (b:long isoform) and both the 2 isoforms (c). mRNA 
abundance of both the isoforms is significantly decreased in all the tissues. n=7 *** p<0.001 
 
 
 
 
 
 
 
 
Figure 6.3 Validation of Cracr2a protein knockout in mouse liver endothelial cells 
(mLECs). Representative immunoblots for anti-Rab46 or anti-beta actin in mLECs from 
WT control and Cracr2a -/- mice. The anti-EFCAB4B antibody (Invitrogen) shows reactivity 
for the mouse target recognising a specific band at the expected molecular weight (95 kDa) 
in control mice and reduction in signal in the knockout mice. N=2. 
Liver Lung Spleen Heart
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
******
***
C
ra
c
r2
a
 (
sh
o
rt
)
m
R
N
A
 e
x
p
re
ss
io
n
 Control (wt)
 Cracr2a -/-
***
a 
Liver Lung Spleen Heart
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
*** *** ***
R
a
b
4
6
m
R
N
A
 e
x
p
re
ss
io
n
 
 Control (wt)
 Cracr2a -/-
***
b 
Liver Lung Spleen Heart
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
*********
C
ra
c
r2
a
 +
 R
a
b
4
6
m
R
N
A
 e
x
p
re
ss
io
n
 
 Control (wt)
 Cracr2a -/-
***
c 
β-actin 
Rab46 90- 
37- 
W
T
 
C
ra
c
r2
a
 -/
-  
kDa 
- 136 - 
 
 
Liver Lung Spleen Heart
0,000
0,005
0,010
0,015
0,2
0,4
0,6
0,8
1,0
1,2
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
ss
io
n
/
H
G  Rab46
 Rab44
 Rab45
 
Figure 6.4 Relative expression of Rab46 and the two closest structural related Rab 
GTPases in control mice. qPCR ΔCt analysis of Rab46, Rab44 and Rab45 gene expression 
relative to housekeeping genes (HG: GAPDH and β-actin) (x100) in the liver, lungs, spleen 
and heart of WT control mice. Rab46 mRNA is the most abundant compared to the other 
two. Rab44 mRNA expression appear to be quite low expressed compared to the 
housekeeping genes with 10 cycles difference between HG and Rab44. In contrast, Rab45 
mRNA was almost not detected with 16 cycles difference compared to HG. 
 
 
 
 
 
 
 
 
 
Figure 6.5 Effect of Cracr2a knockout on the expression of Rab44 gene. qPCR ΔCt 
analysis of Rab44 (top) and Rab45 (bottom) gene expression relative to HG and normalised 
to control (WT) in the liver, lungs, spleen and heart of Cracr2a knockout mice and WT 
control mice. mRNA abundance of Rab44 doesn’t change in the liver, lungs and heart. Only 
a slightly increased is observed in the spleen. n=7 * p<0.05 
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6.3 Phenotypic characterization 
The preliminary phenotypic characterization of the homozygous Cracr2a knockout mice line 
includes macroscopic examinations such as viability, body weight and organs weight. 
Considering the timeframe when the following experiments were performed, much of the 
phenotyping data is limited to female mice at 12 weeks. 
Mice with disrupted Cracr2a are superficially normal with identical physical appearance 
compared to WT+/+ mice. Life span up to 12 weeks is not different between genotypes.  
Mice were fed with standard chow diet and body weight assessed at 8 and 12 weeks (Figure 
6.6). No difference was seen in body weight at the considered time points between control 
and knockout mice. At 12 weeks mice were sacrificed and a selection of organs were 
harvested for future studies. Although the body weight does not change between the 
genotypes, the main organs were weighted and the organ to body ratio calculated by 
normalising each organ weight to total body weight of the mouse (Figure 6.7). Interestingly, 
a significant difference was observed in the livers weight, Crac2a knockout mice have 
increased liver mass compared to control mice. A small but significant increase in the visceral 
fat was also observed in mice with deleted Cracr2a.  
Considering these preliminary observations, histological exanimation of liver tissues was 
performed (Figure 6.8). Mice liver tissues, collected from the right lobe of the liver, were 
fixed, embedded in paraffin and then sliced in order to use Haematoxylin and Eosin (H&E) 
staining to reveal the main hepatic features. H&E stained liver histology images are 
characterized by multiple types of tissue structures, including hepatocyte nuclei and 
cytoplasm, non-parenchymal cells and sinusoidal spaces. The histological analysis of livers 
from the control WT+/+ group indicated a normal liver lobular architecture with central vein 
and surrounding hepatocytes, sinusoids and nucleus. Cracr2a knockout mice show normal 
liver morphology, however hepatic mononuclear cell infiltration, congestion of portal vein 
and blood sinusoids appear to be a common feature. Accumulation of fat droplets was not 
seen in any of the analysed tissues section. The presence of focal periportal immune cell 
infiltration, with enlargement of the portal tract may suggest an early inflammatory condition 
due to Cracr2a deletion. 
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Figure 6.6 Cracr2a -/- mice don’t show any difference in body weight.  Body weight at 
the age of 8 and 12 weeks of female control (WT) and female Cracr2a -/- mice. Scatter plot 
shows body weight (g) of each mice and straight line indicates the mean in each group. No 
significant difference is observed at these time points between WT (black diamonds) and 
knockout mice (red diamonds). n=5 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Examination of organ-to-body weight ratio of Cracr2a -/- mice compared 
to control (WT).  Male and female mice were sacrificed at the age of 12 weeks and the main 
organs were harvested and weighted. Scatter plot shows data distribution of each organ from 
control and Cracr2a -/- mice. Straight line indicates the mean value. Liver weight and eWAT 
weight is increased in Cracr2a -/- mice compared to control (WT). n=5 **p<0,01 *p<0,05 
from Student t-test. 
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Figure 6.8 Histological examination of liver of Cracr2a -/- mice compared to control 
(WT). Mice were sacrificed at the age of 12 weeks and the liver was harvested and weighted. 
Liver tissues were examined by H&E staining. Liver from WT control group revealing 
normal morphology with central vein (CV) and hepatic cords and normal triad structure with 
portal vein (PV), bile duct (BD) and the hepatic artery (HA) (top); Liver from Cracr2a -/- 
mice reveals multiple focal inflammation sites with immune cell infiltration (white arrows) 
and portal vein and sinusoids congestion. Scale bar= 200 μm. 
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6.4 Metabolic phenotyping 
Considering these preliminary differences observed in Cracr2a knockout mice compared to 
control WT, a basic metabolic phenotyping assessing glucose homeostasis was performed to 
determine whether this mouse model exhibits an alteration in glucose metabolism. 
Glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) are first-line experiments 
to assess glucose and insulin tolerance, respectively, since they are relatively easy to perform 
and minimally invasive. They consist of measuring blood glucose levels in response to a bolus 
administration of glucose (GTT) or insulin (ITT). Both GTT and ITT were performed at 
the age of 8-9 weeks. 
Before glucose administration, overnight fasting (16h) was used to provide stable baseline 
measurements and to obtain consistent excursions in plasma glucose after glucose loading. 
Baseline (fasting) blood glucose measurements are taken before glucose administration, by 
intraperitoneal injection, and further measurements are made at regular intervals. Figure 6.9 
shows a GTT test where changes in blood glucose levels, following the administration of a 
bolus of glucose, were measured over 2 hours at 30 minute intervals. The time course of 
absolute glucose levels shows no significant difference between the two genotypes. 
Furthermore, no statistically significant difference was observed when fasting glucose levels 
were compared. 
Like GTTs, ITTs monitor glucose concentration over time, but in response to a bolus of 
insulin instead of glucose. The convention is to conduct ITTs in mice following a short (2-
hour) fast. Glucose concentration is monitored every 30 minutes for 90 minutes following a 
bolus of insulin administered via intraperitoneal injection. Results from ITTs are presented 
as a time course of glucose levels (Figure 6.10a). No difference in blood glucose level in 
response to insulin administration was observed. However, fasting glucose levels differ 
between the groups (Figure 6.10b). The glucose baseline of Cracr2a knockout mice seems to 
be higher than control WT mice.  
These are very preliminary results conducted on only female mice which need to be 
confirmed in future studies using more powerful tests to interrogate specific mechanisms, 
such as insulin secretion, sensitivity and glucose effectiveness. 
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Figure 6.9 Glucose Tolerance Test (GTT). (a) Line plots show the blood glucose 
concentration in control and Cracr2a -/- mice during glucose tolerance test. Intraperitoneal 
glucose load (1 mg/g) was given after O.N fasting and the glucose measurement performed 
every 30 mins. (b) Bar chart shows glucose concentration after 24 hours fasting. N=5  
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Figure 6.10 Insulin Tolerance Test (ITT). (a) Line plots show the blood glucose 
concentration in control and Cracr2a -/- mice during insulin tolerance test. Intraperitoneal 
insulin dose (0,75 IU/kg) was given after 2 hours fasting and the glucose measurement 
performed every 30 mins. (b) Bar chart shows glucose concentration after 2 hours fasting. 
N=5 **p<0,01 Student t-test. 
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6.5 Summary 
Briefly, this extra chapter aims to initialize our investigation of Rab46 in vivo. The basic 
phenotyping characterization presented in this chapter do not show any major differences 
between the genotypes of these young adult mice. Although no difference in body weight 
was observed at 12 weeks, the liver mass is higher in Cracr2a knockout mice than control 
WT as well as visceral fat mass. Histological analysis of liver tissues suggests infiltration of 
immune cells and periportal inflammation in the absence of Cracr2a with no evidence of 
lipid accumulation.  
We found no significant differences in measures of glucose or insulin homeostasis between 
the genotypes in young adult mice (age 8-9 weeks), although, a significant difference in 
glucose level after a short-fasting period was noted, with higher glucose level in the knockout 
mice than WT+/+.   
Using a global Cracr2a knockout mice currently limits our conclusion regarding the 
contribution of endothelial Rab46 as well as its attribution to the observed effect as both the 
short and long isoforms were deleted.  
Further work to characterise the nature of the observed differences in liver tissues and 
visceral fat will be important to decipher the physiological consequences of this phenotype. 
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Chapter 7 Discussion 
Rab46 is a novel Rab GTPase which was first discovered in endothelial cells by Wilson et al 
(2015)166. Rab46 is encoded by the EFCAB4B gene which is shown to go through alternative 
splicing enabling the expression of a short (CRACR2A) isoform and a long (Rab46) isoform. 
The extra length of Rab46 is due to the incorporation of a GTPase domain at the C-terminal 
of CRACR2A which has previously been shown to have functional coil-coiled domain and 
EF-hand domains172. While both isoforms are expressed in human and murine T-cells167, only 
the long isoform has been found in endothelial cells. Unlike the majority of small Rab 
GTPases that are characterised by a single GTPase (Rab) domain, Rab46 represents an 
unusually large Rab protein with multiple functional domains. Although the expression of 
Rab46 in endothelial cells has already been validated, the contribution of this unique Rab 
protein to the function of the endothelium is still unknown. 
In this study we unravel the function and preliminary mechanisms of Rab46 in endothelial 
cells. Here, we show distinct Rab46 localization to a subpopulation of WPBs, specific 
secretory granules of endothelial cells involved in pro-inflammatory and pro-thrombotic 
response.  The hypothesis that Rab46 could orchestrate WPB trafficking is confirmed by the 
evidence showing the role of Rab46 in histamine, but not thrombin, evoked WPB trafficking 
to the perinuclear area. Acute histamine activation of Rab46 induces dynein-dependent 
trafficking of WPBs carrying non-inflammatory cargo along microtubules towards the 
MTOC. Further investigations on the mechanisms regulating Rab46-dependent WPB 
trafficking also revealed the dynein-dynactin motor complex as the most promising 
interacting partners of Rab46, suggesting Rab46 as new linker by which WPBs are anchored 
to the dynein motor complex. The formation of WPBs-Rab46-dynein complex may be 
responsible for retrograde trafficking of specific population of WPBs in response to pro-
inflammatory stimulation.  
All together these data describe for the first time a fundamental mechanism by which 
physiologically diverse agonists coordinate intracellular signals in order to discriminate 
between cargo-restricted populations of WPBs.  
 
7.1 Rab46 localization and function 
Preliminary experiments performed in the lab had suggested that exogenous Rab46 localised 
to WPBs in endothelial cells, however, in order to understand physiological role of Rab46 in 
endothelial cells, identification of the localization of endogenous Rab46 was paramount to 
this study. Here, using super-resolution microscopy we show endogenous Rab46 localised to 
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vWF, a marker for WPBs. Immunofluorescent images of non-stimulated endothelial cells 
labelled with an antibody against vWF, revealed numerous elongated WPBs throughout the 
cell with a wide range of sizes. Despite the cigar-like morphology of the majority of WPBs, 
which appear long and straight, some of them present hinges which reflect vWF tubules 
flexibility or an oval/rounded shape which in proximity of the plasma membrane may reflect 
the structural changes occurring upon basal secretion. Short WPBs near the cell nucleus 
probably represent immature granules formed prior to vWF multimerization195. A similar 
vesicle-like pattern was observed in endothelial cells overexpressing Rab46 which indeed 
gave the first hint about Rab46 localization with vWF in endothelial cells, as revealed by 
merged images showing Rab46 and vWF colocalization. Although Rab46 positive vesicles 
show colocalization with vWF, exogenous Rab46 often shows a perinuclear cluster most 
likely due to the low intrinsic GTPase activity and high cytosolic GTP concentration which 
leads to a sustained accumulation of GTP-Rab46 as well as a reduced number of WPBs in 
these cells. Expression of constitutively active Rab46 (Q604L) shows indeed a strong 
perinuclear cluster in contrast to the inactive forms (N658I, T559N) which both present a 
cytosolic phenotype with impaired Rab46 colocalization to WPBs. According to Srikanth et 
al.167, the GTPase activity of Rab46 determines its localization. Rab46 localization to the 
Golgi apparatus in resting T-cell is determined by both the GTPase activity and C-terminal 
prenylation. Therefore, it will be interesting to further explore whether Rab46 prenylation 
influences its location to WPBs in endothelial cells. Exploiting the increased resolution given 
by super-resolution microscopy we could observe and analyse endogenous Rab46 
localization.  Observing endothelial cells labelled with Rab46 and vWF under resting 
conditions allowed exploration of the association of Rab46 with WPB. Rab46 vesicles are 
juxtaposed on the outside of WPBs, facing the cytosolic side of these secretory granules; this 
is a characteristic necessary for many other Rab proteins, that always decorate the cytosolic 
face of many distinct membrane compartment, defining their identity127. Although WPBs are 
the main secretory granules of endothelial cells, endothelial cells are also equipped with other 
vesicles such as tPA granules, lysosomes and  different populations of endosomes which 
have been suggested to be distinct from WPBs. However, my immunofluorescent imaging 
analysis suggests that Rab46 does not associate with any of these intracellular vesicles 
(although these data are not exhaustive), thereby suggesting specific targeting to WPBs.   In 
addition, as only approximately 50% of WPBs are labelled with Rab46, it appears therefore 
to specifically target a subpopulation of WPBs.  Differential recruitment of cargo proteins to 
WPBs, slow recruitment of membrane proteins during WPB maturation, and tissue-specific 
differences in endothelial cell phenotype lead to a heterogeneous population of WPBs29.  
Spatio-temporal contribution of Rab46 to WPB heterogeneity still need to be elucidated. 
When Rab46 is recruited to WPBs and how the process is regulated is still an open question 
which will be investigated in the future. To test the timing of Rab46 recruitment to WPBs, 
live-cell imaging of endothelial cells expressing a fluorescently tagged pre-pro-vWF will allow 
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tracking of the maturation of WPBs over time. Hannah et al33 described this approach to 
show the maturation-dependent recruitment of Rab27a to WPBs, therefore it may be 
interesting to investigate whether Rab46 is recruited to immature and/or mature only WPBs. 
As Rab27a is a marker for mature WPBs, a simpler approach could also be to study the 
association between Rab27a positive WPBs and Rab46 in fixed cells. Determination of the 
dynamics of Rab46 recruitment and to establish whether its recruitment to WPBs is content-
driven or maturation-dependent will be the next step to assess the role of Rab46 in WPB 
biogenesis. Here, we show that neither the total number of cells within a normal population 
of WPBs nor the cellular distribution of WPBs change in Rab46 depleted endothelial cells 
compared to control cells, thus, excluding a positive role in WPB biogenesis. Moreover, 
considering that the driving force of WPB biogenesis is vWF synthesis we also ruled out an 
effect of Rab46 downregulation on vWF mRNA expression. However, Rab46 depleted 
endothelial cells show increased intracellular vWF at the protein level supported by an 
increased number of WPBs per cells. The retention of WPBs inside the cells could interfere 
with WPB trafficking and/or basal vWF secretion, a stimulation independent secretory 
pathway that is described as the main source of plasma vWF in vivo. Lopes and Cutler58 
elegantly describe differences in the three vWF secretory pathways reporting the amount and 
multimeric state of vWF secreted from the constitutive, basal, and regulated pathways in 
polarized HUVECs. It was indeed suggested that different retention time inside the cell could 
drive the differential multimerization pattern observed between the basal and regulated vWF 
secretion. Therefore, measuring the effect of Rab46 downregulation on vWF basal secretion, 
by looking at differences in vWF multimers as well as polarity of secretion, will contribute to 
clarify whether Rab46 contributes to the existence and function of different pool of WPBs. 
In contrast to Rab27a depleted cells which show increased vWF release and accumulation of 
WPBs to the perinuclear area33,69, confirming a role in forward movement of WPBs after 
maturation, Rab46 depleted cells do not show any difference in cellular distribution of WPBs 
but increased intracellular vWF. Thus, Rab46 is most likely responsible for WPB trafficking 
than biogenesis. Moreover, downregulation of Rab46 does not change the expression level 
of Rab27a or other related Rab GTPases, excluding the possibility of any off-target effect 
and/or compensation when cells are depleted by specifically targeted Rab46 siRNAs. All 
together these findings encouraged further investigations into the role of Rab46 in WPB 
trafficking. 
It is known that WPBs are highly dynamic population of secretory granules in endothelial 
cells. In resting cells, these vesicles are not static but consist of pools with different motilities. 
Romani de Wit et al. demonstrated that some vesicles barely moved, as if they were tethered; 
others seem to travel in a stochastic manner and frequently reversed their direction196. 
Intriguingly, on stimulation with several distinct vWF secretagogues, differences in WPB 
dynamics were observed depending on the type of stimulus. Stimulation of endothelial cells 
caused regulated trafficking of WPBs toward the plasma membrane to orchestrate 
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endothelial response to different stimuli. WPBs are released from endothelial cells in 
response to a large number of secretagogues56. Increased levels of cytosolic free Ca2+ have 
been implicated in the mechanism of exocytosis for many of the agonists, such as histamine 
and thrombin. Endothelial exocytosis occurs within minutes of stimulation and WPB release 
is an immediate early response of endothelial cells, a rapid response to injury independent of 
gene transcription197.  Most Ca2+-raising agonists are mediators of inflammation and/or 
thrombosis which cause a rapid, immediate (5-15 mins) WPBs fusion with the plasma 
membrane. cAMP raising agonists, such as epinephrine or vasopressin, function more 
systemically, with a slow onset of vWF secretion, thereby controlling general vWF levels in 
the vasculature. Here, considering the presence of the EF-hand domains in Rab46 structure 
and the possibility to rapidly respond to changes in intracellular Ca2+ in order to direct WPB 
trafficking, we turned our attention on Ca2+ raising agonists.  
Thrombin triggers an immediate endothelial response during vascular injury: within minutes 
of exposure to thrombin, endothelial cells release vWF, which mediates platelets rolling along 
the endothelium198. Moreover, endothelial cell activation evoked by thrombin is associated 
with a profound alteration of cell morphology199. Both thrombin and histamine stimulation  
results in stress fibre formation and loss of endothelial cell barrier function by disassembly 
of tight and adherens junctions, however thrombin promotes barrier permeabilization to a 
greater extent than histamine.63,200 Histamine is an amine involved in transient immune and 
acute inflammatory responses, evokes leukocyte attraction without the necessity for 
endothelial cell migration or vasoconstriction66,201. Therefore, although histamine and 
thrombin are both Ca2+ raising agonists, they have distinct physiological roles. Despite their 
prominent role in the initiation of vascular thrombosis and leukocyte adherence, little is 
known about the molecular machinery driving WPB regulated exocytosis in response to 
those two main secretagogues. In order to achieve a functionally appropriate response, it is 
vital that endothelial cells couple physiological stimuli to the release of specific WPB cargo. 
The selective release of vWF from WPBs is controlled by multiple factors in addition to 
transcription. Different types of fusion of secretory organelles with the plasma membrane 
has been proposed as mechanism underlying the selective release or retention of granule 
contents.  Recent studies have proposed some mechanisms underlying the differential release 
of cargo from WPBs docked at the cell surface202. A lingering kiss (small pore formation 
during weak histamine stimulation), excludes the release of cargo > 40 kDa whilst agonist-
dependent recruitment of an actomyosin ring controls the force necessary for expulsion of 
vWF without affecting release of other cargo. To date there has been no description of 
differential storage and release of cargo in a contextual responsive process or if a cellular 
machinery exists to support such regulation. For example, to properly function in the control 
of thrombosis and the capture of platelets and/or leukocytes in the early stages of 
inflammation, the WPB constituents must be released on-demand. This prompt release has 
to be ensured by the molecular machinery which regulate exocytosis of WPBs.  
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Here we present Rab46 as a new regulator of differential WPB trafficking. Acute histamine 
(but not thrombin) stimulation evoked Rab46-dependent perinuclear trafficking of a subset 
of WPBs which accumulated at the MTOC. WPBs are considered rapid emergency 
responders, therefore to reproduce this on-demand response to either pro-thrombotic or 
pro-inflammatory stimuli, endothelial cell were treated with histamine or thrombin for only 
10 mins, inducing acute release of WPBs. While thrombin stimulation showed large 
extracellular patches of vWF, a typical feature already described in several studies196,203, we 
observed for the first time perinuclear clusters of vWF upon acute histamine stimulation. To 
date WPB perinuclear redistribution was only observed by stimulation of cAMP pathway196. 
Rondaji and co-workers204 suggested that endothelial cell stimulation with epinephrine results 
in retrograde movement of a subset of WPBs to the microtubule organizing centre via PKA-
dependent regulation of the dynein– dynactin complex204. This suggests that WPBs clustering 
is mediated by different signalling pathways according to different physiological needs. 
Histamine and thrombin both induce an increase in intracellular Ca2+ but our results showed 
that WPBs are able to distinguish between these two stimuli. Because the direction and timing 
of organelle movement needs to be tightly controlled by the cell, a variety of small GTPases 
have been implicated in WPB trafficking. We therefore speculated that Rab46 might be the 
mechanism by which WPBs can recognise different stimuli, regulating direction and timing 
of movement of these granules. Accordingly, downregulation of Rab46 by targeted siRNA 
reduced WPB clustering towards the MTOC upon histamine stimulation.  Although Rab46 
is a unique Rab GTPase with extra functional domains, it has the highly conserved Rab 
domain known to be essential for GTPase activity in other Rab proteins. Therefore we 
questioned the role of GTP in Rab46-dependent WPB trafficking in endothelial cells by 
heterologous expression of conserved nucleotide-binding mutants. Our findings showed that 
GTPase activity of Rab46 is required for histamine-evoked trafficking of WPBs to the 
MTOC. In agreement with GTP-bound Rab46 being necessary for WPB motility, vWF was 
colocalised with the constitutively active form of Rab46 at a perinuclear region even in the 
absence of stimulation. In contrast, histamine fails to induce redistribution of Rab46 or 
perinuclear clustering of WPBs in cells overexpressing the N658I inactive Rab46 mutant 
which localizes to the cytosol. These data suggest that Rab46 GTPase domain is functionally 
active and that GTP binding is necessary for the perinuclear localisation of Rab46 and WPBs 
as well as for its localization. Whether the Rab domain is necessary and sufficient to target 
Rab46 to WPBs and initiate the trafficking events could also be confirmed by expressing the 
individual Rab domain as well as Rab46 with deleted coil-coiled/EF-hand domains. 
Microtubules, actin filaments and their associated molecular motors drive bidirectional 
movement of different intracellular organelles186. Evidence from different studies suggests 
that microtubules provide the tracks for rapid, long-distance transport, whereas actin may be 
used for local transport or anchorage of cargo to specific locations205. The bidirectional 
movement of WPBs in resting HUVECs and the plasma membrane-directed movement of 
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WPBs resulting in exocytosis of these organelles, were found previously to require an intact 
microtubular network206. Here, we show that histamine-evoked perinuclear clustering of 
WPBs also require the integrity of the microtubular network. This microtubular-dependent 
retrograde trafficking suggested that motor proteins may be involved. While kinesin mediates 
plus-end (forward) movements, minus-end directed movement toward the MTOC is 
mediated by the dynein motor protein207. Involvement of dynein in the Rab46-dependent 
retrograde movement of WPBs is supported by our findings showing reduced perinuclear 
clustering when dynein activity is inhibited by pre-treatment of endothelial cells with 
ciliobrevin D prior to histamine stimulation. Therefore, we propose a model where histamine 
stimulation, evokes Rab46 GTPase activity and mediates WPB retrograde movement using 
the dynein motor, which tracks WPBs back to the MTOC.  
 
7.2 Rab46 mechanisms 
In recent years, interactions between microtubule motor proteins and Rab GTPases have 
been identified and these motor proteins are recognised as Rab effector molecules107. Thus, 
through association with motor complexes, Rab proteins allow directional movement of 
various vesicular cargos along the microtubule cytoskeleton. The major minus-end-directed 
microtubule motors in eukaryotic cells are multi-component ATPases termed dyneins208. 
Wang et al proposed Rab46 as a new dynein adaptor in T-cells, necessary for dynein-
dependent transport of subsynaptic vesicles to the MTOC. In agreement, my initial findings 
discussed above suggest a Rab46 and dynein/dynactin interaction in endothelial cells that is 
enhanced upon histamine stimulation.  
To further explore the mechanisms underlying Rab46-dependent WPB trafficking, I 
performed protein affinity purification followed by mass spectrometry analysis to identify 
Rab46 interacting proteins. Proteomic analysis and immunoprecipitation assays led to the 
identification of the dynein heavy chain (DHC) as a new Rab46 interacting protein.  
Although I confirmed the interaction of these two proteins in an overexpression system as 
well as at the endogenous level in endothelial cells, these experiments have some limitations 
such as the existence of a complex including endogenous endothelial cells proteins 
interacting with Rab46 or DHC, thus masking direct interaction between these two proteins. 
Therefore, I sought to explore this interaction using ectopic expression of human Rab46 in 
Cos-7 (monkey) cells and a recombinant purified portion of the tail domain of DHC. Using 
a recombinant DHC protein and Rab46 expression in an ectopic (non-human) system will 
narrow down the possibility of endogenous interacting proteins, leading to a more likely 
proof of direct interaction. These data suggested  a direct interaction between these two 
proteins. Although we do not know if Cos-7 cells express endogenous Rab46, as they are 
monkey cells it is likely that its sequence is quite different to human, as if they were very 
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similar we could expect some detection as our antibody covers half the protein sequence. 
However, there is a possibility that adaptors that bind to monkey Rab46 could bind to human 
Rab46 and pull down with dynein, thereby the interaction would occur in a complex and not 
via a direct interaction. Wang et al suggested that Rab46 directly interacts with the dynein 
motor protein, however proof of direct interaction between Rab46 and dynein motor 
protein, in our system, requires further validation using purified proteins. Biochemical and 
biophysical assays, such as FRET experiments to detect location and distance of the 
interacting domains or isothermal titration calorimetry assay to have quantitative 
measurement about properties of protein-protein interaction can be used to further 
characterize the nature of Rab46 and dynein interaction. Given the similarity with other 
dynein adaptors, sequence alignment predicted some potential conserved binding sites on 
Rab46 sequence which may be necessary for the protein -protein interaction. A common 
feature between some dynein adaptors is the presence of CC1 box at the beginning of their 
coil-coiled domain where two alanine are responsible for the interaction with dynein194. These 
conserved residues, plus another conserved alanine at the C-terminal, were found in the 
Rab46 sequence, therefore as suggested in previous studies, mutation of these alanine 
residues into valine residues should allow us to determine if it causes loss of the dynein 
interaction. Future ongoing structural studies highlighting Rab46 conformation will also 
demonstrate the position of these conserved residues, allowing predictions of where they are 
exposed in space and time thereby elucidating the potential interaction with the dynein motor 
protein.  
The Vale group suggested Rab46 directly recruits dynein in a Ca2+-dependent manner.  
However, our preliminary results in endothelial cells suggest that Rab46 interaction with 
dynein is Ca2+-independent. A mutation of Rab46 that is unable to bind to Ca2+ (Rab46EFmut), 
as showed by Srikanth et al., does not influence its interaction with the dynein motor protein. 
Mammalian dyneins do not display processive motility by itself due to the auto-inhibited 
configuration of its motor domain209. Association of dynein with the dynactin complex in the 
presence of adaptor proteins with coiled-coil domains induces conformational changes 
which stimulate dynein long-range motility. Wang et al suggested that elevation of the Ca2+ 
concentration significantly increased the processivity of dynein–dynactin–Rab46 complexes 
on microtubules. Thus, although in endothelial cells Rab46 EF-hand mutant is still able to 
bind to dynein, it does not exclude that intracellular Ca2+ is required on the behalf of dynein-
dynactin complex to be able to interact with its adaptors/activators prior any stimulation. 
Although dynein interaction with Rab46 is enhanced upon histamine stimulation, the 
interaction appears to exist prior the stimulation suggesting the possibly of ready pool of 
WPBs anchored to the dynein complex through Rab46 acting as an adaptor. Upon acute 
histamine stimulation this subset of WPBs is ready to rapidly move backward thus, helping 
endothelial cell to fine-tune WPB secretion.  
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The difference in Ca2+-dependency between endothelial and T cells might reflect differences 
in the physiology and/or the accessory protein expression between the two cell types. Upon 
T-cell activation, the MTOC and Rab46 traffic to the immunological synapse and this is 
necessary for signal transmission between the T-cell receptor and the JNK pathway167. In 
addition, whilst endothelial cells only express Rab46, T cells also express the short non-Rab 
isoform (CRACR2A) that lacks the Rab domain but can interact with Rab46 via the coil-
coiled region. Both Rab46 and CRACR2A are necessary for regulating store-operated Ca2+ 
entry (SOCE) in T-cells but we found no function of Rab46 in SOCE in endothelial cells166. 
Studying the role of Ca2+ in modulating the interaction or how it may influence Rab46 
conformation before and after stimulation will be one of the main points of the next study. 
Also, more specific approaches to measure dynein motility upon stimulation will help to 
understand whether and how Rab46 is able to stimulate dynein motility in endothelial cells. 
Assembly and disassembly dynamic of Rab46 with dynein complex would also allow to find 
out more about binding properties of these proteins. 
In addition to the dynein heavy chain, proteomic analysis identified the Na+/K+ ATPase 
subunit α (ATP1α) as a new Rab46 interacting partner and subsequent immunoprecipitation 
experiments supported this. Similarly to DHC, ATP1α interaction occurs with endogenous 
Rab46 either in non-stimulated or histamine stimulated cell. However, histamine stimulation 
seems to enhance this interaction. Does histamine stimulation stabilize the interaction 
and/or enable recruitment of other Rab46 effectors? These remain open questions. 
Additionally, the nature of the interaction (e.g. transient or stable direct interaction) still need 
to be elucidated. The Na+/K+ ATPase functions as an ion pump exchanging three Na+ across 
the plasma membrane for two K+ following hydrolysis of ATP, a crucial function for ion 
homeostasis. Interestingly, recent studies indicate that the same Na+/K+-ATPase also 
functions in activating signalling cascades independently of its ion‐transport role. It is 
proposed that a separate pool of non‐pumping Na+/ K+‐ATPases mediate this noncanonical 
function depending on interactions of the Na+/K+ ATPase with various proteins including 
protein and lipid kinases, membrane transporters, channels, and cellular receptors210. The 
Na+/K+ ATPase is a heterodimeric transmembrane complex consisting of a 10-
transmembrane domain α-subunit and a single transmembrane regulatory β-subunit. Four 
isoforms of the α-subunit have been identified, with the α1 isoform (ATP1α) being 
ubiquitously expressed. Recently, for the first time, a study from Booth et al187 identified a 
new role for the α1 subunit of Na+/K+-ATPase (ATP1α) as a novel Rab27a interacting 
protein in melanocytes and showed that this interaction is direct with the intracellular loop 
of ATP1α and independent of nucleotide bound status of the Rab. Several lines of evidence 
strongly support an essential role for ATP1a1 in the targeting of Rab27a to melanosomes. 
Rab27a regulates the transport and secretion of lysosome related organelles and secretory 
granules from a variety of cell types211. Particularly, in endothelial cells Rab27a plays a central 
role in WPB trafficking and secretion. Considering the identification of ATP1α as a putative 
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interactive Rab46 protein in endothelial cells, it would be extremely interesting to further 
investigate this relationship in endothelial cells. In contrast to other cell types which present 
the Na+/K+-ATPase at the plasma membrane, endothelial cells present a more intracellular 
vesicles-like localization (data not shown). Its intracellular localization in relation to Rab46 
as well as to WPBs will be the next step in this investigation. Considering that depletion of 
ATP1α alter Rab27a-dependent distribution of melanocyte causing perinuclear clustering, 
future studies will aim to depict whether ATP1α is responsible for Rab46 targeting to WPBs 
as well as regulation its function in WPBs trafficking in response to histamine.  Another 
interesting question is the extent to which Na+/K+ ATPase ion pump function might be 
involved in Rab46 recruitment via regulation of WPBs ion homeostasis. WPBs are lysosome-
related organelles therefore characterised by acidic pH. vWF tubulation underpins the 
elongated shape of WPBs, and that is dependent on an acidic pH. However, to date, little is 
known about maintain acidic intraluminal pH of WPBs after their budding from the TGN. 
A relationship exists between the pH within WPBs and their shape: WPBs are predominantly 
round at pH 7, mostly elongated at pH 6 or pH 5.5, and exhibit an intermediate phenotype 
at pH 6.5212. Therefore, a follow-up study may be about understanding the role of the 
Na+/K+-ATPase in regulating endothelial cells ion homeostasis and Rab46-dependent 
regulation of WPBs intraluminal pH via ATP1α interaction (i.e. is the ATP1α a pH-sensing 
protein mediating specific recruitment of Rab46 to WPBs?). 
In this study, we attempted to biochemically purify novel Rab-binding proteins from 
endothelial cell by GFP-trap pull-down using GFP-tagged active and inactive form of Rab46 
followed by mass spectrometry analysis. However, the nucleotide free (N658I) mutant, which 
appeared to be mis-colocalized is quite unstable, as suggested by Srikanth et al. This instability 
could be the reason why the proteins identified in our N658I pull-down are enriched for 
degradation pathways and nucleic acid binding activity. Therefore, rather than locking the 
Rab GTPase in their functional states, we could attempt to identify Rab46 interacting 
partners either by overexpression of WT-Rab46 or by using endogenous activation of Rab46 
via histamine stimulation. Moreover, the use of purified Rab46 protein in the presence of 
GDP or GTP will also be useful for large-scale screening of potential GEF and GAP 
proteins. Rab interactors have mostly been defined through in vitro pulldown and yeast two-
hybrid approaches which are a powerful tool to assess direct binding between a Rab and a 
specific protein. However, they preclude identification of context specific Rab GEFs, GAPs, 
or effectors, since the temporal aspects of effector recruitment are lost. Recently, APEX2 
proximity labelling of Rab neighbouring proteins, combined with mass spectrometry, has 
been proposed as a new and efficient tool to rapidly map endogenous Rab 
regulators/effectors213. This latter approach was also recently used by Holthenrich and 
colleagues to carry out a comprehensive screening of factors associated with WPBs, 
confirming the presence of Rab46214.  
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Nevertheless, our proteomic analysis identified several candidate proteins which still need to 
be investigated. Thus, it provides a useful first screening tool of Rab46-interacting proteins 
which could be useful for identification of new mechanisms of action for this novel Rab 
GTPase in endothelial cells.   
 
7.3 Proposed Rab46-function 
Although not part of my submitted data (but shown in our recent JCB paper191), I will briefly 
mention what I consider to be the function of Rab46 mediated trafficking. In addition to the 
mechanisms underlying Rab46 function we have to consider the function of Rab46-
dependent WPB trafficking, for example, why is there a sub-population of WPBs in 
histamine stimulated cells that is not secreted (i.e. is it a subset of WPBs rescued from 
exocytosis or is it a polarised response?). We hypothesize that this allows agonist specific 
secretion of WPB cargo191(proposed model in Figure 7.1). Previously, P-selectin and the pro-
angiogenic tie-2 ligand angiopoietin-2 have been shown to reside in mutually exclusive 
WPBs, therefore, we questioned whether there is a difference in trafficking of these distinct 
WPBs in response to different stimuli. In our recent paper, we proved that trafficking of 
these distinct WPB populations is contextual since perinuclear clustering of P-selectin-
negative WPBs is specific to histamine but not thrombin. We demonstrated that histamine 
promotes Rab46-dependent MTOC localisation of WPBs carrying angiopietin-2 indicating a 
mechanism to restrict release of angiopoietin-2 and possibly other cargo not necessary for 
an acute inflammatory response. Thus, whilst histamine stimulates release of P-selectin from 
WPBs at the cell surface, thereby supporting an inflammatory reaction, histamine limits an 
excessive vascular injury response by anchoring WPBs containing cargo extraneous to 
inflammation to the MTOC.  We also suggested that mobilisation of intracellular Ca2+ 
binding to the EF-hand of Rab46 is required for dissociation of the perinuclear localised 
WPBs. In this way, Rab46 integrates transport and Ca2+ signals to regulate trafficking of 
WPBs that is relevant to the physiological signal and thus limits the extensive emergency 
response evoked by vascular injury.  
All together these evidence present Rab46 as a novel and unique key regulator of WPB 
trafficking which enable specialized secretory responses depending on the applied stimulus. 
Rab46 could provide a mechanism by which processes such as inflammation might be 
regulated with a reduced risk of thrombosis. Such a mechanism would have important 
implications for the understanding of the role of WPBs in health and disease.   
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Figure 7.1 Proposed model of Rab46 function. Histamine stimulation of H1 receptor 
evokes the release of the proinflammatory ligand, P-selectin, while diverting WPBs carrying 
non-inflammatory cargo away from the plasma membrane to the MTOC. This differential 
trafficking is dependent on Rab46, a newly identified Ca2+-sensing GTPase, which localizes 
to a subset of P-selectin–negative WPBs. After acute histamine stimulation GTP-bound 
Rab46 evokes dynein-dependent retrograde transport of a subset of WPBs along 
microtubules. Upon continued histamine stimulation, Rab46 senses localized elevations of 
intracellular calcium and evokes dispersal of MTOC–clustered WPBs. 
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7.4 Rab46 in vivo 
This study describes the role of Rab46 in cultured endothelial cells suggesting an important 
contribution in specialized WPB secretory response depending on the applied stimulus. 
However, confirmation of these data using an in vivo model are still at very early stages.  
Several difficulties in using a knockout-first strategy to generate a conditional specific 
knockout which will be eventually used to generate an endothelial specific Rab46 knockout, 
led us to an alternative commercially available in vivo approach. A global Cracr2a knockout 
was available from the KOMP repository, therefore we started our in vivo investigations using 
this model. We are fully aware of the limitations of this model , which include deletion in the 
whole body of both the short (CRACR2A) isoform and the long (Rab46) isoform. However, 
it provided a useful model to initialise our in vivo research, settling the foundation for further 
studies. 
Initially, the mouse model was validated by confirming deletion of both isoforms in different 
tissues as well as from mouse endothelial cells extracted from the liver. Using an anti-
CRACR2A antibody which targets both human and mouse sequence we provided 
preliminary evidence that only the long isoform (Rab46) is expressed in mouse endothelial 
cells, supporting the in vitro results. Thus, Cracr2a knockout was validated at the mRNA level 
as well as at protein level.   
Srikanth et al., described tissue expression of CRACR2A in different human and mice 
samples, showing higher expression in the lung and immune cells. Our preliminary analysis 
in murine tissues shows abundance of Rab46 in the lung tissue and it is the most abundant 
Rab compared to the structurally related Rab44 and Rab45. Rab45 was not detected in any 
of the analysed tissues, however, Rab44 was detected at low level. Although the level of 
Rab44 expression is slightly upregulated in the spleen of Cracr2a knockout mice, its mRNA 
expression did not change in the liver, lung and heart following Cracr2a deletion. Therefore, 
genetic compensation could be ruled out.  
The metabolic profile of the mice included in chapter 4 was investigated with body weight, 
organ weight and preliminary histology, glucose and insulin tolerance testing. These 
parameters were recorded in mice aged 8-12 weeks. Although the body weight was similar 
between the genotypes, an interesting difference in liver weight was observed with increased 
mass in the knockout female mice analysed. Trying to get some insights about the extent of 
the increased liver weight, a first H&E staining gave us a general overview of the liver 
morphology of both the genotypes.  Lipid deposition could explain the increased mass; 
however, no fat accumulation was present. In contrast, Cracr2a knockout liver present 
multiple focal inflammation sites with immune cell infiltration in the peri-portal tract. 
Sinusoidal and portal vein congestion also appear to be a frequent feature in liver section 
analysed. Although characterization of these features with specific identification and 
quantification of the mononucleated infiltrated cells still need to be clarified, all together 
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these features may suggest that deletion of Cracr2a leads to an early inflammatory condition 
in young adult mice. Therefore, it would be extremely interesting to age these mice in order 
to look how this condition evolves over time. Several studies suggested that genetic variations 
in Rab46 gene may lead to the pro-inflammatory environment necessary for development of 
many human diseases characterized by chronic inflammation. In particular, a GWAS study 
revealed specific associations between a SNP in Rab46 gene (EFCAB4B) and lobular 
inflammation evident in non-alcoholic fatty liver disease (NAFLD)176. Further studies will 
evaluate whether some common inflammation markers are upregulated in the liver in 
absence of Cracr2a and specific staining identifying immune cells such as CD68 for 
macrophage identification, will be performed.  
Preliminary glucose measurements show no significant difference between genotypes on 
either glucose or insulin tolerance testing. However, Cracr2a knockout mice have higher 
basal glucose level after short time fasting compared to control WT. These data need to be 
confirmed by increasing the number of mice studied as well as by using male mice. 
Nevertheless, as mice are active and eat more at night using only 2 hours fasting in the 
morning before ITT does not give a real fasting glucose measurement. Therefore, many 
studies suggest a short fasting period of 5-6 hours before the ITT in order to reduce 
variability in basal blood glucose. To determine the overall physiological tolerance of these 
mice to glucose and their ability to maintain glucose homeostasis within the normal 
physiological range, further studies are needed. Whether and how Cracr2a deletion affect 
glucose metabolism is still an open question. 
It is important to recognise the general limitations of the in vivo model presented in chapter 
6. Firstly, as already mentioned, deletion of Cracr2a gene abolish the expression of both the 
isoforms which so far have been presented with very different tissue-specific functions. 
Therefore, determining a cause-effect correlation is much more difficult, i.e. whether an 
observed effect is attributed to the short or the long variant require an extra level of 
investigation. Furthermore, the data presented are largely exploratory, and several datasets 
require further work in order to be completed and confirm some of the preliminary data. 
Nevertheless, using an endothelial specific Rab46 knockout mouse remain the best option 
to truly determine the in vivo contribution of Rab46 under physiological and pathological 
conditions.  
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Chapter 8 Conclusion and Future Directions 
 
8.1 Summary of Key Findings 
This thesis presents data examining the role of Rab46 in WPB trafficking in response to acute 
pro-inflammatory stimulation, adding a new player to the endothelial molecular machinery 
controlling differential WPB trafficking and exocytosis.  
We propose a model where Rab46 is activated following histamine stimulation inducing a 
subset of WPBs to move backward to the perinuclear area, exploiting dynein motility along 
the microtubules. Highlighting the molecular mechanism, Rab46 interaction with the dynein 
complex suggests Rab46 as a new dynein adaptor maybe providing a scaffold to link WPBs 
(cargo) to its respecting motor protein (dynein) which motility is induced following histamine 
stimulation.  
The key findings of this thesis which support the described model can be summarized by the 
following main points. 
• Endogenous Rab46 localises to WPBs in endothelial cells with Rab46 vesicles 
juxtaposed to vWF, on the cytosolic face of WPBs.  
• WPBs are the primary target of Rab46 in endothelial cells. However, Rab46 localises 
to a subset of WPBs corresponding to almost half of the full population. 
• Acute histamine and thrombin stimulation induce differential WPB trafficking. 
• Rab46 regulates histamine, but not thrombin, WPB trafficking to the perinuclear area 
identified as the MTOC. 
• Functional GTPase domain regulates Rab46 localization to WPBs and GTP binding 
is necessary for the perinuclear localization of WPBs. 
• Rab46-dependent retrograde trafficking of WPBs in response to histamine requires 
intact microtubule network and dynein activity. 
• Endogenous Rab46 is able to interact with the dynein-dynactin complex either in 
non-stimulated or histamine stimulated condition. 
• A customised pull-down assay reveals direct interaction between Rab46 and the tail 
domain of dynein heavy chain. 
• Rab46 is suggested as new dynein adaptor used by a subset of WPBs to be rescued 
from exocytosis upon acute pro-inflammatory stimulation. 
• Basic phenotyping characterization of a global Rab46 knockout mouse represents 
the very beginning of extending our existing in vitro model to future in vivo studies to 
detect the physiological role of this novel Rab GTPase. 
In conclusion, Rab46 is a new piece of the big puzzle representing WPB contribution to the 
endothelial tailored secretory response to different stimuli.    
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8.2 Future work 
The work performed in this project provides a basis for future research in several areas. In 
addition to some specific approaches outlined throughout the discussion section above, a 
number of broader goals will be important to build on the work produced in this project. 
More work is needed to answer new emerging questions to fulfil the functions and 
mechanisms of Rab46 in endothelial cells. 
 
Spatio-temporal resolution  
Although in this study we used the AiryScan imaging system which improve the confocal 
resolution, it is still unable to resolve distances below a certain threshold. Single molecule 
localization microscopy (SMLM) allows samples to be imaged at resolutions well below the 
diffraction limit. New SMLM techniques, such as dSTORM or PALM will provide an 
invaluable tool for the study of biological structure and function at the nanoscale. Therefore, 
the spatial distribution of Rab46 with WPBs could be further characterize based on their 
proximity to each other, reaching a 50 nm spatial resolution along all three spatial dimensions. 
This study provides several evidence of Rab46-dependent WPB trafficking, however it lacks 
dynamic observations. Rab46 vesicular dynamic analysis and WPB trafficking using live-cell 
imaging will be the main goal of the near future to show the common spatio-temporal 
distribution. So far, the main limitation was the effect of GFP tag on Rab46 localization, 
therefore we are developing a new labelling approach using the spot-tag/nanobody 
technique to measure their dynamics and interactions, with better temporal resolution, in 
biological contexts. The use of alternatives to antibodies in super-resolution microscopy, 
including nanobodies, affibodies, and affimers has been recently increased to overcome the 
limitation size of antibodies (these reagents are approximately 10 times smaller than 
antibodies). Therefore, we are also planning to generate affimers against Rab46 which could 
represents useful tool for super-resolution microscopy as well as potential specific inhibition 
function. 
 
vWF secretion 
Although we reported that siRNA-mediated downregulation of Rab46 affects the vWF 
content and WPB number in endothelial cells, we did not investigate vWF secretion in the 
analysed conditions. We aim to characterize secreted vWF phenotype in response to acute 
stimulation, determining which secretory pathway may be affected by Rab46. Using the Ibidi 
pump system set in our lab, functional release of vWF will be analysed by measuring vWF 
string length under flow. Sting formation reflects vWF haemostatic function as well as it 
could be indicative of the multimer pattern of vWF and its ability to be stored in WPBs. 
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Furthermore, the functionality of the released vWF strings will be verified by assessing the 
recruitment of platelets to the endothelium under physiological flow. 
 
Structural studies 
It is known that conformational changes occur during Rab GTPase cycle. Since no structural 
studies on Rab46 have been performed to date, future studies from our lab aim to investigate 
the structure, folding and dynamic properties of Rab46. Production of recombinant full-
length Rab46 protein and individually recombinant Rab46 domains will provide a useful tool 
for a number of different studies. First of all, structure and conformational change following 
activation and inactivation could be investigated by using high-resolution Nuclear Magnetic 
Resonance (NMR) spectroscopy. Homology modelling will be also used to identify 
functionally important residues and guide new experiments such as site-directed mutagenesis. 
Predicted binding-sites between Rab46 and dynein could be analysed to determine whether 
they are exposed and available for interaction. Availability of purified Rab46 protein will 
eventually confirm direct interaction with the dynein complex. Moreover, the role of Ca2+ 
could be further analysed by observing conformational change induced by Ca2+ binding to 
the EF-hands of Rab46. 
Structural studies will provide an in depth understanding of Rab46 atomic structure, perhaps 
revealing specific binding pockets that could be modulated by small molecules; thus, 
providing novel therapeutic targets for cardiovascular disease. 
 
Mechanisms underlying Rab46 function 
More work is needed to reveal the exact pathway regulating Rab46 context-dependent 
trafficking of WPBs. Small GTPase are regulated by many GEFs and GAPs proteins. 
However, how Rab46 cycle between an ON and OFF state is still unknown. Future studies 
will aim to identify Rab46 effectors either by using a different proteomic approach, such as 
the APEX technique, or by characterizing some of the already identified candidates. 
Immunoprecipitation assays confirms ATP1α interaction with Rab46, however its function 
still need to be explored. We will initially study its localization in endothelial cells and using 
siRNA targeting ATP1a we will investigate the effects on Rab46 function as well as 
differences in Rab46 cellular distribution to WPBs. Recently, it also been show that ATP1α 
interacts with multiple myosin proteins215 like Myosin-9, a protein which is also present in 
our pull-down assay. Therefore, the role of Myosin-9 will also be to be investigated in order 
to identify mechanisms of Rab46 action. As we have already proved that Rab46-dependent 
trafficking to the perinuclear area is Ca2+ independent, we hypothesise that some 
phosphorylation events can take place and regulate the histamine response; thus, a phospho-
proteomic approach will help us to do a first screening of potential candidates.  
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Although we are just at the beginning of defining a novel Rab46 pathway in endothelial cells, 
future studies employing all the different approaches mentioned above will help to put 
together different pieces of Rab46 puzzle.   
 
Endothelial specific Rab46 knockout mice 
In order to be able to draw solid conclusions, global Cracr2a knockout mice need further 
characterization. Initially, there are a number of datasets which remain incomplete, and 
therefore the first priority will be to complete these experiments in both female and male 
mice. In order to address the hypothesis about the presence of early stage inflammation 
process in the liver of Cracr2a knockout mice, specific staining to identify the presence of 
immune cells infiltration will be performed. Moreover, qPCR analysis will evaluate whether 
inflammation markers such as C-reactive protein, IL-6 and TNF are upregulated in Crac2a 
knockout mice compared to control WT. Aging studies as well as stress conditions to assess 
their physiological response to different challenges will be performed. 
Furthermore, endothelial cells need to be isolated from these mice to confirm that the 
endogenous Rab46 is functional. qPCR analysis showed that Rab46 is highly expressed in 
the lung thus, extraction of endothelial cells will be carried out from both liver and lung 
tissues. So far, the main limitation for confirming Rab46 function in murine cells has been 
the lack of anti-Rab46 antibody which is able to recognize mouse target for 
immunofluorescence assays. However, we are planning to start an affimer screening which 
could be used for future imaging studies.  
Although characterization of global Cracr2a knockout mouse will provide useful insights 
about the Rab46 gene on whole body phenotype, in order to explore the contribution of 
endothelial Rab46 on the vascular physiology a more targeted approach is needed. The 
development of endothelial specific Rab46 knockout mice could be a considerable turning 
point and will facilitate experiments to further understand Rab46 biology in endothelial cells. 
Using this model, the role of Rab46 in stimulated release of vWF in vivo will be assessed by 
measuring plasma vWF in response to different stimulation as well as by measuring bleeding 
time. Furthermore, we aim to analyse the ability of vWF to induce platelet aggregation by 
using intravital microscopy to visualise clot formation. 
Following our in vitro studies, there are a number of possible avenues for exploration in order 
to characterise the endothelial specific phenotype further and to elucidate the possible 
mechanisms underlying Rab46 contribution to the vasculature. 
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8.3 Conclusions 
The broad spectrum of endothelial functions requires the existence of a highly responsive 
system which is able to rapidly respond to both physiological and pathological changes in 
the vascular environment. Many scenarios will result in the generation or release of multiple 
endothelial agonists that even when working through the same pathway, can lead to quite 
distinct functional consequences. WPBs are the “perfect vascular emergency kit” which is 
responsible to elicit different functional outcomes following stimulation, in order to maintain 
vascular homeostasis. Given the importance of endothelial cells to maintain vascular 
homeostasis, WPB exocytosis need a tight regulatory molecular machinery to precisely 
modulate their haemostatic and inflammatory function. Unravelling the molecular 
mechanisms underlying differential release of WPB content is a key challenge which can have 
important consequences for clinical interventions. Limiting dangerous thrombosis whilst 
allowing normal inflammatory response (or vice versa) will open new directions to tackle the 
endothelial dysfunction occurring in different cardiovascular diseases. 
Our data present Rab46, a novel and unique GTPase, as a new member of the WPB-
associated machinery driving the on-demand endothelial cells response. Rab46 is necessary 
for dynein-dependent WPB trafficking to the MTOC in response to acute inflammatory 
stimuli but not to pro-thrombotic stimulation. Therefore, Rab46 could be a key regulator of 
differential WPB cargo secretion, allowing the separation of haemostatic and inflammatory 
responses. This extra layer of regulation supports the emerging concept of WPB plasticity, 
which can tune specialized secretory responses depending on the applied stimulus. 
Further work will be needed to explore these findings in a wider variety of settings, from in 
vitro to in vivo studies, but the insights presented here provided a solid foundation on which 
to build future studies. Work towards a greater understanding of the complex signalling 
processes underlying Rab46 function and WPB tailored secretion could provide novel 
therapeutic targets for cardiovascular disease.   
 
. 
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Appendix 
 
Macro code “WPBs and Rab46 cellular distribution” 
 
The code is to be saved as a .txt file and loaded in ImageJ as macro 
//for 16bit Z-stack images 
//Channel 1 -> DAPI nucleus staining 
//Channel 2 -> Green Rab46 staining 
//Channel 3 -> Red vWF staining 
//2018-05-25 
//created by L.Pedicini 
 
macro "distanceMapRed&Green [y]" 
 { 
//variables definition 
imageTitle = getTitle();      
imageDir = getDirectory("image");  
dotIndex = indexOf(imageTitle, ".");  
imageTitleNoExt = substring(imageTitle, 0, dotIndex);     
 
// input z-stack image 
run("Z Project...", "projection=[Max Intensity]");  //max.intensity projection 
run("Duplicate...", "duplicate"); 
saveAs("Tiff", imageDir + "\\results\\Max_" + imageTitleNoExt + "-1.tiff" ); 
close(); 
selectWindow("MAX_" + imageTitle); 
run("Split Channels"); 
selectWindow("C2-MAX_" + imageTitle); 
waitForUser( "Pause","Measure Background C2"); // background subtraction  according to the noise 
level for each channel 
selectWindow("C3-MAX_" + imageTitle); 
waitForUser( "Pause","Measure Background C3"); 
 
selectWindow("C1-MAX_" + imageTitle);     //DAPI channel 
run("Auto Threshold", "method=Default white"); 
setOption("BlackBackground", true); 
run("Make Binary"); 
run("Fill Holes"); 
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run("Despeckle"); 
run("Close-"); 
run("Fill Holes");  
run("Median...");  // the user sets the radius between 2 and 5  according to the image 
run("Fill Holes"); 
run("Despeckle"); 
run("Watershed");     // divides overlapping nuclei  
waitForUser( "Pause","Quality check"); // QC for the watershed step 
run("Invert"); 
run("Distance Map"); 
 
//Analyse Red channel 
selectWindow("C3-MAX_" + imageTitle); 
run("Red"); 
run("Duplicate...", " "); 
selectWindow("C3-MAX_" + imageTitle); 
run("Auto Threshold", "method=MaxEntropy white"); 
 
//to measure particles distance from the nucleus 
run("Set Measurements...", "area mean min integrated redirect=C1-MAX_" + imageTitle + " decimal=3");  
        
selectWindow("C3-MAX_" + imageTitle); 
run("Analyze Particles...", "size=0.03-Infinity display exclude slice"); 
saveAs("Results", imageDir + "\\results\\distance_Red" + imageTitleNoExt + ".csv" ); 
waitForUser( "Pause","Close results window"); 
 
//to measure particles intensities from the raw image 
selectWindow("C3-MAX_" + imageTitle); 
run("Set Measurements...", "area mean min integrated redirect=C3-MAX_" + imageTitleNoExt + "-1.dv 
decimal=3"); 
selectWindow("C3-MAX_" + imageTitle); 
run("Analyze Particles...", "size=0.03-Infinity display exclude slice"); 
saveAs("Results", imageDir + "\\results\\intensity_Red" + imageTitleNoExt + ".csv" ); 
selectWindow("C3-MAX_" + imageTitleNoExt + "-1.dv"); 
run("RGB Color"); 
saveAs("Tiff", imageDir + "\\results\\Red_" + imageTitleNoExt + "-1.tiff" ); 
close(); 
waitForUser( "Pause","Close results window to analyse the next channel"); 
 
// Analyse Green channel 
selectWindow("C2-MAX_" + imageTitle); 
run("Green"); 
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run("Duplicate...", " "); 
selectWindow("C2-MAX_" + imageTitle); 
run("Auto Threshold", "method=MaxEntropy white") 
run("Set Measurements...", "area mean min integrated redirect=C1-MAX_" + imageTitle + " decimal=3"); 
selectWindow("C2-MAX_" + imageTitle); 
run("Analyze Particles...", "size=0.03-Infinity display exclude slice"); 
saveAs("Results", imageDir + "\\results\\distance_Green" + imageTitleNoExt + ".csv" ); 
waitForUser( "Pause","Close results window"); 
selectWindow("C2-MAX_" + imageTitle); 
run("Set Measurements...", "area mean min integrated redirect=C2-MAX_" + imageTitleNoExt + "-1.dv 
decimal=3"); 
selectWindow("C2-MAX_" + imageTitle); 
run("Analyze Particles...", "size=0.03-Infinity display exclude slice"); 
saveAs("Results", imageDir + "\\results\\intensity_Green" + imageTitleNoExt + ".csv" ); 
selectWindow("C2-MAX_" + imageTitleNoExt + "-1.dv"); 
run("RGB Color"); 
saveAs("Tiff", imageDir + "\\results\\green_" + imageTitleNoExt + "-1.tiff" ); 
close(); 
selectWindow("C1-MAX_" + imageTitle); 
saveAs("Tiff", imageDir + "\\results\\distMap_" + imageTitleNoExt + ".tiff" ); 
close(); 
selectWindow("C3-MAX_" + imageTitle); 
close(); 
selectWindow("C2-MAX_" + imageTitle); 
close(); 
selectWindow(imageTitle); 
close(); 
} 
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Raw Proteomic data 
 
Dataset QLvsNI 
 
Group 
p-
value 
Mean 1 
Mean 
2 
Media
n 1 
Media
n 2 
Fold 
chang
e QL to 
NI 
Myosin-9 OS=Homo sapiens 
GN=MYH9 PE=1 SV=4 
0.00881 1035107.3 5513859.2 575288.5 4575465.2 5.3268 
Fatty acid synthase OS=Homo 
sapiens GN=FASN PE=1 SV=3 
0.00047 216432.4 818854.6 124286.8 1011299.6 3.7834 
Clathrin heavy chain OS=Homo 
sapiens GN=CLTC PE=1 SV=1 
0.00006 141206.3 465390.0 123329.0 533316.4 3.2958 
DnaJ homolog subfamily A 
member 2 OS=Homo sapiens 
GN=DNAJA2 PE=1 SV=1 
0.00577 3867.4 12115.4 2188.6 11760.4 3.1327 
Isoleucine--tRNA ligase, 
cytoplasmic OS=Homo sapiens 
GN=IARS PE=1 SV=2 
0.00080 27719.0 81643.9 30623.5 99219.3 2.9454 
CAD protein OS=Homo sapiens 
GN=CAD PE=1 SV=1 
0.00208 129910.2 356813.2 71983.4 423091.0 2.7466 
Filamin-B OS=Homo sapiens 
GN=FLNB PE=1 SV=2 
0.00067 206444.6 500749.7 110338.3 483883.1 2.4256 
Thrombospondin-1 OS=Homo 
sapiens GN=THBS1 PE=1 SV=2 
0.00318 811406.8 1952072.7 705225.0 1903450.4 2.4058 
DNA-dependent protein kinase 
catalytic subunit OS=Homo 
sapiens GN=PRKDC PE=1 SV=3 
0.00286 128885.6 305170.4 120622.0 234149.1 2.3678 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
OS=Homo sapiens GN=ATP1A1 
PE=1 SV=1 
0.00001 115250.0 271029.4 118095.9 308547.2 2.3517 
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Poly [ADP-ribose] polymerase 4 
OS=Homo sapiens GN=PARP4 
PE=1 SV=3 
0.01376 20209.3 47435.7 16712.9 60639.9 2.3472 
Filamin-A OS=Homo sapiens 
GN=FLNA PE=1 SV=4 
0.00005 208314.7 452316.5 165847.8 418776.2 2.1713 
U5 small nuclear ribonucleoprotein 
200 kDa helicase OS=Homo 
sapiens GN=SNRNP200 PE=1 
SV=2 
0.01954 31203.9 65489.9 30556.7 79343.4 2.0988 
Four and a half LIM domains 
protein 2 OS=Homo sapiens 
GN=FHL2 PE=1 SV=1 
0.04377 12210.5 24285.2 11542.4 25873.9 1.9889 
Ras-interacting protein 1 
OS=Homo sapiens GN=RASIP1 
PE=1 SV=1 
0.03748 6624.0 12688.1 5939.1 13229.4 1.9155 
B-cell receptor-associated protein 
31 OS=Homo sapiens 
GN=BCAP31 PE=1 SV=3 
0.00997 35504.3 66868.7 40157.2 73321.4 1.8834 
Cytoplasmic FMR1-interacting 
protein 1 OS=Homo sapiens 
GN=CYFIP1 PE=1 SV=1 
0.02565 23321.8 43590.7 19695.4 53383.2 1.8691 
Coatomer subunit alpha 
OS=Homo sapiens GN=COPA 
PE=1 SV=2 
0.04028 357178.5 652580.2 463160.0 858988.1 1.8270 
Ubiquitin-associated protein 2-like 
OS=Homo sapiens GN=UBAP2L 
PE=1 SV=2 
0.01053 11178.9 20084.7 10086.8 22670.7 1.7967 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens 
GN=DYNC1H1 PE=1 SV=5 
0.00235 152549.1 269519.9 158459.0 285311.4 1.7668 
Myoferlin OS=Homo sapiens 
GN=MYOF PE=1 SV=1 
0.00694 77092.3 135350.1 69350.1 137563.2 1.7557 
Histone deacetylase 6 OS=Homo 
sapiens GN=HDAC6 PE=1 SV=2 
0.01879 514561.4 900963.4 507403.6 927612.6 1.7509 
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Centrosomal protein of 170 kDa 
OS=Homo sapiens GN=CEP170 
PE=1 SV=1 
0.02782 33489.5 58025.5 25507.2 62699.4 1.7326 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 2, 
mitochondrial OS=Homo sapiens 
GN=NDUFS2 PE=1 SV=2 
0.02549 52743.7 87182.1 51238.7 106379.8 1.6529 
Exportin-1 OS=Homo sapiens 
GN=XPO1 PE=1 SV=1 
0.02067 44029.5 71910.5 48160.6 84822.8 1.6332 
Platelet endothelial cell adhesion 
molecule OS=Homo sapiens 
GN=PECAM1 PE=1 SV=1 
0.02011 68714.8 108840.2 70640.9 90373.9 1.5839 
DNA replication licensing factor 
MCM3 OS=Homo sapiens 
GN=MCM3 PE=1 SV=3 
0.00442 240685.4 375702.3 242406.5 422236.3 1.5610 
A-kinase anchor protein 12 
OS=Homo sapiens GN=AKAP12 
PE=1 SV=4 
0.01332 54114.4 83997.6 55086.6 76489.4 1.5522 
Lysosome-associated membrane 
glycoprotein 1 OS=Homo sapiens 
GN=LAMP1 PE=1 SV=3 
0.02832 130786.5 196839.7 144108.4 158986.6 1.5050 
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Dataset NIvsQL 
 
Group 
p-
value 
Mean 
1 
Mean 
2 
Media
n 1 
Media
n 2 
Fold 
change 
NI to QL 
REVERSED Cysteine protease 
ATG4C OS=Homo sapiens 
GN=ATG4C PE=1 SV=1 
2.48E-09 2799745 1427.21 2583028 1069.504 1961.6918 
60S ribosomal protein L36a-like 
OS=Homo sapiens GN=RPL36AL 
PE=1 SV=3 
0.02244 63319.2 13739.39 86435.62 7039.723 4.6086 
28S ribosomal protein S34, 
mitochondrial OS=Homo sapiens 
GN=MRPS34 PE=1 SV=2 
0.00855 22936.05 5068.914 22375.1 4346.953 4.5248 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
0.04192 3065066 739103.3 1376825 688341.1 4.1470 
Eukaryotic translation initiation factor 
2A OS=Homo sapiens GN=EIF2A 
PE=1 SV=3 
0.04001 23282.97 6399.625 16046.33 3089.723 3.6382 
Histone H2A.Z OS=Homo sapiens 
GN=H2AFZ PE=1 SV=2 
0.02852 37479.6 10501.31 22353.84 7300.094 3.5690 
Cell cycle and apoptosis regulator 
protein 2 OS=Homo sapiens 
GN=CCAR2 PE=1 SV=2 
0.04517 113335.3 34378.73 58145.15 31023.55 3.2967 
Histone H1x OS=Homo sapiens 
GN=H1FX PE=1 SV=1 
0.00078 60091.94 20383.62 64876.2 15422.7 2.9481 
Histone H2A type 1-B/E OS=Homo 
sapiens GN=HIST1H2AB PE=1 
SV=2 
0.00913 27022.46 9327.686 26548.36 7099.551 2.8970 
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60S ribosomal protein L14 
OS=Homo sapiens GN=RPL14 
PE=1 SV=4 
0.04765 1989137 724276 1030298 724012.5 2.7464 
39S ribosomal protein L4, 
mitochondrial OS=Homo sapiens 
GN=MRPL4 PE=1 SV=1 
0.00181 125273.7 46566.86 105088.1 25986.04 2.6902 
High mobility group protein HMG-
I/HMG-Y OS=Homo sapiens 
GN=HMGA1 PE=1 SV=3 
0.03662 341458.5 128162.5 205386.1 92175.96 2.6643 
Chromatin assembly factor 1 subunit 
B OS=Homo sapiens GN=CHAF1B 
PE=1 SV=1 
0.04176 59176.73 22804.27 37934.78 22385.57 2.5950 
6-phosphogluconate dehydrogenase, 
decarboxylating OS=Homo sapiens 
GN=PGD PE=1 SV=3 
0.04717 14309.56 5658.703 11946.41 5038.89 2.5288 
Pentatricopeptide repeat domain-
containing protein 3, mitochondrial 
OS=Homo sapiens GN=PTCD3 
PE=1 SV=3 
0.00961 117757.8 46914.84 113532 27429.95 2.5100 
Reticulocalbin-2 OS=Homo sapiens 
GN=RCN2 PE=1 SV=1 
0.00428 11298.25 4502.685 9663.809 4621.307 2.5092 
Guanine nucleotide-binding protein-
like 3 OS=Homo sapiens GN=GNL3 
PE=1 SV=2 
0.03839 6224.475 2492.092 4316.785 2461.33 2.4977 
Heterogeneous nuclear 
ribonucleoprotein H3 OS=Homo 
sapiens GN=HNRNPH3 PE=1 
SV=2 
0.0003 105425.4 42419.25 95504.12 36362.73 2.4853 
Eukaryotic translation initiation factor 
5B OS=Homo sapiens GN=EIF5B 
PE=1 SV=1 
0.02726 116763 48264.25 140411.1 33589.68 2.4192 
Dysferlin OS=Homo sapiens 
GN=DYSF PE=1 SV=1 
0.0288 35783.85 14870.17 31405.94 12535.55 2.4064 
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39S ribosomal protein L13, 
mitochondrial OS=Homo sapiens 
GN=MRPL13 PE=1 SV=1 
0.01969 32576.53 13919.8 26348.04 12372.25 2.3403 
Barrier-to-autointegration factor 
OS=Homo sapiens GN=BANF1 
PE=1 SV=1 
0.01571 46991.62 20774.48 42992.07 10631.95 2.2620 
40S ribosomal protein S2 OS=Homo 
sapiens GN=RPS2 PE=1 SV=2 
0.01903 736981.4 326378.6 630084 297595.9 2.2581 
UPF0568 protein C14orf166 
OS=Homo sapiens GN=C14orf166 
PE=1 SV=1 
0.01973 56915.5 25205.92 45051.32 13781.63 2.2580 
Eukaryotic translation initiation factor 
5 OS=Homo sapiens GN=EIF5 
PE=1 SV=2 
0.00404 44765.32 20116.99 54607.7 15450.4 2.2252 
RNA-binding protein 3 OS=Homo 
sapiens GN=RBM3 PE=1 SV=1 
0.041 71588.6 32478.85 48938.48 35359.28 2.2042 
60S ribosomal protein L27a 
OS=Homo sapiens GN=RPL27A 
PE=1 SV=2 
0.04999 1372758 624404.3 741042.5 680821.5 2.1985 
116 kDa U5 small nuclear 
ribonucleoprotein component 
OS=Homo sapiens GN=EFTUD2 
PE=1 SV=1 
0.00801 187007.1 85664.56 151487.1 88676.4 2.1830 
40S ribosomal protein S23 OS=Homo 
sapiens GN=RPS23 PE=1 SV=3 
0.03797 758102.5 353186.8 494973.3 354610.4 2.1465 
40S ribosomal protein S29 OS=Homo 
sapiens GN=RPS29 PE=1 SV=2 
0.03014 190156.5 92523.5 130475.7 85971.65 2.0552 
39S ribosomal protein L49, 
mitochondrial OS=Homo sapiens 
GN=MRPL49 PE=1 SV=1 
0.03336 9200.989 4485.909 9419.155 3818.794 2.0511 
E3 ubiquitin-protein ligase TRAF7 
OS=Homo sapiens GN=TRAF7 
PE=1 SV=1 
0.00129 33950.45 16559.36 40693.99 16436.71 2.0502 
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Actin-related protein 2/3 complex 
subunit 1B OS=Homo sapiens 
GN=ARPC1B PE=1 SV=3 
0.02762 41194.77 20213.75 43880.83 15099.43 2.0380 
Small nuclear ribonucleoprotein Sm 
D1 OS=Homo sapiens 
GN=SNRPD1 PE=1 SV=1 
0.00838 68559.19 34258.77 64549.44 32673 2.0012 
Heterochromatin protein 1-binding 
protein 3 OS=Homo sapiens 
GN=HP1BP3 PE=1 SV=1 
0.00132 164228.6 82107.14 173595.1 91383.04 2.0002 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 OS=Homo 
sapiens GN=HNRNPC PE=1 SV=4 
0.04064 950382.9 481267.5 768478.9 347116.3 1.9748 
40S ribosomal protein S10 OS=Homo 
sapiens GN=RPS10 PE=1 SV=1 
0.03373 611180.2 313402.7 442633.4 273488.4 1.9501 
60S ribosomal protein L37a 
OS=Homo sapiens GN=RPL37A 
PE=1 SV=2 
0.02311 50412.84 25852.79 45357.01 25287.26 1.9500 
60S ribosomal protein L35 
OS=Homo sapiens GN=RPL35 
PE=1 SV=2 
0.03188 389909.2 204366.5 284909.8 192471.2 1.9079 
40S ribosomal protein S4, X isoform 
OS=Homo sapiens GN=RPS4X 
PE=1 SV=2 
0.04722 1374195 721981.4 928460.7 696791.8 1.9034 
ATP-dependent RNA helicase 
DDX3Y OS=Homo sapiens 
GN=DDX3Y PE=1 SV=2 
0.03941 8818.671 4651.626 12403.36 5173.79 1.8958 
Cold-inducible RNA-binding protein 
OS=Homo sapiens GN=CIRBP 
PE=1 SV=1 
0.0098 73339.32 38819.45 66361.54 32655.27 1.8892 
Fragile X mental retardation 
syndrome-related protein 1 
OS=Homo sapiens GN=FXR1 PE=1 
SV=3 
0.0271 37125.28 19694.29 28951.86 22111.91 1.8851 
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Lamin B2, isoform CRA_a 
OS=Homo sapiens GN=LMNB2 
PE=1 SV=1 
0.03562 79292.85 43302.97 69675.84 41272.13 1.8311 
X-ray repair cross-complementing 
protein 5 OS=Homo sapiens 
GN=XRCC5 PE=1 SV=3 
0.0071 312700 171423.1 277648.1 196869.2 1.8241 
40S ribosomal protein S15a 
OS=Homo sapiens GN=RPS15A 
PE=1 SV=2 
0.0486 1165641 661162.4 735952 608180.9 1.7630 
40S ribosomal protein S17 OS=Homo 
sapiens GN=RPS17 PE=1 SV=2 
0.01845 157704.9 92589.97 141413.9 103144.3 1.7033 
60S ribosomal protein L23a 
OS=Homo sapiens GN=RPL23A 
PE=1 SV=1 
0.02703 430780.5 253980.8 468251.6 237435.6 1.6961 
Serine/arginine-rich splicing factor 1 
OS=Homo sapiens GN=SRSF1 
PE=1 SV=2 
0.0292 320849.9 198343.3 295228.7 203274 1.6176 
ELAV-like protein 1 OS=Homo 
sapiens GN=ELAVL1 PE=1 SV=2 
0.00412 231362.2 145768.9 227976.8 160993.9 1.5872 
Probable ATP-dependent RNA 
helicase DDX6 OS=Homo sapiens 
GN=DDX6 PE=1 SV=2 
0.03051 77260.89 49460.11 78265.49 38767.9 1.5621 
Insulin-like growth factor 2 mRNA-
binding protein 1 OS=Homo sapiens 
GN=IGF2BP1 PE=1 SV=2 
0.04789 127066 81581.48 150685.9 57828.43 1.5575 
X-ray repair cross-complementing 
protein 6 OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
0.0048 444537.7 296231 440989.2 273008.3 1.5006 
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Dataset QLvsGFP 
 
Group 
p-
value 
Mean 1 
Mean 
2 
Media
n 1 
Media
n 2 
Fold 
Chang
e 
EF-hand calcium-binding domain-
containing protein 4B OS=Homo 
sapiens GN=CRACR2A PE=1 
SV=1 
4.94E-
09 
36450750 20971.34 37078683 18588.3 1738.122 
EF-hand calcium-binding domain-
containing protein 4B (Fragment) 
OS=Homo sapiens GN=CRACR2A 
PE=1 SV=1 
2.90E-
03 
345998 50363.58 449403.1 19274.1 6.870 
Protein transport protein Sec61 
subunit beta OS=Homo sapiens 
GN=SEC61B PE=1 SV=2 
6.30E-
04 
19890.25 3222.497 15964.12 625.1 6.172 
10 kDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPE1 PE=1 SV=2 
6.70E-
04 
32498.65 7034.95 27734.58 6472.2 4.620 
26S proteasome non-ATPase 
regulatory subunit 4 OS=Homo 
sapiens GN=PSMD4 PE=1 SV=1 
2.25E-
02 
214412.6 48074.81 121648.3 34000.2 4.460 
EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 
1.15E-
03 
182355.5 53274.78 243018.9 45014.4 3.423 
Collagen alpha-1(VIII) chain 
OS=Homo sapiens GN=COL8A1 
PE=1 SV=2 
2.17E-
02 
572816.9 183165.4 577558.2 137847.1 3.127 
Archain 1, isoform CRA_a 
OS=Homo sapiens GN=ARCN1 
PE=1 SV=1 
1.03E-
02 
93421.45 30699.43 58342.39 27473.4 3.043 
DnaJ homolog subfamily A member 
2 OS=Homo sapiens GN=DNAJA2 
PE=1 SV=1 
5.99E-
03 
11112.97 3805.443 10794.24 3918.5 2.920 
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Matrix Gla protein OS=Homo 
sapiens GN=MGP PE=1 SV=2 
4.74E-
02 
17182.56 6173.229 13544.39 6935.6 2.783 
CAD protein OS=Homo sapiens 
GN=CAD PE=1 SV=1 
1.36E-
03 
327299.3 124544.2 388047 134778.6 2.628 
40S ribosomal protein S27-like 
OS=Homo sapiens GN=RPS27L 
PE=1 SV=3 
1.86E-
02 
42622.33 17783.79 51894.95 13053.4 2.397 
7-dehydrocholesterol reductase 
OS=Homo sapiens GN=DHCR7 
PE=1 SV=1 
6.70E-
03 
60634.23 25382.85 71693.96 21752.3 2.389 
cAMP-dependent protein kinase 
catalytic subunit alpha OS=Homo 
sapiens GN=PRKACA PE=1 SV=2 
2.72E-
02 
25684.71 10910.91 31918.64 11351.5 2.354 
Protein CYR61 OS=Homo sapiens 
GN=CYR61 PE=1 SV=1 
1.79E-
02 
660083.7 284612.8 704581 290462.5 2.319 
Macrophage migration inhibitory 
factor OS=Homo sapiens GN=MIF 
PE=1 SV=4 
2.27E-
02 
1621261 724478 1639035 310534.4 2.238 
Serpin B6 OS=Homo sapiens 
GN=SERPINB6 PE=1 SV=1 
5.30E-
04 
82668.79 40596.84 80625.01 36824.3 2.036 
Protein phosphatase 1F OS=Homo 
sapiens GN=PPM1F PE=1 SV=3 
1.59E-
02 
47905.3 23986.53 53801.93 20756.3 1.997 
Microsomal glutathione S-transferase 
1 (Fragment) OS=Homo sapiens 
GN=MGST1 PE=1 SV=1 
3.81E-
02 
39368.42 20365.37 34207.89 18162.0 1.933 
Ig heavy chain V-III region TUR 
OS=Homo sapiens PE=1 SV=1 
1.46E-
02 
144280.7 74764.13 132748.7 73668.2 1.930 
Lysozyme OS=Homo sapiens 
GN=LYZ PE=1 SV=1 
2.79E-
02 
98693.55 51442.75 74275.49 59511.8 1.919 
Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
3.57E-
03 
218847.7 115006.5 225369.5 89760.0 1.903 
Interferon-induced protein 44 
OS=Homo sapiens GN=IFI44 
PE=2 SV=2 
8.79E-
03 
46109.92 24522.43 55519.34 28510.2 1.880 
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GTPase IMAP family member 8 
OS=Homo sapiens GN=GIMAP8 
PE=2 SV=2 
3.89E-
02 
31104.11 16558.12 37067.99 8164.7 1.878 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
2.20E-
02 
188512.5 106268.1 208176 89898.3 1.774 
Profilin OS=Homo sapiens 
GN=PFN2 PE=1 SV=1 
1.37E-
03 
212607.2 121524.5 214836 103203.7 1.750 
40S ribosomal protein S3 
OS=Homo sapiens GN=RPS3 
PE=1 SV=2 
1.84E-
02 
2432289 1438922 3130268 1447215.6 1.690 
ATP synthase subunit gamma, 
mitochondrial OS=Homo sapiens 
GN=ATP5C1 PE=1 SV=1 
1.66E-
02 
535509.9 317196.4 651726.5 315997.7 1.688 
RNA 3'-terminal phosphate cyclase 
OS=Homo sapiens GN=RTCA 
PE=1 SV=1 
4.39E-
02 
46675.19 27766.7 54539.64 28114.0 1.681 
Thrombospondin-1 OS=Homo 
sapiens GN=THBS1 PE=1 SV=2 
2.04E-
02 
1790628 1065906 1745867 1035020.6 1.680 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM 
PE=1 SV=2 
7.10E-
03 
992966.5 593937.2 1178492 626400.7 1.672 
Zyxin OS=Homo sapiens 
GN=ZYX PE=1 SV=1 
1.43E-
03 
172548 104052.2 176332.2 107541.7 1.658 
Synaptic vesicle membrane protein 
VAT-1 homolog OS=Homo sapiens 
GN=VAT1 PE=1 SV=2 
4.12E-
02 
39302.98 24041.95 36693.46 24593.9 1.635 
26S proteasome non-ATPase 
regulatory subunit 3 OS=Homo 
sapiens GN=PSMD3 PE=1 SV=2 
4.89E-
02 
304469.2 187294.8 374661.3 173747.7 1.626 
Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 
6.66E-
03 
3590261 2253553 3878215 2204240.4 1.593 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
3.17E-
02 
79970.4 50205.66 97567.17 50639.6 1.593 
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OS=Homo sapiens GN=NDUFS2 
PE=1 SV=2 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens 
GN=DYNC1H1 PE=1 SV=5 
1.86E-
03 
247223.3 155451.4 261668.8 162179.6 1.590 
Cold shock domain-containing 
protein E1 OS=Homo sapiens 
GN=CSDE1 PE=1 SV=2 
4.30E-
02 
81258.32 51715.82 86396.19 51307.3 1.571 
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Dataset NIvsGFP 
 
Group 
p-
value 
Mean 
1 
Mean 
2 
Media
n 1 
Media
n 2 
Fold 
Chang
e 
EF-hand calcium-binding domain-
containing protein 4B OS=Homo 
sapiens GN=CRACR2A PE=1 
SV=1 
1.3E-07 20454767 23236.38 17334192 20597.41 880.2906 
REVERSED Cysteine protease 
ATG4C OS=Homo sapiens 
GN=ATG4C PE=1 SV=1 
2.5E-09 2845596 3609.32 2625261 1431.963 788.4022 
10 kDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPE1 PE=1 SV=2 
1.7E-03 65464.76 7795.113 76596.29 7170.227 8.3982 
Pentatricopeptide repeat domain-
containing protein 3, mitochondrial 
OS=Homo sapiens GN=PTCD3 
PE=1 SV=3 
3.3E-05 119685.8 14827.76 115388.4 9809.47 8.0717 
26S proteasome non-ATPase 
regulatory subunit 4 OS=Homo 
sapiens GN=PSMD4 PE=1 SV=1 
9.9E-03 377925.4 53270.25 316204.9 37675.26 7.0945 
EF-hand calcium-binding domain-
containing protein 4B (Fragment) 
OS=Homo sapiens 
GN=CRACR2A PE=1 SV=1 
4.8E-02 307065.8 55806.07 134967.8 21357.35 5.5024 
Protein transport protein Sec61 
subunit beta OS=Homo sapiens 
GN=SEC61B PE=1 SV=2 
2.7E-03 16398.95 3570.78 22179.45 692.5911 4.5925 
Uncharacterized protein OS=Homo 
sapiens PE=3 SV=1 
2.1E-02 38942.02 10599.56 34602.7 7412.545 3.6739 
40S ribosomal protein S29 
OS=Homo sapiens GN=RPS29 
PE=1 SV=2 
3.0E-03 193269.6 58696.53 132611.6 44693.39 3.2927 
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Barrier-to-autointegration factor 
OS=Homo sapiens GN=BANF1 
PE=1 SV=1 
2.3E-03 47760.76 15025.61 43694.5 6358.187 3.1786 
Cell cycle and apoptosis regulator 
protein 2 OS=Homo sapiens 
GN=CCAR2 PE=1 SV=2 
4.6E-02 115193 36761.41 59095.82 37049.64 3.1335 
Microsomal glutathione S-
transferase 1 (Fragment) OS=Homo 
sapiens GN=MGST1 PE=1 SV=1 
8.8E-04 64191.29 22566.39 45099.72 20125.06 2.8446 
40S ribosomal protein S15a 
OS=Homo sapiens GN=RPS15A 
PE=1 SV=2 
1.1E-02 1184722 427233.5 747999.6 241526.5 2.7730 
Collagen alpha-1(VIII) chain 
OS=Homo sapiens GN=COL8A1 
PE=1 SV=2 
1.3E-02 545217.7 202953.1 621056.7 152722 2.6864 
cAMP-dependent protein kinase 
catalytic subunit alpha OS=Homo 
sapiens GN=PRKACA PE=1 
SV=2 
7.5E-03 31968.81 12089.61 35710.95 12578.45 2.6443 
EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 
2.5E-03 151901.6 59030.37 187637.8 49879.86 2.5733 
26S proteasome non-ATPase 
regulatory subunit 7 OS=Homo 
sapiens GN=PSMD7 PE=1 SV=2 
4.1E-02 23827.24 9581.498 21116.57 6572.9 2.4868 
Dysferlin OS=Homo sapiens 
GN=DYSF PE=1 SV=1 
3.1E-02 36369.31 14692.05 31923.82 11923.67 2.4754 
Matrix Gla protein OS=Homo 
sapiens GN=MGP PE=1 SV=2 
2.0E-03 16615.62 6840.249 17978.88 7685.293 2.4291 
7-dehydrocholesterol reductase 
OS=Homo sapiens GN=DHCR7 
PE=1 SV=1 
2.2E-03 66981.46 28124.87 50270.29 24103.46 2.3816 
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Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 
1.3E-04 5897532 2497019 5873136 2442097 2.3618 
Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
4.2E-03 300876 127434.7 273835.9 99440.97 2.3610 
39S ribosomal protein L13, 
mitochondrial OS=Homo sapiens 
GN=MRPL13 PE=1 SV=1 
1.6E-02 33110.14 14191 26777.15 14201.42 2.3332 
UPF0568 protein C14orf166 
OS=Homo sapiens GN=C14orf166 
PE=1 SV=1 
1.7E-03 57847.17 25458.1 45793.56 28088 2.2723 
40S ribosomal protein S2 
OS=Homo sapiens GN=RPS2 
PE=1 SV=2 
1.8E-02 749045 331891.9 640398.5 216536.1 2.2569 
Splicing factor U2AF 35 kDa 
subunit OS=Homo sapiens 
GN=U2AF1 PE=1 SV=3 
1.1E-02 31111.79 13830.3 25437.73 16935.51 2.2495 
PDZ and LIM domain protein 7 
OS=Homo sapiens GN=PDLIM7 
PE=1 SV=1 
4.8E-02 14167.55 6300.214 13334.81 4198.381 2.2487 
Squamous cell carcinoma antigen 
recognized by T-cells 3 OS=Homo 
sapiens GN=SART3 PE=1 SV=1 
3.1E-02 23509.36 10801.62 21677.03 6801.831 2.1765 
Macrophage migration inhibitory 
factor OS=Homo sapiens 
GN=MIF PE=1 SV=4 
2.9E-02 1724566 802775.4 1464931 344099.1 2.1483 
Heterogeneous nuclear 
ribonucleoprotein Q OS=Homo 
sapiens GN=SYNCRIP PE=1 
SV=2 
1.2E-02 97238.07 45432.22 88811.36 45825.51 2.1403 
60S ribosomal protein L37a 
OS=Homo sapiens GN=RPL37A 
PE=1 SV=2 
9.1E-03 51238.09 24214.62 46098.08 24298.57 2.1160 
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60S ribosomal protein L23 
OS=Homo sapiens GN=RPL23 
PE=1 SV=1 
2.8E-02 991906 483057.4 805014.3 320824.5 2.0534 
Zinc finger CCHC domain-
containing protein 3 OS=Homo 
sapiens GN=ZCCHC3 PE=1 
SV=1 
3.0E-03 23996.41 11701.98 26539.26 11964.54 2.0506 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
3.2E-03 234757.7 117750.8 238410.3 99615.16 1.9937 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 2 
OS=Homo sapiens GN=AIMP2 
PE=1 SV=2 
3.3E-03 6893.202 3620.845 7165.761 3787.688 1.9038 
Small nuclear ribonucleoprotein Sm 
D2 OS=Homo sapiens 
GN=SNRPD2 PE=1 SV=1 
1.4E-02 87741.98 46623.22 82329.6 49300.69 1.8819 
Proteasome subunit beta type-3 
(Fragment) OS=Homo sapiens 
GN=PSMB3 PE=1 SV=1 
2.5E-02 54499.87 29126.43 64283.94 27707.71 1.8711 
Histone H1x OS=Homo sapiens 
GN=H1FX PE=1 SV=1 
1.3E-02 61075.49 32908.24 65932.8 31769.07 1.8559 
Profilin OS=Homo sapiens 
GN=PFN2 PE=1 SV=1 
2.3E-03 247966.8 134655.9 232054.9 114340.3 1.8415 
26S protease regulatory subunit 7 
OS=Homo sapiens GN=PSMC2 
PE=1 SV=3 
1.5E-02 15833.5 8960.797 16046.32 14798.65 1.7670 
RNA 3'-terminal phosphate cyclase 
OS=Homo sapiens GN=RTCA 
PE=1 SV=1 
2.4E-03 54203.86 30766.63 55102.11 31152.75 1.7618 
39S ribosomal protein L38, 
mitochondrial OS=Homo sapiens 
GN=MRPL38 PE=1 SV=2 
3.6E-02 40190.84 23052.77 35062.34 22915.12 1.7434 
Insulin-like growth factor 2 mRNA-
binding protein 2 OS=Homo 
3.8E-02 97048.27 57049.7 98342.93 56150.84 1.7011 
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sapiens GN=IGF2BP2 PE=1 
SV=1 
Thioredoxin OS=Homo sapiens 
GN=TXN PE=1 SV=3 
5.0E-02 388171.7 234174.7 353873.6 126218 1.6576 
ATPase family AAA domain-
containing protein 3A (Fragment) 
OS=Homo sapiens GN=ATAD3A 
PE=1 SV=1 
7.5E-03 145729.6 88540.21 113788 89409.44 1.6459 
Heterochromatin protein 1-binding 
protein 3 OS=Homo sapiens 
GN=HP1BP3 PE=1 SV=1 
8.6E-04 166917.2 102555.1 176436.9 96264 1.6276 
Serpin B6 OS=Homo sapiens 
GN=SERPINB6 PE=1 SV=1 
2.4E-02 72536.86 44983.39 70233.3 40797.9 1.6125 
Calponin OS=Homo sapiens 
GN=CNN2 PE=1 SV=1 
2.5E-02 94616.84 59586.53 100767 64470.54 1.5879 
ATP synthase subunit gamma, 
mitochondrial OS=Homo sapiens 
GN=ATP5C1 PE=1 SV=1 
1.5E-08 548805.7 351467.4 527193.7 350152.9 1.5615 
L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA 
PE=1 SV=2 
2.4E-02 2632868 1691518 2920045 1686296 1.5565 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM 
PE=1 SV=2 
5.1E-03 1022326 658105.1 1069408 694106.4 1.5534 
Synaptic vesicle membrane protein 
VAT-1 homolog OS=Homo 
sapiens GN=VAT1 PE=1 SV=2 
4.8E-02 41156.26 26639.58 40696.02 27252.24 1.5449 
Interferon-induced protein 44 
OS=Homo sapiens GN=IFI44 
PE=2 SV=2 
4.0E-02 41770.22 27171.54 42393.65 31585.08 1.5373 
Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 
4.1E-02 707839.1 461166.4 787897.6 442902 1.5349 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 
1.8E-02 39993.74 26099.08 41517.7 19985.23 1.5324 
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OS=Homo sapiens 
GN=HNRNPUL1 PE=1 SV=2 
 
